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PREFACE 
 
 
Stress-related psychiatric disorders are one of the most common mental disorders in the United 
States, affecting approximately 18% of the U.S. population. Given both its prevalence and 
debilitating nature, many studies have sought to determine the neurological underpinnings of 
these disorders in an attempt to identify potential therapeutic targets. Such studies have 
successfully determined a number of neuroanatomical regions of interest, one of which is the 
central amygdala (CeA). The CeA is a key brain structure that mediates the processing of 
physiological and behavioral aspects of the stress response and its activity strongly correlates 
with the symptomology of stress-related psychiatric illnesses, such as post traumatic stress 
disorder (PTSD). 
Interestingly, the brain’s endocannabinoid (eCB) system has also been implicated in 
stress-related behavior processing as well as the pathophysiology of stress-related psychiatric 
illnesses. This functional and pathological overlap between the CeA and the eCB system suggest 
a potential interaction between both systems in stress-related pathologies. A putative locus for 
this potential interaction may lie at the terminals of excitatory inputs that drive CeA function. 
However, eCB signaling mechanisms at these terminals remain largely unexplored. To examine 
this intriguing possibility, we hypothesized that: 1) eCB signaling mechanisms are present at 
glutamatergic terminals within the lateral division of the CeA (CeAL) and recruit the CeAL 
cholinergic system to enhance eCB mobilization and 2) repetitive exposure to aversive stimuli 
modulates eCB signaling at CeAL excitatory synapses to potentially support eCB-mediated 
adaptive processes that mitigate the pathological consequences of chronic stress exposure.  
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To test these hypotheses, we first characterized the expression of the endocannabinoid 
signaling (eCB) machinery within the CeAL. Thereafter, we utilized ex vivo electrophysiological 
techniques to examine functional eCB signaling at excitatory synapses of the CeAL using a 
combination of pharmacological and genetic tools. These experiments revealed both the 
expression and subcellular localization of CB1 receptors and the eCB synthetic machinery at 
CeAL glutamatergic synapses. The functional significance of these findings was subsequently 
demonstrated by the discovery of short-term eCB signaling mechanisms, in the form of 
depolarization-induced suppression of excitation (DSE), at the glutamatergic terminals of the 
CeAL. Furthermore, we also determined that the cholinergic system of the CeAL recruits distinct 
endocannabinoids using disparate signaling mechanisms via: 1) acute- and persistent- muscarinic 
receptor (mAChR)-driven eCB release as well as 2) calcium-assisted mAChR-driven eCB 
mobilization. As such, CeAL excitatory terminals exhibit mechanistically distinct modes of eCB 
signaling mechanisms that may potentially support diverse synaptic functionalities. Lastly, in an 
effort to determine these putative functionalities, we assessed the effects of chronic stress on 
eCB signaling at glutamatergic CeAL synapses. These experimental approaches revealed that 
homotypic chronic restraint stress enhances 2-AG mobilization and CB1 receptor signaling at 
CeAL glutamatergic synapses. 
Collectively, these results suggest that the eCB machinery is present at CeAL 
glutamatergic terminals and functionally decreases the efficacy of CeAL excitatory drive through 
multiple signaling mechanisms. As such, the eCB system is well-positioned to modulate the 
overall excitatory balance of the CeAL microcircuitry and to decrease the pathological drive for 
CeAL-mediated physiological and behavioral outputs elicited by stress exposure. As such, eCB 
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signaling at CeAL excitatory synapses is a potential locus for eCB mediated regulation of 
physiological and behavioral adaptations to acute and repetitive stress exposure.  
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INTRODUCTION 
 
 
Introduction to Endogenous Cannabinoid System 
The Cannabis sativa plant has been used for centuries for its therapeutic and stress-attenuating 
properties. Its psychoactive actions such as mood alterations, memory and motor control 
impairments were later found to be mediated by Δ9-tetrahydrocannabinol (Δ9 THC), the major 
psychoactive component of cannabis (Adams and Martin, 1996; Gaoni and Mechoulam, 1971). 
Since then, a number of biological analogs of Δ9 THC have been synthesized and are collectively 
called cannabinoids, due to their cannabimimetic actions (Howlett, 1995).  
The Cannabinoid Type 1 Receptor is the Primary Cannabinoid Receptor in the CNS 
The discovery of Δ9 THC paved the way for the discovery of the two major cannabinoid 
receptors, CB1 and CB2 (Matsuda et al., 1990; Munro et al., 1993). Though Δ9 THC binds to 
both receptors, they have very different distribution patterns, with CB2 receptors shown to be 
mainly present in the periphery (Munro et al., 1993), although more recent studies have begun to 
reveal low levels of CB2 receptor expression in microglia and neuronal cells in several brain 
regions (Gong et al., 2006; Van Sickle et al., 2005). Of the two cannabinoid receptors,  CB1 
receptors are more abundant in the central nervous system (CNS) and global CB1 knockout mice 
(CB1
-/-
) as well as pharmacological inhibition of CB1 receptors have determined that CB1, as 
compared to the CB2, receptors are primarily responsible for the psychoactive actions of 
exogenous cannabinoids as well as the physiological effects of endogenous cannabinoids within 
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the CNS (Elphick and Egertova, 2001; Ledent et al., 1999). Additionally, CB1 receptors are one 
of the most common GPCRs in the CNS (Glass et al., 1997) which potentially explains the broad 
effects of CB1 activation on CNS-mediated functions. 
The Cannabinoid Type 1 Receptor Structure and Functional Signaling   
The CB1 receptor is a ~ 473 amino acid Gαi/o-coupled protein coupled receptor (GPCR) with 97-
99% homology between rodents and humans (Chakrabarti et al., 1995; Gerard et al., 1990). Once 
activated, presynaptically localized CB1 receptors trigger multiple signaling transduction 
pathways via the Gαi/o family of G proteins (Pertwee, 1997), which functions to activate 
mitogen-activated protein kinases, as well as inhibit adenylate cyclase and calcium influx, via 
inhibition of voltage gated Ca
2+
 channels. This results in the attenuation of neurotransmitter 
release, particularly at glutamate and GABAergic synapses (Kano et al., 2009a). Furthermore, 
CB1-Gαi/o activation also modulates a number of ion channels and enzymes in a cAMP-
dependent or –independent manner resulting in, for example, the activation of A-type and 
inwardly rectifying potassium channels (Mackie et al., 1995), as well as, the inhibition of N-and 
P/Q type calcium channels (Twitchell et al., 1997) and D- and M type potassium channels 
(Morishita et al., 1998; Schweitzer, 2000). As such, eCBs primarily regulate synaptic strength by 
attenuating neurotransmitter release (Betke et al., 2012; Freund et al., 2003). 
The characteristics of the CB1 receptor ligands, however, play a significant role in 
determining the signaling transduction mechanism recruited following CB1 receptor activation. 
Gαi/o-proteins interact with the C-terminus and/or 3
rd
 intracellular loop of the CB1 receptor 
(Mukhopadhyay et al., 2000; Nie and Lewis, 2001). However, distinct Gαi/o-protein types 
interact with specific regions of the CB1 receptor. For example, Gαi1 and Gαi2 interact with the 
3
rd
 intracellular loop of the CB1 receptor, while Gαi3 and Gαo interact only with the C-terminus 
3 
 
(Mukhopadhyay and Howlett, 2001). In light of this, orthosteric and allosteric ligand binding 
(e.g. classical or non-classical cannabinoids, etc.), activate different types of Gαi/o proteins, 
suggesting that multiple active conformations of the CB1 receptor exists each of which can be 
differentially stabilized by distinct ligands to facilitate disparate forms of CB- Gαi/o signaling 
(e.g. CB1–mediated, calcium independent vesicle release mechanisms) (Hudson et al., 2010a; 
Mukhopadhyay and Howlett, 2005). Adding to this ligand-directed functional selectivity there is 
evidence to suggest that: 1) activation of CB1 receptors also results in signaling via Gαs (Sugiura 
et al., 2002) and Gαq/11 proteins to activate adenylate cyclase and increase intracellular calcium 
concentrations [Ca
2+
]i (Lauckner et al., 2005) and 2) CB1 receptors may form heterodimers with 
several other receptors indicating that CB1 receptors not only exhibit ligand-directed but also 
heterodimer-directed functional selectivity. Collectively, CB1 receptor activation has the 
potential to recruit a diverse array of signaling pathways that may differentially underlie its 
actions at synapses within the CNS (Hudson et al., 2010).  
The Cannabinoid Type 1 Ligand Binding Sites   
Site-directed mutagenesis experiments reveal that the binding sites of cannabinoids are 
embedded in the transmembrane helices of the CB1 receptor (Song and Bonner, 1996). 
Additionally, NMR spectroscopy experiments have shown that cannabinoids laterally diffuses 
within one membrane leaflet and interact with a hydrophobic grove formed by the CB1 receptor 
helices 3 and 6 (Makriyannis et al., 2005; Tian et al., 2005). It has been proposed that the 
receptor exists as a homodimer in vivo (Wager-Miller et al., 2002) or, as mentioned in the 
previous paragraph, heterodimerize with  a number of other GPCRs such as the type 2 dopamine 
receptor (D2) (Kearn et al., 2005) or the orexin 1 receptor (Hilairet et al., 2003). In addition to 
interactions with other synaptic GPCRS broadening CB1 receptor synaptic functions, more 
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recent studies by Niehaus and co-workers (2007) have determined that CB1 receptor interactions 
with synaptically localized proteins, such as the CB1 receptor interacting protein (CRIP), can 
limit the constitutive activity of the CB1 receptor (Niehaus et al., 2007). Thus, mechanisms for 
increased diversity as well as increased regulation of CB1 receptor signaling exits at central 
synapses (Mackie, 2005).  
Distribution and Density of CB1 receptors at Central Synapses 
Subcellular analyses of CB1 expressing synapses within the CNS, have revealed that these 
receptors are preferentially targeted to presynaptic elements. As is observed in our study, this 
selective localization results in the dissociation between the regional distribution of CB1 mRNA 
and CB1 immunoreactivity particularly under conditions where CB1 receptors are predominantly 
expressed in projection neurons (Kawamura et al., 2006). Of additional note, CB1 receptors are 
largely condensed within the perisynaptic element on the synaptic side of the axolemma as 
compared to the synaptic and extrasynaptic axonal compartments (Kawamura et al., 2006; Nyilas 
et al., 2008). Thus, CB1 receptors are ideally positioned to bind endocannabinoids (eCBs) that 
are produced on the perisynaptic and extrasynaptic surface of dendritic shafts, cell bodies, and 
spines of the postsynaptic neuron (Katona et al., 2006b; Yoshida et al., 2006). Analyses of CB1 
receptor sub-cellular localization have also revealed that inhibitory synapses generally have a 
higher concentration of CB1 receptors relative to excitatory synapses, with the enrichment at 
inhibitory synapses varying dependent upon the brain region. For example, CB1 labeling on 
inhibitory synaptic elements are 30 times and 6 times higher for hippocampal CA1 pyramidal 
and cerebellar Purkinje cells, respectively, as compared to excitatory synapses on similar cell 
types in these regions (Kawamura et al., 2006; Uchigashima et al., 2007a).  
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General Features of CB1 Receptor mRNA within the Amygdala 
Expression studies have demonstrated that CB1 receptors are found in high concentrations in 
cortico-limbic brain regions responsible for emotional processing and the coordination of the 
stress response. Of particular interest for this study is CB1 receptor expression and subcellular 
localization within the amygdala. In the amygdala, in situ hybridization (ISH) studies have 
separated CB1-mRNA expressing neurons into low expressing and high expressing groups. High 
CB1 mRNA-expressing cells are largely found only within cortical-like structures of the 
amygdala, such as the BLA. On the other hand, low CB1-expressing cells are more evenly 
distributed and found within both the BLA and central amygdala (Berrendero et al., 1998; 
Berrendero et al., 1999; Chhatwal et al., 2005; Hermann and Lutz, 2005; Mailleux et al., 1992a; 
Mailleux et al., 1992b; Marsicano and Lutz, 1999; Matsuda et al., 1993; Matsuda et al., 1990; 
McLaughlin et al., 1994; Wang et al., 2003). As such, a large number of high and low-CB1 
mRNA expressing cells are found within the BLA, while low-expressing CB1 mRNA cells are 
found within the central amygdala (CeA) (Yoshida et al., 2011b).   
 Within the rodents CeA, CB1 mRNA expression has generally been described as lower, 
than that observed within the BLA, but yet still present (Chhatwal et al., 2005; Hermann and 
Lutz, 2005; Marsicano and Lutz, 1999; Matsuda et al., 1993; Yoshida et al., 2011b). 
Furthermore, these low levels of CeA CB1 mRNA is at levels comparable to other brain regions 
such as the global pallidus and the lateral hypothalamus (Hermann and Lutz, 2005). Though CB1 
mRNA expression appears to be low but present within the CeA, earlier studies have not 
addressed whether subregional differences in CB1 mRNA expression exist within subdivisions 
of the CeA.  
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CB1 Receptor Protein Expression within the Amygdala 
Using rodent models, immunohistochemical studies have also revealed high levels of CB1 
receptor protein expression within the amygdala (Egertova et al., 2003; Egertova and Elphick, 
2000; Eggan and Lewis, 2006; Katona et al., 2001; McDonald and Mascagni, 2001; Ong and 
Mackie, 1999; Patel et al., 2005b; Pettit et al., 1998; Tsou et al., 1998b). The first examinations 
of CB1 protein expression was carried out by Tsou and colleagues (1988) using an antibody 
directed against the CB1 receptor N-terminus which showed that CB1 receptor protein was 
found in both the BLA and CeA (Tsou et al., 1998b). A subsequent study by Katona and co-
workers (2001) utilized a CB1 receptor antibody directed against the C-terminus of the CB1 
receptor protein. In parallel with the CB1 mRNA studies discussed in the last paragraph, a high 
expression of CB1 receptor protein was found in the BLA while CB1 receptor protein expression 
remained below detection threshold in the CeA (Katona et al., 2001). Consistent with this below 
threshold CB1 immunoreactivity observed within the CeA, activation of the CB1 receptor using 
the CB1 receptor agonist, WIN 55,212-2, revealed a lack of CB1 receptor signaling on inhibitory 
synaptic transmission (Katona et al., 2001). Conversely, later experimental evidence presented 
by Roberto and colleagues (2008) as well as Kamprath and co-workers (2011) demonstrated the 
functional presence of CB1 receptors within the CeA (Kamprath et al., 2011; Roberto et al., 
2010a). Of particular note, Kamprath and co-workers (2008) also demonstrated that within the 
CeA, CB1 receptor protein is present but largely localized to the medial (CeAM), but not the 
lateral subdivision of the CeA (CeAL) (Kamprath et al., 2009)—suggesting that subregional 
differences in CB1 receptor protein expression may exist within this region. Given the 
conflicting evidence of CB1 receptor protein expression within the CeA, additional assessments 
of CB1 receptor expression and function are needed to conclusively characterize CeAL CB1 
receptors. 
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Introduction to Endocannabinoids 
Endocannabinoids are a class of bioactive lipids, produced by neurons and glia, that act as 
endogenous ligands of the cannabinoid receptors (Kano et al., 2009a). The first endocannabinoid 
was isolated from pig brain and was named N-arachidonoylethanolamide (AEA) or 
“anandamide” based on the Sanskrit word anada which means “bliss”. AEA was later found to 
be a partial agonist of the CB1 and CB2 receptors and present in the brain at concentrations of 
picomoles per gram of tissue (Sugiura et al., 2002). Subsequently, the other major 
endocannabinoid, 2-arachidonoylglycerol (2-AG), was isolated from canine gut and rat brain and 
found to be present at relatively higher concentrations (nanomoles per gram of tissue). Unlike 
AEA, 2-AG was also found to act as a full agonist at both the CB1 and CB2 receptors (Sugiura et 
al., 2006). Despite these differences, AEA and 2-AG share the lipophilicity of Δ9 THC and are 
both structurally similar given that they are arachidonate-derived neuroactive lipid signaling 
molecules (Hill et al., 2010c). Aside from these structural similarity, AEA is an N-
acylethanolamine (NAE) whilst 2-AG is a monoacylglycerol (MAG) and are, thus, regulated by 
distinct biosynthetic and metabolic pathways that will be discussed further in the subsequent 
section (Kano et al., 2009a).  
Other putative endocannabinoids include O-arachidonoylethanolamine (viodhamine) 
(Porter et al., 2002) and 2-arachidonoyl glycerol ether (noladin ether) (Hanus et al., 1993). The 
latter, noladin ether, was originally prepared as a metabolically stable analog of 2-AG but was 
later isolated from porcine brain by Mechoulam and co-workers (2001) (Hanus et al., 2001b) and 
found to bind to CB1 receptors with higher affinity than that observed at CB2 receptors. Later 
studies, however, have reported that noladin ether could not be detected in mammalian brain 
(Oka et al., 2003). Given these conflicting data as well as the paucity of information regarding 
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other putative endocannabinoids, it is not clear whether noladin ether or other putative 
endocannabinoids function as agonists at cannabinoid receptors within the CNS. 
Biosynthesis and Metabolism of Endocannabinoids 
In response to a variety of cellular stimuli, endocannabinoids and related bioactive lipid signaling 
molecules are postsynaptically generated from membrane phospholipids by specific hydrolase or 
a combination of acyltransferases and hydrolases. Unlike classical neurotransmitters, eCBs are 
not stored in vesicles, but are produced and released on demand at central synapses. Upon 
release, eCBs retrogradely activate presynaptic CB1 receptors which, in turn, inhibit 
neurotransmitter release through Gαi/o signaling pathways discussed earlier in the Introduction 
(Wilson and Nicoll, 2002). Significant experimental evidence suggests that the eCBs, AEA and 
2-AG, are recruited by distinct neuronal activity patterns and, once mobilized, appear to mediate 
the unique actions of the eCB system. Following receptor binding, these eCBs are degraded by 
hydrolases. In general, the synthesizing enzymes for AEA and 2-AG are tightly regulated and 
expressed at much lower levels than the degrading enzymes, thus enabling their on demand 
synthesis and fast metabolism (Valenti et al., 2004). Despite this similarity, however, AEA and 
2-AG have very distinct biosynthetic and metabolic pathways, with the latter taking place in 
disparate subcellular localizations with respect to the synapse (Nazzaro et al., 2012). Given these 
non-overlapping characteristics, it is therefore not surprising that AEA and 2-AG appear to play 
distinct roles in eCB-mediated functions within the CNS. Collectively, AEA and 2-AG are not 
merely redundant signaling molecules but perform different roles in eCB functionality in the 
CNS (Long et al., 2009d). 
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Biosynthesis of 2-AG 
2-arachidonoylglycerol (2-AG) is the primary eCB that mediates retrograde synaptic signaling at 
central synapses (Castillo et al., 2012). Numerous biochemical studies have revealed that 2-AG 
is post-synaptically synthesized by a number of pathways. The primary pathway for 2-AG 
synthesis is PLC-mediated hydrolysis of arachidonic acid containing phospholipids which, in 
turn, produces an arachidonyl-containing diacylglycerol (DAG). Thereafter, DAG is converted to 
2-AG by the actions of diacylglycerol lipase, a membrane associated enzyme that preferentially 
hydrolyzes DAG at the sn-1 position (Okazaki et al., 1981). During development, DAGL is 
localized to axon terminals (Brittis et al., 1996), whereas in adulthood, DAGL appears to be 
predominately localized in the axon terminals (Kano et al., 2009a). Early cloning experiments 
revealed that two closely related genes encode two forms of DAGL, DAGL and DAGLβ 
(Bisogno et al., 2003). Experimental over-expression of DAGLα (Bisogno et al., 2003) and 
pharmacological blockade or knockdown of endogenous DAGL α/β (Jung et al., 2005) suggest 
that DAGLα and/or DAGLβ  are the primary 2-AG synthetic enzymes. To determine the 
contributions of the two DAGL isoforms in 2-AG synthesis and retrograde signaling in the brain, 
Tanimura and colleagues (2010) generated rodent models of global DAGLα and DAGLβ loss. 
These experimental analyses revealed that DAGLα deficiency decreased total 2-AG levels and 
eCB-mediated retrograde signaling at central synapses while DAGLβ loss had no effect on these 
measures. Conversely, similar experimental analyses by Gao and co-worker (2010) showed that 
DAGLα reduces brain 2-AG levels by 80% while global DAGLβ loss reduced brain 2-AG levels 
by 50%. Despite this 50% loss of total 2-AG levels in DAGLβ knockout mice, retrograde eCB 
signaling was only impaired in DAGLα knockout mice. Collectively, these results suggest 
strongly suggest that DAGLα is the primary enzyme responsible for 2-AG production and 
retrograde suppression at central synapses.   
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Expression of DAGLα in the Amygdala 
Two studies have examined the expression of DAGL in the amygdala. Patel and co-workers 
(2009) demonstrated heterogeneity in DAGL expression within the amygdala. High levels were 
observed in the BLA and dLA, whereas much lower levels were observed in the vLA and BMA. 
Within the CeA, the CeAL had a higher expression of DAGLα as compared to the medial 
subdivision of the CeA (CeAM). A more recent study by Yoshida et al. (2011) demonstrated a 
similar pattern of DAGLα (Yoshida et al., 2011b). These studies showed that DAGLα protein is 
more heavily expressed in the BLA as compared to the CeA. Further examination of the BLA 
determined that DAGL protein in close apposition to CB1 expressing terminals and is clustered 
at invaginating inhibitory synapses on pyramidal cells within this region. Unlike the BLA, the 
CeA do not exhibit these unique nerve terminals despite having robust DAGL protein 
expression.   
2-AG Synthesis in the Central Synapses 
As mentioned in the previous paragraph, 2-AG can be produced by a number of DAGLα 
mediated biosynthetic pathways (see Figure 1). The first is a calcium-dependent mechanism, 
prototypically elicited by postsynaptic depolarization. This postsynaptic depolarization activates 
L-type calcium channels and enhances the conversion of diacylglycerol to 2-AG via the 
activation of DAGL (Ohno-Shosaku et al., 2005). This form of eCB-mediated retrograde 
suppression is otherwise known as Ca
2+
-dependent endocannabinoid release (Ca
2+
ER) or 
depolarization induced suppression of excitation or inhibition (DSE or DSI). The second and 
third forms of DAGL- mediated 2-AG synthesis are mediated by Gαq-protein-coupled receptor 
(GαqPCR) signaling. The second is a Gαq-protein-coupled receptor (GαqPCR) driven pathway 
mediated via the activation of PLCβ under basal intracellular calcium levels ([Ca2+]i). Under 
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basal [Ca
2+
]i, PLCβ activation increases DAG and  subsequently drives 2-AG synthesis via a 
DAGL-dependent process (Hashimotodani et al., 2007). This second form of DAGL- 
mediated 2-AG synthesis is otherwise known as basal receptor driven endocannabinoid release 
(basal RER). Finally, the third form of 2-AG mediated synthesis occurs as a result of increased 
PLCβ activity following increased [Ca2+]i (Hashimotodani et al., 2005). This leads to a 
combinatory mechanism whereby depolarization-induced calcium influx facilitates Gαq-receptor 
driven 2-AG release by enhancing PLCβ activity (Hashimotodani et al., 2005; Ohno-Shosaku et 
al., 2012). This third form of endocannabinoid mobilization is also referred to as Ca
2+
-assisted 
receptor driven endocannabinoid release (Ca
2+
-assisted RER) (Kano et al., 2009b).  
Termination of 2-AG Signaling At Central Synapses 
Significant experimental evidence shows that monoacylglycerol lipase (MAGL) is the primary 
enzyme that catalyzes the 2-AG hydrolysis in vivo (see Figure 1). MGL is a member of the serine 
hydrolase family that hydrolyzes 2-AG into arachidonic acid and glycerol (Dinh et al., 2002). 
Studies by the Cravatt group (2010) showed that MAGL accounts for 85% of 2-AG hydrolysis in 
vivo while additional work from this group and others have found that the remaining 15% of 2-
AG hydrolysis is catalyzed by the serine hydrolases, ABHD6 and ABHD12 (Blankman et al., 
2007; Schlosburg et al., 2010). 
 Earlier immunohistochemical studies, using an N-terminal antibody against the rodent 
MGL, revealed punctuate MAGL protein expression within the BLA, but much weaker MAGL 
expression within CeA (Gulyas et al., 2004b)—results that were later confirmed by work 
presented by the Watanabe group (2010). Furthermore, subcellular examinations of MAGL 
within the amygdala revealed that MAGL is localized presynaptically at a subset of axon 
terminals that form asymmetrical and symmetrical synapses within the BLA (Gulyas et al., 
12 
 
2004b). These experimental results are consistent with MAGL subcellular localization in other 
brain regions (Kano et al., 2009a). Despite subcellular analyses demonstrating MAGL expression 
at BLA synapses, similar analyses are lacking within the CeA. 
Biosynthesis of Anandamide: NAPE-PLD Dependent Pathway 
In contrast to 2-AG, the mechanisms regulating synaptic AEA synthesis are not well understood 
and has been shown to involve the activation of GαqPCRs (Chavez et al., 2010a; Grueter et al., 
2010a; Huang and Woolley, 2012) ) (see Figure 1). Currently, the canonical pathway for AEA 
biosynthesis is thought to be composed of two enzymatic reactions, collectively referred to as the 
‘transacylation-phosphodiesterase pathway’. The first step of this pathway involves the Ca2+ 
dependent- N-acyltransferase catalysis of N-arachidonoylphosphatidylethanolamine (NAPE) 
production, via the transfer of the sn-1 acyl group of glycerophospholipids to 
phosphotidylethanolamine (PE) (Di et al., 2005). Subsequent to its production, NAPE is 
hydrolyzed to AEA as well as phosphatidic acid in a reaction that is catalyzed by the enzyme, N-
acylphophatidylethanolamine-hydrolyzing phospholipase D (NAPE-PLD). As such, NAT and 
NAPE-PLD are considered to critical for AEA biosynthesis, with the latter demonstrating age-
dependent increases in activity and expression (Morishita et al., 2005), whilst the former exhibits 
the opposite trend (Moesgaard et al., 2000). Subsequent in vivo examinations of the role of 
NAPE-PLD in AEA synthesis have, however, produced inconsistent results. Work by Leung and 
co-workers (2006) showed that NAPE-PLD knockout mice are viable and do not exhibit any 
change in total brain AEA levels (Leung et al., 2006), suggesting that NAPE-independent AEA 
synthetic pathways exist in vivo. Arguing against this, however, is more recent work by the Ueda 
group which showed a greater than 60% decrease in brain AEA levels in their global NAPE-PLD 
knockout mice (Tsuboi et al., 2011). 
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Expression of NAPE-PLD in the CNS 
Analyses of NAPE-PLD presence within the brain reveal that NAPE-PLD mRNA and protein 
exhibit complementary patterns of expression (Egertova et al., 2008). NAPE-PLD is abundantly 
expressed in neuronal cell-types within hippocampus, with weaker expression observed in other 
brain regions such as amygdala. There, NAPE-PLD immunoreactivity is higher in the BLA as 
compared to the CeA (Egertova et al., 2008). Interestingly, this study also revealed that within 
the hippocampus, NAPE-PLD immunoreactivity is present in the granule cell bodies and axons. 
These results suggest that NAPE-PLD catalysis of AEA synthesis occurs presynaptically which 
is inconsistent the canonical postsynaptic locus of eCB synthesis. Consistent with these findings, 
analyses of NAPE-PLD localization by Nyilas and colleagues (2008) demonstrate that NAPE-
PLD is predominantly localized presynaptically on the smooth endoplasmic reticulum of the 
hippocampus. In contrast to these reports, work by Cristino and colleagues (2008) argue that 
NAPE-PLD is postsynaptic expressed within the hippocampus (Cristino et al., 2008) suggesting 
that NAPE-PLD may be localized pre-and postsynaptically in the CNS. In support of these 
findings, recent high resolution immunogold EM analyses demonstrate that NAPE-PLD is 
localized both pre- and post-synaptically in the ventromedial nucleus of the hypothalamus 
(VMH), with a preferential dendritic localization (Reguero et al., 2014). Collectively, these 
studies suggest that: 1) NAPE-PLD may facilitate AEA biosynthesis in both synaptic 
compartments and 2) NAPE-PLD mediated AEA-CB1 receptor signaling may occur in a 
retrograde and/or anterograde manner within the hippocampus and VMH. However, high 
resolution analyses of NAPE-PLD subcellular localization in other brain regions that also exhibit 
NAPE-PLD protein expression, such as the amygdala, will have to be undertaken to determine 
whether NAPE-PLD expression on both sides of the synapse is a generalizable theme in the 
CNS. 
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AEA Biosynthesis: NAPE-PLD Independent Pathways 
Though additional studies (e.g. pharmacological, etc.) will have to be undertaken to characterize 
the role of NAPE-PLD in global and regional AEA synthesis within the brain, NAPE-PLD 
knockout studies suggest that NAPE-dependent and –independent pathways for AEA exists in 
vivo. Indeed, more recent studies have suggested that NAPE-PLD independent AEA synthetic 
pathways exist in vivo (Ueda et al., 2005). These newly discovered multi-step pathways include: 
1) via N-acylated lysophospholipid, 2) members of the PLA/acyltransferase family, and 3) the 
collective action of PLC and protein phosphatase (Kano et al., 2009a; Ueda et al., 2013).  
Termination of AEA Synaptic Signaling at Central Synapses 
FAAH is a serine hydrolase that catalyzes the degradation of anandamide into arachidonic acid 
and ethanolamine (Cravatt et al., 1996) (see Figure 1). It is an important regulator of brain 
anandamide content (Cravatt et al., 2001a; Kathuria et al., 2003; Patel et al., 2005a) and is an 
emerging target for drug discovery for a variety of disease states such as stress-related 
psychiatric disorders (Cravatt and Lichtman, 2003; Kathuria et al., 2003; Lichtman et al., 2004; 
Patel et al., 2004). Initial ISH studies by Cravatt and co-workers (1997) revealed an intense 
hybridization signal within the amygdala specifically within the BLA complex, with a weaker 
signal observed in the CeA (Thomas et al., 1997). These studies were closely followed by 
immunohistochemical localization of FAAH within the central nervous system using a C-
terminal antibody (Tsou et al., 1998c). Within the BLA, FAAH immunoreactivity was described 
to be moderate to strong. Within the CeA, however, only a few cells were found to express 
cytoplasmic FAAH immunoreactivity―which is consistent with the expression of other 
components of the eCB system within this region. Similarly, Elphick and co-workers, using an 
antibody raised against amino acids 38-579 (Patricelli et al., 1998), describe FAAH 
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immunoreactivity within the somata of neurons throughout the BLA (Egertova et al., 2003; 
Egertova et al., 1998). Freund and co-workers, using this same antibody (Patricelli et al., 1998), 
and another generated against a native 6X-His tagged truncation of FAAH (Bracey et al., 2002), 
also published detailed light and EM descriptions of FAAH within the rat and mouse amygdala 
(Gulyas et al., 2004b). At the light microscopic level, strong cellular (cytoplasmic and proximal 
dendritic) and a granular/reticular neuropil staining was observed within the BLA. In the CeA, 
only faint and occasional neurons were FAAH immunoreactive in this study (Gulyas et al., 
2004b). 
Conclusion 
Given the effects of the Cannabis sativa plant on emotionality and stress responsivity, it is not 
surprising that CB1 receptors and other biosynthetic and metabolic components of the eCB 
system are expressed in the amygdala―a critical component of the cortico-limbic circuit that 
regulates emotionality (Hill et al., 2010c). Though these studies suggest that the BLA may act as 
an anatomical substrate for eCB-mediated regulation of emotionality, a number of questions 
remain unanswered. Two such questions include: 1) what is the subcellular localization of the 
eCB synthetic and metabolic machineries in other key subdivisions of the amygdala, such as the 
CeA, and 2) what is the functional consequence of the localization of eCB biosynthetic 
machinery at central synapses within subdivisions of the amygdala? In the remaining sections of 
the Introduction we will examine the role of the amygdala, with a focus on the CeA, in mediating 
the behavioral consequences of exogenous and endogenous cannabinoids.    
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Figure 1. Endocannabinoid Biosynthetic and Metabolic Pathways at Central Synapses. 
2-AG and AEA have distinct biosynthetic and metabolic pathways.( 1) Though both 
postsynaptically produced, 2-AG synthesis can be triggered by the activation of Gαq-PCR and/or 
depolarization-induced activation of voltage-dependent calcium channels. Relatively less is 
known about the biosynthetic pathway for AEA but recent studies reveal Gαq-mediated AEA 
synthetic pathways at central synapses.( 2) Once produced, both eCBs activate presynaptically 
localized CB1 receptors. (3) Thereafter, 2-AG and AEA are metabolized via hydrolysis which is 
catalyzed by two distinct enzymes that display disparate subcellular localizations. AA, 
arachidonic acid; EA, ethanolamine. 
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The Stress Response Represents an Adaptive Mechanism  
Building upon Claude Bernard’s concept of the “internal milieu”, French physiologist Walter 
Canon, described an organism’s homeostasis (derived from the Greek words for “the same”-
homeo and “standing”-stasis) as the net result of mechanisms that maintain stable conditions 
necessary for survival (Cannon, 1929). By describing homeostasis as a necessary means for 
survival, Cannon imbues this state with a sense of priority that all organisms must achieve 
(Ulrich-Lai and Herman, 2009). Of equal importance, Cannon also noted that homeostasis is a 
dynamic process where “changes [are] …automatically met by increased effectiveness of… 
factors that resist this change” (Cannon, 1932).  
In line with Cannon’s earlier work, Hungarian physiologist Hans Selye and colleagues 
performed seminal characterizations of the “factors that resist [homeostatic]…change” following 
challenges to or disruptions of homeostasis” (Selye, 1951). The resulting body of work led to the 
discovery that physical or psychological perturbations to homeostasis elicited by internal or 
external threats—otherwise known as stressors—evoke biological mechanisms to counter these 
disturbances and regain homeostasis. These challenges to homeostasis evoked what Selye 
described as a “General Adaptation Syndrome” (GAS) or stress response. Selye’s early work and 
subsequent experimental evidence in this field (Hill and McEwen, 2010; Ulrich-Lai and Herman, 
2009) has since characterized the stress response as an adaptive process, i.e. a collection of  
biological and/or behavioral change(s) mounted to counteract stressor-activated homeostatic 
perturbations with the goal of maintaining physiologic integrity  in the most demanding of 
circumstances (Herman, 2013; McEwen and Wingfield, 2003; Selye, 1951; Ulrich-Lai and 
Herman, 2009).  
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Response to Aversive Stimuli Is Composed of Three Stages 
As further described by Selye, adaptive processes are supported by three stages of the GAS (See 
Figure 2). The first, is the Alarm stage and is triggered by stressor-related cues that are conveyed 
to the brain by all primary sensory systems which, in turn, mobilizes the stress circuitry— an 
evolutionary conserved synergism of neuronal and neuroendocrine systems that support 
physiological and behavioral changes to appropriately cope with the real or perceived threat 
(Ulrich-Lai and Herman, 2009). At the apex of this rapidly activated stress circuitry is arousal of 
both the adrenomedullary arm of the autonomic nervous system (ANS) and the hypothalamic-
pituitary-adrenal (HPA) axis (Herman, 2013). 
Following this initial stress exposure, the body shifts into the second phase of the General 
Adaptation Syndrome known as the Resistance stage (Selye, 1951). This second stage consists of 
either of two possibilities: the stressor is quickly resolved and ongoing feedback processes are 
recruited to restore homeostatic balance; consequently the stress response is a short-term 
adaptation to the original threat. The alternate possibility manifests when the stressor persists, 
whether continuous or continual, resulting in the protracted recruitment of mechanisms to resist 
threat impact and maintain a state of arousal. One such mechanism is a learning and memory 
process engaged to refine the stress response to subsequent homeostatic challenges. This form of 
adaptation manifests as either habituation, decreased responsivity to highly predictable low-
intensity stimulus presentation, or sensitization, non-specific generalization of a highly aversive 
stimuli— both of which are largely controlled by cortico-limbic brain regions (Castellucci et al., 
1970; Kamprath and Wotjak, 2004) and dependent upon the severity and predictability of the 
stressor. Overall, such mechanisms maintain a persistent state of vigilance in response to 
continuous stress exposures (Herman, 2013). 
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However, the process of adaptation is costly. Chronic stress responses represent attempts 
at adaptation, but can constitute physiologic challenges themselves (Herman, 2013; Sterling and 
Edelmann, 1988). If the exposure to the stressor continues for a substantial time or increases in 
severity /unpredictability, the organism enters the third phase of the GAS, i.e. the exhaustion 
phase. During this period, adaptive processes earlier garnered to resist homeostatic changes 
begin to approach exhaustion (e.g. depletion of energy stores, etc.). Furthermore, continued 
efforts of ANS and HPA axis activation to cope with persistent stressor exposure become 
deleterious to the organism. For example, increased HPA axis activation can impair numerous 
bodily functions, enhance sympathetic drive leading to cardiovascular disease, and precipitate 
pathological changes within the neuronal circuitry that regulate emotional processing (Price and 
Drevets, 2010). Thus, the initially adaptive characteristics of the stress response become 
maladaptive, as biological and behavioral responses to stressors become counterproductive to the 
interests of the organism (Herman, 2013). Given these deleterious characteristics of chronic 
stress, it is not surprising that preclinical and human studies have shown that protracted exposure 
to stress is one of the underlying factors for the generation of stress-related psychiatric disorders, 
such as anxiety and post traumatic stress disorder (PTSD) (Hill et al., 2009d; McEwen, 2007; 
Rosenkranz et al., 2010; Taber and Hurley, 2009; Vyas et al., 2002). 
As will be discussed in this thesis, the endocannabinoid (eCB) system is strongly 
implicated in the three stages of the General Adaptation Syndrome and plays a critical role in 
regulating adaptive processes that attenuate the deleterious consequences of chronic stress 
exposure. As will be further discussed, significant evidence suggests that the eCB system’s stress 
attenuating properties results from its actions within the cortico-limbic stress circuitry that 
control the neuroendocrine, physiological, and behavioral components of the stress response. 
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Figure 2. The General Adaptation Syndrome. 
The General Adaptation Syndrome, originally described by Dr. Hans Selye (1951), consists of 
four consecutive stages: (1) Homeostasis, (2) Alarm, (3) Resistance, and (4) Exhaustion and 
describes the biological patterns triggered by stress exposure over time. Adapted from Han 
Seyle’s General Adaptation Syndrome and Diseases of Adaptation. 
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The Alarm Stage is Facilitated by the Initial Activation of the ANS and the HPA axis  
The central nervous system (CNS) is pivotal to the stress response as it perceives aversive 
stimuli and orchestrates appropriate physiological and behavioral responses to threat (Sanacora 
et al., 2012). Within the CNS, the autonomic nervous system (ANS) and the hypothalamic-
pituitary-adrenocortical (HPA) axis are the primary mechanisms for reinstating homeostasis in 
response to homeostatic challenges. The ANS provides the most immediate response to stressors, 
through its sympathetic and parasympathetic divisions, which incorporate opposing yet 
complementary functions to mediate rapid changes in physiological and behavioral states via 
neural innervations of end organs. First, the sympatho-adrenomedullary axis of the autonomic 
nervous system quickly, i.e. within seconds, change visceral functions (e.g. increased breathing, 
heart rate, etc.) via adrenergic mediated changes in respiratory and cardiovascular systems, 
thereby preparing the organisms to cope with the physiological challenge. Subsequently, the 
activation of the parasympathetic division of the ANS attenuates the activity of the sympatho-
adrenomedullary axis, resulting in a short-lived stress response (Ulrich-Lai and Herman, 2009). 
Activation of the (HPA) axis represents the principal neural regulation of the endocrine 
system and supplements the ANS’s rapid initiation and termination of the stress response. When 
faced with a stressor, activation of the HPA axis begins by the stimulation of the parvocellular 
neuroendocrine cells (PNCs) of the paraventricular nucleus (PVN) of the hypothalamus. These 
cells are the apex of the HPA axis and drive neuroendocrine responses to stress. This stimulation 
allows for the secretion of corticotropin releasing hormone (CRH) from parvocellular terminals 
of the PVN into the portal circulation of the median eminence. PNCs also send axonal 
projections to autonomic targets in the brainstem and spinal cord (Swanson and Kuypers, 1980; 
Ulrich-Lai and Herman, 2009) suggestive of additional co-ordination of neuroendocrine and 
autonomic output at the level of the hypothalamus. Once released, CRH bind to CRH receptors 
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expressed on corticotroph cells within the anterior pituitary to stimulate the synthesis and 
secretion of adrenocorticotropic hormone (ACTH). ACTH, in turn, initiates the synthesis and 
release of glucocorticoids (corticosterone in rodents and cortisol in humans) from the adrenal 
cortex directly into the peripheral circulation. This facilitates the coordination of brain and bodily 
functions, via the actions of the glucocorticoid receptors, geared towards coping with stress, 
recovery, and adaptation (Laryea et al., 2012) (Groeneweg et al., 2011; Roozendaal and 
McGaugh, 1996a, b; Roozendaal et al., 1996). 
Basal HPA Axis Activity 
Though the HPA axis is activated by exposure to imminent threat, this neuroendocrine system is 
also active under basal conditions and this, in tune, supports the homeostatic state of the 
organisms (Herman, 2013). Under basal conditions, the synthesis and release of glucocorticoids 
are also dynamically regulated by circadian cues (Biddie et al., 2012). The peak glucocorticoid 
secretion correlates with the anticipation of an organism’s active phase and is supported by an 
hourly ultradian rhythm of hormone secretion. This pulsivity of circulating glucocorticoid 
hormone secretion provides the basis of “continuous dynamic equilibrium” which is believed to 
be critical for optimizing the functional tone of numerous systems (Joels and Vreugdenhil, 1998) 
and maintaining an organism’s stress responsivity, i.e., the flexibility to respond to and recover 
from stress (Lightman and Conway-Campbell, 2010). As will be discussed later, changes in basal 
HPA activity act as an adaptive response to repetitive stress exposure (Hill et al., 2009b). 
Endocannabinoid Signaling Acts as Stress Buffer During the Alarm and Resistance Stages 
of Psychosocial Stress 
As mentioned above, significant evidence points to the endocannabinoid system (eCB) as a 
dynamic facilitator of adaptive processes in response to chronic stress exposure. Such evidence 
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include the critical role of the eCB system in decreasing protracted neuroendocrine, 
physiological, and behavioral responses elicited by persistent exposure to aversive stimuli 
(Haller et al., 2004b; Martin et al., 2002; Steiner et al., 2008c; Uriguen et al., 2004), as well as 
preclinical studies which demonstrate a negative correlation between acute cannabinoid 
consumption (via the Cannabis sativa plant, etc.) and stress responsiveness/ basal anxiety states 
in humans and rodents (Haller et al 2002; Green et al 2003). Collectively, these data demonstrate 
that the eCB system acts as an intrinsic stress buffering mechanism by both limiting the 
deleterious homeostatic changes elicited by the chronic recruitment of the stress response and 
facilitating positive neuroendocrine and behavioral adaptations (such as, increased vigilance and 
active stress coping behaviors) (Campolongo et al., 2009; Haller et al., 2004a; Herman, 2013; 
Marsicano et al., 2002). Though the stress regulating properties of the endocannabinoid system is 
well established, an outstanding question in this field is what are the neuroanatomical substrates 
of eCB stress attenuating actions? Given the ubiquitous distribution of the CB1 receptor in the 
cortico-limbic circuitry (Matsuda et al., 1990; Turner and Herkenham, 1991) as well as the 
regulatory effects of exogenous and endogenous cannabinoids on stress response mechanisms 
elicited by limbic pathways (Atkinson et al., 2010; Cota et al., 2007; Patel et al., 2004; Steiner et 
al., 2008a; Steiner et al., 2008b; Steiner et al., 2008c), most experimental interrogations have 
focused on the limbic system in an attempt to address this outstanding question. 
Stressor Type Influences the Neuroanatomical Regions Recruited by the Stress Response 
The stressor type significantly influences the repertoire of neural populations that perceive the 
stressor and engage in adaptive responses to stress (Joels and Baram, 2009). Physical and 
psychological threats to homeostasis recruit two distinct domains of stress activation. The first, 
i.e. physical stressors (e.g. blood loss, respiratory distress, or pain), represents a homeostatic 
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challenge that is recognized by somatic, visceral, or circumventricular sensory pathways and 
requires an immediate ‘systemic’ reaction that is triggered by reflexive mechanisms (Herman et 
al., 2003).  
The second, i.e. psychological stressors (e.g. immobilization or forced swim stress), 
recruits brain regions involved in higher order processing/ decision-making and represents 
responses mounted in anticipation of, rather than in reaction, to a homeostatic threat. This type of 
stress is generated by previous experiences (i.e. associative learning) or species-specific 
predispositions (e.g. the aversion to snakes in humans or the innate fear of fox feces odor in 
mice) and allows the organism to detect novel stimuli that predict sources of harm (Ohman and 
Mineka, 2001). When activated by threat, psychological stressors engage stress mediators in the 
cortico-limbic circuitry that subserve decision making (e.g. prefrontal cortex), learning and 
memory, and emotionality (e.g. amygdala).  
Though both type of stressors largely recruit different neuronal populations and brain 
regions, they are not entirely segregated systems as physical stressors may have a psychological 
facet and vice versa (Joels and Baram, 2009). Furthermore, the environment associated with a 
physical stressor can itself be conditioned, resulting in an anticipatory response when the 
conditioned physical stressor is next encountered (Herman et al., 2003). One limbic region that 
acts as an anatomical and functional convergence point for both systemic and psychological 
domains of stress activation, as well as a potential substrate for eCB system’s role in the stress 
response, is the amygdala. 
The Amygdala is a Key Player in the Adaptive Processes in Response to Physical and 
Psychological Stressors 
The amygdala supports the neural mechanisms underlying the emotional interpretation of and 
appropriate response to salient environmental stimuli (Davis, 1992; LeDoux, 1995; Sah et al., 
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2003; Weiskrantz, 1956). It accomplishes this through its connectivity with visceral, cortical, and 
subcortical circuits to orchestrate neuroendocrine, such as activation of the HPA axis, as well as 
autonomic and behavioral responses to aversive stimuli (Hill et al., 2010c). Though there appears 
to be inter-species differences in the size and organization of the amygdala, there are strong 
physiological similarities between human and rodent amygdala-mediated functionalities  
(Darwin, 1872; Davis, 1992; LaBar et al., 1998), particularly as it relates to defense actions and 
reactions to threat. In support of this, bilateral amygdala lesion studies in humans (Bechara et al., 
1995; Feinstein et al., 2011), primates (Mair et al., 1979) and rodents (LeDoux et al., 1990a; 
LeDoux et al., 1990b; Roozendaal et al., 1990) demonstrate  attenuated autonomic and 
behavioral stress responses to stimuli previously conditioned to be associated with a threatening 
stimuli. 
The Amygdala is Composed of Functionally Integrated Subnuclei 
The amygdala is a functionally integrated complex, subcortical to the medial temporal lobe, and 
consists of 13 anatomically and physiologically heterogeneous nuclei.  These nuclei evolved 
during different phylogenetical stages and possess distinct cytoarchitectural and neurochemical 
features, as well as specific patterns of connectivity (Berretta et al., 2005). Based on these 
characteristics, these nuclei can be broadly grouped as: frontotemporal (lateral, basal, and 
accessory basal nuclei), autonomic (central and medial nuclei), olfactory groups (main olfactory 
and accessory olfactory nuclei), and a separate set of nuclei that do not separate well with the 
other nuclei (intercalated cell masses and the amygdalo-hippocampal area) (Sah et al., 2003; 
Swanson and Petrovich, 1998). Of these nuclei, the lateral, basolateral and the central 
amygdalas’ integral role in the stress response have been investigated extensively and appear to 
represent an integrated unit in the processing of responses to emotionally relevant stimuli such as 
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environmental threats (Herman et al., 2003; LeDoux, 2003; Tye et al., 2011; Walker and Davis, 
2002a, b). 
Focal lesion, anatomical tracing, ontogenetic, and electrophysiological studies have 
revealed a unique functional and anatomical interconnectivity within the amygdala. Such studies 
have demonstrated that the lateral amygdala nuclei (LA) act as an early site of convergence for 
sensory-related information (LeDoux et al., 1990a; LeDoux et al., 1990b; Quirk et al., 1997) 
from a number of brain regions such as the thalamus and cortex. Following  exposure to a 
stressor, thalamic inputs rapidly deliver sensory information whereas cortical inputs convey 
delayed information from visual, auditory, or somatosensory cortices (LeDoux, 2000). As such, 
there are “multiple roads” of sensory processing recruited to initiate stress responses (LeDoux, 
1994, 1995). The LA, in turn, projects to the central amygdala (CeA) either directly or indirectly 
via the basolateral amygdala (BLA), another amygdala nuclei that receives strong inputs from 
sensory-related brain region and has garnered considerable attention as a stress-regulatory 
structure that, though the activation of GRs and the eCB system, facilitates stress-related cued 
learning and emotional memory (Bhatnagar et al., 2004; Roozendaal et al., 1997a; Roozendaal 
and McGaugh, 1996a). The CeA is considered the output nucleus of the amygdala and, as will be 
described later, lacks the intra-amygdala reciprocal connectivity characteristic of other amygdala 
nuclei, exhibits patterns that strongly implicate the CeA as a site of information integration, and 
mobilizes neuroendocrine, autonomic, and behavioral responses that support an organism’s 
adaptive responses to stress exposure.  
Amygdala Exhibits Subregional Stress Response Specialization  
Stress-induced amygdala activation is essential for responses to novel stressors and adaptation to 
persistent stressors (Kim and Jung, 2006)). However, there is a marked subregional 
27 
 
specialization of stress integrative functions within the amygdala.  The medial (MeA) and BLA 
appears to be preferentially activated, as measured by early gene expression changes as an index 
of neuronal activation, by psychological stressors (Cullinan et al., 1995; Dayas et al., 2001a; 
Dayas et al., 2001b; Patel et al., 2005c; Patel et al., 2005d). Conversely, the CeA exhibits a more 
complex activation profile, as similar early gene activation studies suggest that the CeA is not 
only stimulated by psychological stressors but by systemic stressors as well. Furthermore, it 
appears that the CeA is preferentially activated by systemic stressors as compared to 
psychogenic stressors (Cullinan et al., 1995; Ericsson et al., 1994; Xu et al., 1999); suggestive of 
the CeA’s role in the regulation of responses to a broad array of stress responses (Iwata et al., 
1987; LeDoux et al., 1988a; Roozendaal et al., 1990, 1991a, b) . 
Endocannabinoid Signaling in the Amygdala Modulates Endocrine Responses to Repetitive 
Homotypic Stressors  
As mentioned earlier in the Introduction, the endocannabinoid system exhibits dynamic 
responses to the changing climate of stress, thus it is well-suited to mediate adaptive mechanisms 
in response to persistent recruitment of the stress response. In vitro chronic corticosterone 
treatment or repetitive exposure to low aversive homotypic stress paradigms, such as restraint 
stress, results in the habituation of HPA axis activation (Hill et al., 2008a; Rademacher et al., 
2008; Wamsteeker et al., 2010) such that persistent stress exposure induces basal HPA 
hypersecretion and restraint-stress induced hyposecretion. Respectively, these changes increase 
vigilance (Kamprath et al., 2006b; Kamprath et al., 2009; Kamprath and Wotjak, 2004), yet 
decreases energy resources allotted to stressors that prior experience demonstrates as low-
aversive. Consistent with advantageous stress adaptations elicited following homotypic stress 
exposure, habituations in neuroendocrine responses are also accompanied by increases in active 
escape behaviors (Patel et al., 2005d). Subsequent experimental evidence revealed that these 
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advantageous adaptations in the HPA axis and stress-elicited behaviors are mediated by the eCB 
system (Patel et al., 2005c; Rossi et al., 2008b; Steiner et al., 2008a; Steiner et al., 2008b; Steiner 
et al., 2008c) (Haring et al., 2013). Furthermore, evidence presented by Hill and co-workers 
(2010b) demonstrate that dynamic changes in both eCB content and eCB signaling within the 
BLA underlies repetitive homotypic stress-induced adaptations of the HPA axis activation (Hill et 
al., 2010b). Collectively, this evidence strongly suggesting that eCB signaling within the 
amygdala is a key node in mediating the regulatory actions of the eCB system on the stress 
response. 
2-AG and AEA Signaling Plays Distinct Roles in Adaptations to Chronic Stress Exposure 
Chronic homotypic restraint stress exposure (CRS) progressively increases BLA 2-AG content 
and 2-AG mediated short- and long-term eCB synaptic plasticity at inhibitory BLA synapses. 
These changes are hypothesized to underlie the CRS-induced HPA axis hyposecretion (Hill et 
al., 2010c; Ostrander et al., 2006; Patel et al., 2009a) as activity dependent increases in 2-AG- 
mediated signaling may dampen the BLA-HPA circuitry. In support of this hypothesis, Hill and 
others (2009) demonstrate that intra-BLA infusions of the CB1 agonist, HU-210, attenuate 
repetitive stress-induced glucocorticoid release (Hill et al., 2009c). Furthermore, systemic 
increases in 2-AG levels are associated with decreased indices of stress-induced anxiety 
suggesting that CRS-induced cellular, synaptic and endocrine adaptations may be the functional 
consequence of increased BLA-2AG signaling (Patel et al., 2005c; Patel et al., 2005d; Steiner et 
al., 2008b; Steiner et al., 2008d). Consistent with increased CB1 signaling conferring  
advantageous adaptations in the stress response, experimental evidence from Campolongo and 
colleagues (2009) show that BLA infusions of the CB1 receptor agonist, WIN 55, 212-2, 
promotes enhanced memory consolidation which, as the authors argue, may support learning and 
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memory processes engaged to refine the stress response to repetitive homeostatic challenges. 
Collectively, these studies suggest that augmented 2-AG content and 2-AG signaling at central 
facilitates stress habituation in response to repetitive homotypic stress exposure (Campolongo et 
al., 2009). 
BLA-AEA Tonic Signaling Facilitates Tonic inhibition of Basal HPA Axis Activation  
AEA content within the BLA is also affected by chronic homotypic stress exposure but the 
pattern of AEA content change and, thus, its functional consequences are different than that of 2-
AG. Experimental evidence demonstrates that chronic homotypic stress paradigms rapidly 
decrease BLA-AEA content which most likely results from a progressive increase in amygdalar 
FAAH Vmax, the rate of FAAH-catalyzed reactions (Hill et al., 2013b; Rademacher et al., 2008). 
The functional consequence of decreased BLA-AEA content appears to be basal HPA axis 
hypersecretion (Hill et al., 2010c), as demonstrated by evidence generated by Hill and colleagues 
(2005) which show the attenuation of stress-induced corticosterone secretion following 
pharmacological inhibition of BLA-FAAH (Hill et al., 2009b). These experimental results 
support the function of BLA-AEA as a “HPA gatekeeper” (Hill et al., 2010b; Hill et al., 2009b; 
Patel et al., 2004) through tonic basal inhibition.   
These data also strongly suggest that CRS-induced decreases in BLA-AEA levels support 
the adaptive state of heightened vigilance at the neuroendocrine and behavioral levels (Hill et al., 
2010b; Hill et al., 2009c). In support of this, HPA axis activity and behavioral responsiveness are 
more enhanced by novel stressors following prior exposure to a chronic stress paradigm as 
compared to behaviorally naïve controls exposed to similar novel stressors (Bhatnagar et al., 
1998; Bhatnagar and Meaney, 1995; Hauger et al., 1990). Furthermore, following repetitive 
stress exposure, increased HPA axis secretion is observed during the rising phase of HPA axis 
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activity and this rise may further contribute to the observed facilitation of HPA secretion (Windle 
et al., 1998). As such, AEA mediated regulation of HPA axis activity may act as a potential 
mechanism by which eCBs attenuate stress responsivity. Overall, it appears that both 2-AG and 
AEA signaling in the amygdala allows an organism to increase its defensive responses to novel 
aversive stimuli, where the threat value is of an unknown magnitude, whilst decreasing it stress-
related responses to stimuli with threat of known magnitude (Bhatnagar et al., 2003). 
Repetitive exposure to homotypic stressors also results in neuroendocrine, physiological, 
and behavioral changes that rely on the activity of extra-BLA regions within cortico-limbic 
circuitry.  For example, chronic homotypic stressors elicit adaptations in autonomic (e.g. heart 
rate, and blood pressure increases) (Bartolomucci et al., 2003; Moore et al., 2001) and passive 
behavioral stress responses (decreased freezing/startle response)  (Bielajew et al., 2002; 
Kamprath et al., 2006a; Kamprath and Wotjak, 2004). As alluded to above, significant 
experimental evidence demonstrates that these components of the stress response are regulated 
by the eCB system (Hill et al., 2010b). Interestingly, significant evidence also strongly suggest 
that the central amygdala (CeA), an extra-BLA amygdalar region, plays a significant role in 
controlling similar neuroendocrine, physiological, and behavioral responses to aversive stimuli 
via its extensive afferent and efferent connections with other stress responsive brain regions 
which will be discussed in the next section. Given these qualities, the CeA may potentially be a 
critical site for eCB-mediated regulation of neuroendocrine, autonomic, and behavioral 
components of the stress response (Kamprath et al., 2011; LeDoux et al., 1988b). 
The Central Amygdala Regulates Physiological and Behavioral Components of Stress 
Responses  
Experimental evidence supports the role of the CeA as a key site for the integration of stress-
related information and the subsequent regulation of physiological and behavioral components of 
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the stress response. Both acute and chronic stress increases c-fos gene expression within the 
CeA, indicating that increased neuronal activity is recruited within this region following 
exposure to aversive stimuli (Bhatnagar and Dallman, 1998; Bhatnagar et al., 1998; Kollack-
Walker et al., 1997). Early studies demonstrate that these changes in CeA neuronal activity are 
the result of stress-induced adaptations of the intra-CeA circuitry as single-and multi-unit activity 
measurements of antidromically-identified CeA neurons, which project to cardiovascular 
regulatory nuclei in the medulla, decrease following repeated presentations of conditioned 
stimuli (Pascoe and Kapp, 1985). Furthermore, this decrease in CeA neuronal activity is 
paralleled by decreases in heart rate changes following repeated presentation of conditioned 
stimuli (Applegate et al., 1982; Pascoe and Kapp, 1985). As such, the CeA appears to be a 
critical anatomical region for regulating changes in stress responsivity following persistent 
exposure to stressors.  
Consistent with experience-dependent changes in CeA neuronal activity, experimental 
evidence points to the CeA as a key site for the regulation of physiological and autonomic 
responses to stress. Early pharmacological and lesion studies show that bilateral CeA 
inactivation significantly reduced ACTH and glucocorticoid secretion in response to aversive 
stimuli (Beaulieu et al., 1986; Van de Kar et al., 1991), decreased CRH secretion and medial 
eminence immunoreactivity following photic or acoustic stimulation (Feldman et al., 1994), 
impaired both catecholamine release (Roozendaal et al., 1990) and stress-induced heart rate 
changes (Roozendaal et al., 1991a, b), as well as inhibited startle and freezing behavioral 
responses following conditioned and unconditioned aversive stimuli exposure (Roozendaal et al., 
1990). Furthermore, electrical and chemical CeA stimulation elicits autonomic and behavioral 
responses that resemble unconditioned and conditioned responses to systemic and psychological 
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stressors (Ciocchi et al., 2010; Iwata et al., 1987; Li et al., 2013; Reis and Oliphant, 1964) while 
lesions of brain regions to which the CeA projects attenuate autonomic and behavioral responses 
previously elicited by aversive environmental stimuli (Iwata et al., 1986a; Iwata et al., 1986b; 
LeDoux et al., 1988a; van der Kooy et al., 1984). Collectively, these studies support the role of 
the CeA as an integral neurosubstrate that regulates the physiological and behavioral responses 
to aversive stimuli exposure. These diverse functions of the CeA are thought to be consequences 
of its extensive efferent pathways that innervate a number of brain regions implicated in the 
sympathetic, parasympathetic, neuroendocrine, and passive behavioral responses mobilized 
following exposure to aversive stimuli (Bouret et al., 2003; Jolkkonen et al., 2002; LeDoux et al., 
1988b). Although studies characterizing CeA synapses in efferent target circuitry are lacking 
(Penzo et al., 2014), extensive tracing and optogenetic studies have identified a number of CeA 
mono- and multi-synaptic efferent pathways to stress responsive brain regions and these are 
summarized below in Figure 3.  
The Central Amygdala is Largely Composed of Four Subdivision 
The central amygdala is largely composed of four subdivisions: the capsular (CeC), the lateral, 
the intermediate (CeI), collectively known as the lateral nucleus of the central amygdala (CeAL), 
and the medial subdivision (CeAM) (Cassell et al., 1999a; Jolkkonen and Pitkanen, 1998; 
McDonald, 1982a).  The principal (95%) neuronal type of the CeAL is GABAergic medium-
sized densely spinous neurons (MSNs). These MSNs are embryonically striatal in origin 
(Puelles, 2001; Swanson and Petrovich, 1998) and, thus, are morphologically similar to the 
medium spiny neurons (MSNs) of the striatum (Sun and Cassell, 1993). Electrophysiological 
properties of rodent CeAL neurons can be separated into two groups based on firing properties of 
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the cell: regular (RF) and late firing (LF) and each group represents 50% of the CeAL neuronal 
population (Dumont et al., 2002; Lopez de Armentia and Sah, 2004a). 
Unlike the CeAL, the CeAM demonstrate a different distribution of cell types as RF, LF, 
and low-threshold bursting (LTB) neurons exhibit an incidence of 27%, 2%, and 71%, 
respectively (Dumont et al., 2002; Lopez de Armentia and Sah, 2004a). Furthermore, the CeAM 
is largely composed of pyramiform (fusiform/spindle-shaped), sparsely spiny neurons similar to 
the principal neurons found in the ventral pallidum, with a smaller portion of cells appearing to 
be GABAergic (Haubensak et al., 2010; Sun and Cassell, 1993).  However, both rodent and 
primate CeAM display low GABA expression but a high expression of glutamate decarboxylase 
(GAD), the enzyme responsible for converting glutamate to GABA, which suggests that CeAM 
GABAergic neurons may be underestimated (Haubensak et al., 2010; Li et al., 2013; Pitkanen 
and Amaral, 1994; Sun and Cassell, 1993). These features, in addition to the intrinsic 
neurochemical characteristics and intra- and inter- connectivity of the CeAL and CeAM, suggest 
a complex architecture that closely parallels that of the multi-compartmentalized organization of 
the nucleus accumbens and the ventral pallidum (Cassell et al., 1999a).  
The CeAL-CeAM Circuitry Controls Central Amygdala Efferent Pathways 
The organization of the CeAL and CeAM circuitry closely parallels that of the striatal-pallidum 
complex. Similar to the striatum, anatomical and functional studies demonstrate that the CeAL 
exhibit inhibitory control, via locally targeted axon collaterals within the CeAL and a few long-
range projections to extra-CeA stress-responsive brain regions such as the bed nucleus of the 
stria terminalis (Cassell et al., 1986), midbrain periaqueductal gray (PAG) and the 
paraventricular nucleus of the thalamus (Padilla-Coreano et al., 2012; Sun and Cassell, 1993; 
Swanson and Petrovich, 1998). CeAL long-range projecting neurons innervate extra-CeA brain 
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region largely via non-overlapping neurons (Penzo et al., 2014) and act as additional avenues 
through which the CeAL participates in the autonomic, endocrine, and behavioral regulation of 
stress responses. Additionally, the CeAL also extensively innervates the CeAM and provides 
substantial tonic inhibitory control of CeAM neuronal activity (Jolkkonen and Pitkanen, 1998; 
Tye et al., 2011; Veinante et al., 2003). 
The CeAM is the Major Output Region of the CeAL 
In comparison, the CeAM does not exhibit reciprocal projections to the CeAL but, rather, has 
local axonal arborizations that participate in the CeAM intrinsic circuitry (Ciocchi et al., 2010; 
McDonald, 1982a). Furthermore, the CeAM also exhibits efferent pathways ( via the stria 
terminalis and ventral amygalofugal  pathway (Ciocchi et al., 2010; Delaney et al., 2007; 
Hopkins and Holstege, 1978) that innervate diencephalic, mesencephalic, medulallary regions 
within the central nervous system which form the anatomical substrate for the CeA-mediated 
modulation of autonomic, neuroendocrine, and behavioral responses  to stress exposure (Ciocchi 
et al., 2010; Viviani et al., 2011).  
Though synaptic contacts between CeA projection neurons and target regions have been 
less characterized, it is hypothesized that CeA axonal terminals make largely GABAergic 
contacts onto the dendrites and soma within regions of interest, as is demonstrated in the nucleus 
of the solitary tract (NTS) (Jolkkonen et al., 2002; Jolkkonen et al., 2001; Saha et al., 2000). 
Overall, this evidence indicates that the CeAL provides tonic inhibitory control of the CeA 
output circuitry and is, therefore, well-positioned to powerfully restrain the components of the 
stress response via signaling mechanisms such as the eCB system.   
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Figure 3. Schematic Representation of Known CeA Afferents and Efferent Pathways.  
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Aversive Stimuli Exposure Drives Synaptic Changes within the CeAL Microcircuitry  
Similar to the branching patterns found in the matrix of the striatum, Golgi staining studies 
demonstrate that CeAL MSNs can be divided, based on axonal collaboration, into two 
categories: neurons with extensive local collaterals but a relatively unbranched axon extending 
out of the CeAL and a second neuronal type with few local collaterals but extensive branching 
extending out of the CeAL (Cassell et al., 1999b). Recent in vivo single unit recordings in awake, 
behaving animals have also identified two distinct neuronal populations that display inverse 
directionality in synaptic plasticity following exposure to threat-conditioned stimuli. In response 
to conditioned aversive stimuli one subpopulation, the CeALon neurons, display rapid and 
persistent increases in neuronal activity whilst another subpopulation, CeALoff neurons, exhibit 
a delayed and persistent decrease in neuronal activity that results from feed-forward inhibition by 
locally targeting collaterals of CeALon neurons (Ciocchi et al 2010). Accompanying and more 
recent studies have genetically defined these functional neuronal populations as protein kinase C 
delta negative/somatostatin positive (i.e. CeALon /PKCδ-/SOM+) and protein kinase C delta 
positive/ somatostatin negative (CeALoff /PKCδ+/SOM-) neurons, respectively (Haubensak et 
al., 2010{Li, 2013 #3984). Work by Li and others (2013) have demonstrated that these disparate 
neuronal populations form a distinct CeAL-microcircuitry where aversive stimuli exposure 
differentially elicits persistent changes in the synaptic efficacy of excitatory neurotransmission 
onto both cell types (Li et al., 2013). These changes, as will be discussed in the subsequent 
section, drive distinct changes in the CeAL microcircuitry which, subsequently, modifies the 
expression of CeA-mediated stress-related functions (Gozzi et al., 2010).  
Parallel to these findings in the CeAL, work by Viviani and others have also 
demonstrated that a unique microcircuitry also exists within the CeAM (Viviani et al., 2011). 
Though relatively unexplored, there appears to be cytochemically and functionally distinct 
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neuronal populations within the CeAM that are targeted by non-overlapping CeAL neurons and, 
in turn, facilitate specific behavioral and physiological components of the stress response. 
Collectively, these data suggest that the CeAL-CeAM circuitry is a powerful locus in the 
regulation of autonomic, endocrine and behavioral responses to stress. 
CeAL Glutamatergic Inputs Drive CeA Function 
The lateral division of the central amygdala (CeAL) receives extensive intra-and inter-amygdala 
glutamatergic inputs carrying sensory information from all modalities. This information is 
relayed to the CeAL via the fast excitatory neurotransmission of α-amino-3-hydroxy-5-
methylisoazole-4-proprionic acid type glutamate receptors (AMPARs) (Li and Neugebauer, 
2004; Lopez de Armentia and Sah, 2003) and GluN2B containing N-methyl-D-aspartate 
(NMDA) receptors.  Intra-amygdala glutamatergic inputs arise from amygdala subnuclei such as 
the LA (Jolkkonen and Pitkanen, 1998; Li et al., 2013) and BLA (Delaney et al., 2007; Sarhan et 
al., 2005; Tye et al., 2011, regions heavily implicated in components of the stress response.  
Extra-amygdala regions conveying sensory- related information to the CeAL include brain stem 
inputs from the parabrachial nucleus ({Krukoff, 1993 #7920) which form asymmetrical 
perisomatic synapses onto CeAL dendritic shafts, spines, and soma (Dong et al., 2010), 2) the 
nucleus of the solitary tract (Batten et al., 2002), 3) hypothalamic inputs from ventromedial 
nucleus (Canteras et al., 1994), 3) thalamic inputs from paraventricular nucleus (Moga et al., 
1995; Turner and Herkenham, 1991; Vertes and Hoover, 2008), and 4) cortical brain regions 
such as the ventral entorhinal (McDonald and Mascagni, 1997), insula (Sun et al., 1994) 
infralimbic, and prelimbic cortices (McDonald et al., 1996). 
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Endocannabinoid Signaling in the CeAL: Potential Locus for eCB-Mediated Adaptive 
Mechanisms Following Chronic Stress Exposure 
Although detailed studies examining the subcellular location of the CB1 receptor were 
previously lacking, early expression studies observed CB1 receptor expression within the CeA 
(Cota, 2007a; Kamprath et al., 2011; Mailleux and Vanderhaeghen, 1992; Matsuda et al., 1990).  
Furthermore, systemic application of the CB1 receptor antagonist, SR141716, increased c-fos 
expression in the CeA of behaviorally naïve Winstar rats, which indicates that tonic CB1 
receptor activity dampens inter- or intra-CeA excitatory drive (Singh et al., 2004). More recent 
studies by Roberto and colleagues (2010) demonstrated that CeAM inhibitory synapses were 
persistently inhibited by tonic CB1 signaling. Collectively, these studies support the presence of 
functional CB1 receptors within the CeA (Roberto et al., 2010a). These described studies, 
however, contradict earlier studies by Katona and colleagues (2001) which found a lack of 
functional CB1 receptors, as interrogated by WIN 55212-2, at CeA inhibitory synapses. 
However, based on the data that I will discuss in my thesis, these discrepancies may be explained 
by potential differences in the CB1 sensitivity of inhibitory synapses within CeA. 
eCB-Mediated Synaptic Adaptations within the CeA and its Functional Role in CeA-
Mediated Stress Behavior 
The CeA exhibits experience-dependent modifications of eCB-mediated synaptic plasticity 
following exposure to aversive stimuli. For example, recent studies by Kamprath and colleagues 
(2011) reveal enhanced depolarization-induced suppression of BLA-CeAM as well as CeAL-
CeAM synapses (Kamprath et al., 2011) following exposure to aversive stimuli. To determine 
the functional relevance of experience-dependent adaptations of eCB-signaling within the CeAL, 
the authors infused the CB1 agonist, AM 251, within the CeA prior to exposure to the 
conditioned stimuli. The results from this experiment reveal that  inhibiting CB1 receptors within 
39 
 
the CeA increased the freezing response of mice during the initial exposure to the conditioned 
stimuli, suggesting that CeA-CB1 signaling gates short-term adaptations to aversive stimuli 
(Kamprath et al., 2011). In support of this conclusion, earlier studies by Zarrindast and co-
workers (2008) show that intra-CeA infusion of the CB1 agonist, ACPA, decreased measures of 
anxiety in rats as measured by elevated plus maze (Zarrindast et al., 2008). Collectively, these 
studies support the role of eCB signaling within the CeA as gating behavioral responses to 
aversive stimuli. However, with the exception of work by Kamprath and colleagues (2011), there 
remains a paucity of studies that have examined whether eCB signaling mechanisms within CeA 
microcircuitry, such as muscarinic receptor driven eCB synthesis observed in other stress 
responsive brain regions (Narushima et al., 2007b; Uchigashima et al., 2007c), underlie this 
functional interaction between the CeA and eCB system (Kamprath et al., 2011). 
The Cholinergic Synapse within the CNS 
Acetylcholine (ACh) is the first neurotransmitter to be discovered and primarily modulates  
synaptic transmission in the brain (Picciotto et al., 2012). ACh is synthesized in the nerve 
terminal from acetyl coenzyme A (acetyl-CoA), which is derived from pyruvate generated by 
glycolysis and choline, which is present within the plasma at a concentration of 10mM. Choline 
is transported from the plasma into the nerve terminal by a sodium dependent choline 
transporter. Once within the nerve terminal, the synthesis of ACh via acetyl-CoA and choline 
condensation is catalyzed by the cytosolic enzyme, choline acetyltransferase, (Fischer et al., 
2010a; Fischer et al., 2010b) and packaged into synaptic vesicles by the vesicular ACh 
transporter. Once released within the synapse, acetylcholine concentration rapidly increases 
50,000 fold in milliseconds. Subsequently, cholinergic signaling is rapidly terminated by the 
hydrolysis of ACh by acetylcholinesterase (AChE) (Nair et al., 1994), a serine hydrolase.  AChE 
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has a high catalytic activity (5000 molecules of ACh/AChE/second) and hydrolyzes ACh to 
acetate and choline, which, in turn, cycles back into the ACh biosynthetic pathway. 
Local and Projection Cholinergic Neurons Target Diverse Brain Regions 
ACh is targeted to different brain regions via local cholinergic interneurons (largely found within 
the striatum, nucleus accumbens, and neocortex of rodents and humans) or long-range projection 
neurons that innervate distal brain regions (Benagiano et al., 2003; Mesulam, 1995). Cholinergic 
projections neurons are organized into relatively discrete cell groups, Ch1-Ch6, which innervate 
distinct brain regions (Bubser et al., 2012). The basal forebrain cholinergic projection neurons 
(Ch1-Ch4) consist of synaptically interconnected groups of cells located within the medial 
septum, diagonal band of Broca, and the nucleus basalis of Meynert (NBM). Upon further 
examination, the NBM was found to constitute an aggregation of discontinuous islands of large 
multipolar cells, with extensive dendritic trees, and acts as the major source of ACh for the CeA 
(Bigl and Arendt, 1991; Schwaber et al., 1987). 
mAChRs Display Distinct Regional Distributions and Subcellular Localizations 
Acetylcholine exerts it physiological actions via the activation of a family of GPCRs known as 
muscarinic acetylcholine receptors (mAChRs).  mAChRs are members of the Family-A G-
protein coupled receptors (GPCRs) and consists of five subtypes, M1-M5 (numbered in the order 
of their discovery). These mAChR subtypes are expressed throughout the CNS, but each subtype 
exhibits different regional distributions and subcellular localizations throughout the brain 
(Bonner et al., 1987; Bonner et al., 1988; Levey, 1993; Levey et al., 1991b). Of the 5 subtypes, 
the M5 subtype has the lowest expression in the CNS and is expressed in select brain regions (the 
highest receptor density is found within the striatum: ~25fmol/mg) (Vilaro et al., 1990). On the 
other hand, the M1, M2, and M4 subtypes are the most abundant. Moreover M1/4 and M2 mAChRs 
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have opposite expression patterns with the M1/4 expression being the highest rostral brain regions 
and decreasing caudally while the M2 mAChR has the converse expression pattern (Wall et al., 
1992a, b) (Weiner et al., 1990). As such, M1/4 mAChRs are the most predominant mAChR in the 
cortex, striatum, and hippocampus and is largely thought to be localized postsynaptically. 
Conversely, M2 mAChRs are the most predominant mAChR in the thalamus, hypothalamus, 
cerebellum, and brainstem and are largely thought to be localized presynaptically (Levey, 1993; 
Levey et al., 1991a; Rouse et al., 1998).  
Pharmacology of Muscarinic Receptors 
All five muscarinic subtypes show high sequence homology among the amino acid residues, 
within transmembrane domains 3,5-7, which forms the orthosteric ACh-binding pocket. Greater 
sequence variability is observed at the N-and C-termini as well as the third intracellular loop 
which displays the largest sequence divergence and length and is often the target for subtype 
specific antibodies. As a consequence, M1-M5 mAChRs range from 460 to 589 amino acids 
(Bonner et al., 1987; Hulme et al., 2003a; Hulme et al., 2003b; Wess, 1996; Wess et al., 1996). 
Within the binding domain, a carboxylic acid group from a highly conserved aspartic acid 
residue in the third transmembrane domain of the mAChR provides the negative charge for 
binding to the positively charged ACh headgroup (Burgen, 1965; Hanin et al., 1966; Hulme, 
1990). A consequence of this high sequence homology, however, is that very few sub-type 
specific agonists and antagonists have been developed (Hulme et al., 2003a; Hulme et al., 
2003b). As such, most muscarinic agonists, such as Oxotremorine-M (Oxo-M), have similar 
affinities across subtypes (Kukkonen et al., 1996; Thomas et al., 2008) and, thus, have a broad 
array of in vivo side effects, one of the most notable being the SLUD syndrome (salivation, 
lacrimation, urination, defecation) following systemic Oxo-M application (Karanth et al., 2007). 
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 In addition to the acetylcholine orthosteric binding site, muscarinic receptor subtypes 
have a number of allosteric sites that can modulate agonist function (Digby et al., 2012). These 
mAChR allosteric binding sites are the targets of newly developed, subtype specific mAChR 
ligand such as the M1 specific agonist, VU0357017 (Digby et al., 2012). Furthermore, non-
selective mAChR antagonists ,such as Atropine, are being replaced by more selective antagonists 
such as Pirenzepine, a M1 preferring antagonist (Buckley et al., 1989; Wess et al., 1989) and 4-
diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP), a M3 preferring antagonist 
(Lambrecht et al., 1989). As their selectivity description suggests, none of the currently available 
muscarinic antagonists are highly selective with most compounds only exhibiting a 10-fold 
higher affinity for the mAChR subtypes for which they are most selective. 
mAChR Subtypes Couple to Distinct G-proteins 
The importance of mAChR subtype-specific pharmacological control is further highlighted by 
the diversity of signaling cascades recruited by mAChR activation. Based on sequence 
comparison and the biochemical consequences of mAChR activation, the M1-M5 mAChR 
subtypes can be divided into two functionally distinct groups. One group includes the M2 and M4 
receptors that selectively activate Gαi/o-type G proteins that negatively coupled to adenylate 
cyclase (Migeon and Nathanson, 1994; Migeon et al., 1994; Picciotto et al., 2012). The other 
group is composed of M1, M3, and M5 receptors which show selectivity for Gαq/11 G-proteins and 
diverse PLC-mediated second messenger signaling cascades implicated in eCB biosynthesis 
(Kano et al., 2009a).        
mAChRs Exhibit Dynamic G-protein Coupling in Response to Orthosteric Activation 
In addition to these mAChR-specific signaling cascades, evidence of orthosteric agonism-
induced changes in mAChR G-protein functional coupling has also been reported. Although 10-
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fold right shifted, M1/3 mAChRs have been shown to couple to Gαs signaling (Burford and 
Nahorski, 1996; Thomas et al., 2008) and Gαi/o coupled signaling (Akam et al., 2001; Thomas et 
al., 2008) which suggests that orthosteric agonism of mAChRs can recruit noncanonical  
downstream signaling pathways. For example, M1 mAChR stimulation has been shown to 
stimulate a pertussis-toxin sensitive component of M-current inhibition (Haley et al., 2000; 
Lechner et al., 2003), PKC/Ca
2+
-independent, Gαs-dependent signaling (Migeon et al., 1994), as 
well as M1/3 mAChR recruitment of  PLA2 signaling pathways. To further add to this 
complexity, though much of the literature has focused Gαq/11-PLC coupled signaling of M1/3 
mAChRs some in vitro experiments results suggest that brief high dose orthosteric activation of 
M1/3 mAChRs also induces PLD activity in a dose- (Sandmann and Wurtman, 1990) and time-
dependent manner which, over time, leads to PLD activity desensitization (~30 minutes) and the 
concomitant sensitization of PLC activity (McKenzie et al., 1992b; Schmidt et al., 1995b).  
Given this diversity in mAChRs’ functional coupling, dissimilar secondary signaling cascades 
and their respective effectors may be recruited following orthosteric mAChR activation. This 
promiscuous signal transduction following orthosteric receptor activation is also observed in 
other G-protein families such as the calcium receptor (Rey et al 2005), as well as, the A1 
adenosine receptor (Cordeaux et al., 2000) and represents additional diversity in GPCR 
signaling.  
Gαq-coupled mAChR activation and Endocannabinoid Signaling 
One signaling cascade recruited via the activation of mAChR is that which can elicit eCB 
biosynthesis. The Alger research group (2002) was the first to demonstrate that orthosteric 
agonism of mAChR activation dose-dependently enhances eCB release. Moreover, this synthesis 
and release was found to occur via a postsynaptic mechanism, as measured by two forms of 
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eCB-mediated synaptic plasticity: RER-Ca
2+
 assisted- and RER- eCB release at hippocampal 
inhibitory synapses (Kim et al., 2002b). In subsequent experiments by additional groups, 
mAChR-driven eCB mobilization was also identified in other brain regions (namely the striatum 
and periaqueductal gray) and determined to mediated via M1/3 mAChR signaling (Fukudome et 
al., 2004b; Ohno-Shosaku et al., 2003) and capable of mediating both in vitro AEA (van der Stelt 
et al., 2005) (Stella and Piomelli, 2001) and 2-AG synthesis (Edwards et al., 2006b) (Lau and 
Vaughan, 2008; Narushima et al., 2007a; Uchigashima et al., 2007a). Despite the collective 
evidence for mAChR-driven eCB production in a number of brain regions, two discrepancies 
have arisen: evidence for PLCβ/DAGL Ca2+-dependent and-independent forms of mAChR-eCB 
release within the striatum, cerebellum, and hippocampus. Though the underlying cause of this 
inconsistency is unknown, the lack of functional bias exhibited by orthosteric mAChR activation 
may be a potential reason(Hashimotodani et al., 2005) (Chiu and Castillo, 2008) (Uchigashima et 
al., 2007a). 
Muscarinic Receptor Signaling and Additional Retrograde Signaling 
Inconsistencies in eCB biosynthetic pathways recruited by mAChR activation may also be 
explained by the ability of mAChRs to recruit additional retrograde signaling pathways. 
Significant experimental evidence demonstrate that activation of mAChRs  also drive synthesis 
of the diffusible retrograde signal molecule, nitric oxide (NO) (Christopoulos and El-Fakahany, 
1999; Wang et al., 1994) and NO-mediated synaptic plasticity (Wotta et al., 1998) (Borda et al., 
1998; Makara et al., 2007). Interesting, a number of studies have also demonstrated that 
interactions between the NO and eCB systems can also attenuate synaptic transmission.  
In support of this, components of the nitric oxide synthetic pathway have been shown at CB1 
containing synapses and, similarly to Ca
2+
 and Ca
2+
-RER forms of eCB synthesis, synaptic NO 
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can be mobilized by increases in intracellular calcium (Crosby et al., 2011). Furthermore, NO as 
been shown to augment eCB mediated synaptic plasticity at both inhibitory and excitatory 
synapses within a number of brain regions such as the hypothalamus (Crosby et al., 2011) 
cerebellum (Safo and Regehr, 2005) striatum (Chepkova et al., 2009), and the hippocampus 
(Makara et al., 2007). Though the exact mechanism for this interaction is unknown, it has been 
determined that NO can act upstream (Makara et al., 2007) or downstream (Chepkova et al., 
2009; Safo and Regehr, 2005) of CB1 receptor signaling. Alternatively, NO can also directly 
regulate CB1 receptors and prevent agonist induced desensitization and internalization via the 
nitrosylation of GPCR kinases that mediate GPCR mediated internalization (Kokkola et al., 
2005; Whalen et al., 2007). Alternatively, NO can also modulate synaptic transmission, 
independent of CB1 receptors, via downstream cyclic guanosine monophosphate (cGMP)- 
mediated processes such as the activation of cGMP-dependent protein kinase G which modulates 
the transmitter release machinery (Lange et al., 2012). 
Muscarinic Receptor Signaling in the Central Amygdala 
Though cholinergic signaling at synapses within the lateral division of the central amygdala 
(CeAL) has yet to be examined, components of cholinergic system are expressed within this 
region. The CeAL receives strong cholinergic innervations from the nucleus basalis of Meynert, 
with the majority of VAChT-positive terminal fields forming perisomatic basket-like 
terminations around the soma of CeAL neurons (Heckers et al., 1994) (Schafer et al., 1998b). 
Furthermore, other cholinergic markers such as heavy ChAT and weaker AChE 
immunoreactivity are also present throughout the CeAL in non-human primates (Amaral and 
Bassett, 1989) and rodents (Saha et al., 2000) (Van der Zee and Keijser, 2011).  Pan-mAChR 
staining in the CeAL, using the M-35 mAChR antibody, also demonstrates robust mAChR 
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staining which overlaps strongly with GABAergic markers (overlap between mAChR and GAD 
is 94%) (Van der Zee and Keijser, 2011; van der Zee and Luiten, 1999. ). Additionally, subtype 
specific immunocytochemical analyses reveal that M1-M4 subtypes are robustly expressed within 
the CeAL, with M2/3/4 mAChRs displaying the greatest expression levels (Levey et al., 1993; 
Levey et al., 1991b).  
Potential for mAChR-eCB Mediated Synaptic Plasticity in the Lateral Division of the CeA 
and Its Functional Relevance 
Though yet to be explored, the presence of the cholinergic system within the CeAL alludes to the 
potential for mAChR-mediated synaptic plasticity within the CeAL circuitry. One such mAChR-
mediated synaptic plasticity is mAChR-eCB mobilization particularly given the high expression 
of PLCβ1 mRNA (Watanabe et al 1998), the potential expression of CB1 receptors within this 
region, (Matsuda et al., 1990) (Tsou et al., 1998a) (Cota, 2007b) as well as evidence of weak 
FAAH and MAGL expression (Gulyas et al., 2004a) (Yoshida et al., 2011b) within the CeAL. 
Given the critical role of the CeAL circuitry in controlling the physiological and behavioral 
responses to stress, a potential locus for this eCB-mediated effect on the stress response may lie 
at the glutamatergic synapses that drive CeAL synapses. Furthermore, given evidence of Gαq-
coupled  mAChR-mediated eCB mobilization in other brain regions (Edwards et al., 2006b; 
Kano et al., 2009a; Lau and Vaughan, 2008; Narushima et al., 2007a; Uchigashima et al., 
2007a), mAChR-eCB release at CeAL synapses may enhance eCB signaling under basal and  
even chronic stress conditions. In support of  the latter, acute immobilization and footshock 
stressors increase acetylcholine release in the prefrontal cortex and amygdala, suggesting that 
acute exposure to aversive stimuli facilitates stress-induced adaptive changes in cholinergic 
signaling (Mark et al., 1996). In additional support of stress-induced facilitation of amygdalar 
mAChR signaling, Gilad  and colleagues (1984 and 1985) also demonstrate that chronic stress 
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exposure results in adaptations in cholinergic terminals as measured by post-stress hippocampal 
synaptosomal preparations (Finkelstein et al., 1985; Gilad et al., 1985; Rabey et al., 1984). These 
experiments revealed that repetitive immobilization stress decreased cholinergic uptake while 
progressively increasing acetylcholine release. Taken together, these results suggest that stress 
exposure enhances cholinergic signaling which, in turn, act as the substrate through eCB 
synthesis is increased to buffer against adverse synaptic and subsequent physiological, 
autonomic, and behavioral changes elicited by chronic stress exposure.  
Conclusion 
The amygdala regulates the processing of autonomic, physiological, and behavioral reactions to 
aversive stimuli. Furthermore, compelling evidence in limbic brain regions such as the BLA, 
strongly implicates the eCB system in both the processing of the stress response, as well as 
neuroadaptations to chronic stress exposure. Interestingly, this eCB-mediated function remains 
largely unexplored in the CeA: the amygdala’s “output” structure that mediates the processing of 
stress-related behavior and whose activity strongly correlates with the symptomology of stress-
related psychiatric illnesses, such as post traumatic stress disorder. The CeA’s ability to 
orchestrate stress-related responses lie, in part, with CeAL glutamatergic inputs that bring 
sensory-related information from extra-CeAL stress-responsive brain regions.  
Given this critical role of excitatory CeAL afferents, it is likely that eCB-mediated 
modulation, at these terminals, significantly contributes to the eCB system’s role regulating 
stress responsivity.  In support of this, the CeAL is highly enriched with the Gαq/11-coupled 
mAChR which have been implicated in receptor-driven eCB production in other stress-
responsive brain regions. As such, the aim of my thesis work was is three-fold: 1) to explore the 
expression of the eCB system and  2) to examine mechanisms of eCB- mediated synaptic 
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plasticity at CeAL glutamatergic synapses, as well as 3) to determine whether eCB-mediated 
synaptic plasticity at CeAL glutamatergic synapses are affected by repetitive stress exposure. 
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CHAPTER II 
 
 
MATERIALS AND METHODS 
 
 
Animals  
Anatomical experiments, with the exception of the double immunofluorescence labeling (ICR 
mice, Harlan Indianapolis, IN), were carried out in wild type and CB1
-/-
 C57BL/6 mice. All 
electrophysiology experiments were performed using male ICR mice (Harlan, Indianapolis, IN) 
4-6 weeks old. Wild type, CB1
-/-
 , and FAAH
-/-
 mice, on the ICR background, were derived from 
heterozygote breeding pairs (kindly provided by Dr. C.J. Hillard, Medical College of Wisconsin, 
Milwaukee, WI). Mice were housed on a 12:12 light-dark cycle with food and water available ad 
libitum.  All studies were approved by the Vanderbilt University Institutional Animal Care and 
Use Committee as well as the Committee of the Scientific Ethics of Animal Research 
(22.1/4027/0033/2009). Furthermore, all studies were carried out in accordance with the National 
Institute of Health Guide for the Care and Use of Laboratory Animals, as well as the institutional 
guidelines of ethical code, and the Hungarian Act of Animal Care and Experimentation (1998. 
XXVIII. Section 243/1998). 
Restraint Stress Paradigm 
Mice were brought to the restraint room daily and subjected to 1 hour of restraint in modified 
50ml conical tubes, for 10 consecutive days between 0900-1100 hours. During restraint, mice 
were placed in a ventilated animal housing cabinet and immediately upon termination of the 
restrain stress, the mice were returned to their home cage and animal care facility housing room. 
Control mice were only handled during tail marking at the beginning of, and as needed 
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throughout, the 10 day stress paradigm. Following each stress episode, restraint tubes were 
washed thoroughly with soap and warm water, then rinsed with 70% ethanol. 
Drugs and Chemicals 
SR141716 (Rimonabant) was a gift from the National Institute on Mental Health Drug Supply 
Program. JZL 184 was also a gift from the National Institute on Drug Abuse Drug Supply 
Program. Oxotremorine-M (Oxo-M) and 4-DAMP were purchased from Tocris Bioscience 
(Ellisville, MO) while Pirenzepine dihydrochloride and Atropine were obtained from Sigma-
Aldrich (St. Louis, MO). PF-3845 was kindly provided by Dr. Douglas Johnson (Pfizer). 
Picrotoxin was purchased from Abcam Biochemicals (Cambridge, MA). All other drugs were 
acquired from Cayman Chemicals (Ann Arbor, MI). Drugs sparingly soluble in aqueous 
solutions were first dissolved with DMSO and, thereafter, diluted in artificial cerebral spinal 
fluid (ACSF). For experiments utilizing lipophilic drugs, the ACSF was supplemented with 
0.5g/L fatty acid-free bovine serum albumin (BSA; Sigma-Aldrich) to increase drug solubility 
and minimize nonspecific binding of lipophilic compounds. Equal amounts of DMSO and BSA 
were used in control solutions. 
Brain Slice Preparation  
Mice were anesthetized with isoflurane, then transcardially perfused with ice-cold high sucrose, 
low Na
+
-containing ACSF and sacrificed by decapitation. Following decapitation, the brain was 
removed and a 3mm coronal block of the amygdala was cut using an ice-chilled, coronal brain 
matrix. Thereafter, hemisected coronal slices (200-300µm) were made using a Leica VT1000S 
vibratome (Leica Microsystems, Bannockburn, IL) in a 1-4°C oxygenated (95% v/v O2, 5% v/v 
CO2) high sucrose, low Na
+ 
- containing ACSF comprised of (in mM): 208 sucrose, 2.5 KCl, 1.6 
NaH2PO4, 1 CaCl2∙2H2O, 4 MgCl2∙6H2O, 4 MgSO4∙7H2O, 26 NaHCO3, 1 ascorbate, 3 Na-
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pyruvate, and 20 glucose. Once cut, slices were transferred to a 32°C oxygenated recovery buffer 
composed of (in mM): 100 sucrose, 60 NaCl, 2.5 KCl, 1.4 NaH2PO4, 1.1 CaCl2∙2H2O, 3.2 
MgCl2∙6H2O, 2 MgSO4∙7H2O, 22 NaHCO3, 1 ascorbate, 3 Na-pyruvate, and 20 glucose for 20 
minutes followed by a minimum of 30 minutes in 24°C, oxygenated ACSF (in mM): 113 NaCl, 
2.5 KCl, 1.2 MgSO4∙7H2O, 1 NaH2PO4,2.5 , 2.5 CaCl2∙2H2O, 26 NaHCO3, 1 ascorbate, and 3 
Na-pyruvate, and 20 glucose. Thereafter, slices were placed in a submerged recording chamber 
where they were continuously perfused with oxygenated ACSF (30-32°C) at a flow rate of 2-3 
milliliters/minute. For all electrophysiology experiments, other than those examining 
GABAergic currents, the ACSF was supplemented with the GABAA receptor antagonist, 
pircotoxin (25-50μM), to isolate excitatory neurotransmission. To isolate eIPSCs, the ACSF was 
supplemented with AP-5 (50μM) and CNQX (20μM). 
Field Potential Recordings 
A bipolar stainless-steel stimulating electrode and a borosilicate glass recording electrode filled 
with ACSF were placed in the CeAL to elicit and record extracellular field responses (fEPSPs), 
respectively. fEPSPs were elicited at a rate of 0.05 Hz, with stimulation intensities ranging from 
~100-200µA and measured with a low resistance (2-3 MΩ) extracellular  electrode pulled with 
borosilicate glass on a Flaming-Brown Micropipette Puller (Sutter) and filled with ACSF. 
Stimulating electrode was placed medial to the recording electrode in the lateral division of the 
central amygdala (CeAL). Stable baseline fEPSPs were recorded for 20 min, followed by oxo-M 
(1µM) bath application for the indicated time period. For atropine + oxo-M (1µM) experiments, 
1µM atropine was bath applied prior to (~30 min) and during baseline acquisition, as well as 
during 1µM oxo-M application. For all experiments, the N1 was monitored online and 
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experiments that demonstrated a ≥ 20% change in N1 were discarded. Analyses measured the 
percent change of the N2, following drug application, relative to baseline. 
Whole-Cell Voltage-Clamp Recordings 
Whole-cell voltage-clamp recordings were performed on CeAL neurons easily identified visually 
by their medium-sized, spherical somata. Patch electrodes were pulled on a Flaming/Brown 
microelectrode puller (Sutter Instruments) and filled with solution containing (in mM): 120 K
+
-
gluconate, 4 NaCl, 10 HEPES, 20 KCl, 4 Mg-ATP, 0.3 Na-GTP, and 10 Na-phosphocreatine 
(pH 7.25-7.35, adjusted with KOH). For intracellular loading of the calcium chelator, BAPTA 
(Sigma-Aldrich), 20-40mM K
+
-gluconate was replaced with 20-40mM BAPTA sodium salt. For 
all experiments, access resistance (Ra) was monitored online and cells that demonstrated a >20% 
change in Ra were excluded from analysis. Additionally, a time period of ≥5 minutes, post 
break-in, was allowed for internal solution exchange and stabilization of membrane properties 
prior to initiation of experiments.  
Monosynaptic evoked excitatory postsynaptic currents (eEPSCs) were elicited via 
constant-current stimulation of local glutamatergic fibers via an ACSF-filled glass electrode 
placed ~100µm from the cell soma. All recordings were carried out at a holding potential of        
-70mV. eEPSC amplitudes were typically adjusted to 200-1200pA, with stimulation intensities 
ranging from 10-70µA.  For drug application studies, paired stimulations were elicited at a rate 
of 0.1Hz, with an interstimulus interval of 50ms, and six consecutive responses were averaged to 
generate one data point per minute. Following a five- six minute baseline, drugs of interest were 
bath applied. The magnitude of the drug effect was calculated as a percentage of averaged 
responses relative to baseline. Calculated paired-pulse ratios (PPRs) were defined as the ratio of 
the second eEPSC amplitude relative to that of the first. PPR changes in response to alterations 
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in presynaptic release probability and was compared before and after drug application or DSE 
induction. 
Induction and Quantification of DSE 
For DSE studies, responses were evoked with a single stimulation pulse delivered every 5 
seconds to generate a 50 sec- and 100 sec- epoch prior to and following DSE induction, 
respectively. To induce DSE, a depolarizing pulse (-70 to 0mV) was applied to the postsynaptic 
neuron for 2-10 seconds as specified by the experimental conditions. The maximum DSE was 
classified as the first eEPSC following the depolarizing pulse. Within each DSE trial, eEPSC 
amplitudes were normalized to the averaged baseline response and data from two DSE trials, per 
cell, were averaged for analyses.  
LTD Induction Protocol 
Stimulus induction of MP-CeAL LTD consisted of 1 seconds of 4-Hz alternating with 1 seconds 
of rest for 180 iterations (total protocol time of 6 minutes). Following LTD induction, eEPSPs 
recovered to a new baseline which was generally lower than that of the original.  
Chronic Stress Paradigm 
Daily, mice were brought into the restraint room and subjected to 1 hour of restraint in modified 
50 ml conical tubes for 10 consecutive days (between 0900-1100 hours). During the restraint 
period, mice were placed in a sound attenuating, ventilated animal housing cabinet. Upon 
termination of restraint, mice were placed in their home cage and returned to the animal care 
facility housing room. Control mice were left undisturbed in their home cages, except for tail 
marking at the beginning of the experiment. After each stress episode, plastic tubes were washed 
with soap and water, rinsed with 70% ethanol and left to air dry.  
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Statistical Analysis 
Statistical analyses were performed using GraphPad Prism 6.01. Statistical significance between 
the means of two independent groups was assessed using two-tailed paired or unpaired  t-test 
unless variance differed significantly (Bartlett’s test for equal variances),  in which case non-
parametric Mann-Whitney (U) tests were used. Statistical comparisons between two or more 
groups were performed using one or two-way analysis of variance (ANOVA). F and P values for 
ANOVA are provided above individual figures. Post hoc analyses were conducted by Dunnett’s 
or Sidak’s test as indicated in the text. F-test for equality of variances between two independent 
groups was also used as indicated in the text. Cumulative probability plots were analyzed by 
Kolmogorov-Smirnov (KS) test. Statistical significance is indicated as follows: *p<0.05, ** 
p<0.01, ***p<0.001, ****p<0.0001. Averaged data are presented as means ± S.E.M.   
Anatomical Experiments 
For in situ hybridization, immunoperoxidase labeling, and electron microscopic analyses 
anesthetized male C57BL/6 mice (n=12) were perfused transcardially with 100 ml of 4% 
paraformaldehyde dissolved in 0.1 M phosphate buffer (PB, pH: 7.4). After perfusion, the brain 
was removed from the skull, cut into blocks, and 50 µm thick coronal sections containing the 
amygdala were cut with a Leica Vibratome (Leica Microsystems, Weitzlar, Germany) and kept 
in washing buffer for further treatment. For confocal microscopy, male ICR mice (Harlan, 
Indianapolis, IN), 4 to 6 weeks old, were used. Mice were anesthetized using isoflurane and 
transcardially perfused with cold phosphate buffered solution (10ml) followed by ice-cold 20% 
formaldehyde. Brains were then removed, postfixed for 24 hours in the same fixative, and 
cryoprotected in 30% sucrose for 4 days. 40µm coronal sections of the amygdala were cut on a 
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cryostat (Leica, CM 3050 S) and stored in an anti-freeze solution (0.1M phosphate buffer, 
ethylene glycol, and sucrose), at -20°C, before fluorescent immunohistochemical staining. 
 Non-radioactive free-floating in situ hybridization was carried out following the protocol 
as previously described in detail (Peterfi et al., 2012). We prepared antisense and sense 
riboprobes against a 1170 base pair (bp) long section (from position 1967 to 3136 in the open 
reading frame) of mouse DAGLα coding sequence using the following primers: forward, 5’-TCA 
TGG AGG GGC TCA ATA AG; reverse, 5’-CTA GCG TGC CGA GAT GAC CA (Katona et 
al., 2006). The CB1 riboprobe was generated against a 738 bp long region of mouse CB1 coding 
sequence (from position 548 to 1285 in the open reading frame; forward primer, 5’-CTA ATC 
AAA GAC TGA GGT TA; reverse primer, 5’- CAC AGA GCC TCG GCA GAC GT). Free-
floating immunoperoxidase staining also followed the previously established protocol (Peterfi et 
al., 2012). The antibody (diluted 1:3000) against an internal segment of the DAGLα protein was 
described earlier (Katona et al., 2006a), and its specificity was recently confirmed in DAGLα 
knockout mouse forebrain sections (Ludanyi et al., 2011). The antibody (diluted 1:200) against 
the C-terminus of CB1 was previously described in (Fukudome et al., 2004a)) and its specificity 
has been confirmed in many studies, including the present one. The DAGL-α, MAP2, and M1 
immunohistochemistry presented in Figure 5F-H and Figure 5E were generated using the rabbit 
anti-DAGLα polyclonal antibody (1:500), the mouse anti-MAP2 monoclonal antibody obtained 
from Millipore (1:2000), and the rabbit anti-M1 receptor polyclonal antibody purchased from 
Alamone labs Ltd. (1:200).  Thenceforth, brain sections were washed in 3 changes of tris-
buffered saline (TBS), incubated in 10mM sodium citrate (pH=9; 80°C) for 30 minutes, followed 
by (3x10 min) TBS washes. Subsequently, slices were incubated in TBS+ (TBS supplemented 
with 4% horse serum and 0.2% Triton X-100) for 30 minutes and in primary antibody (room 
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temperature) overnight. The next day, slices were washed in TBS+ (3x10 min) and incubated 
with Alexa Fluor 546 donkey anti-rabbit IgG (Life Technologies, 1:1000) and DyLight 488 
donkey anti-mouse IgG (Jackson ImmunoResearch, 1:500) for 2.5 hours at room temperature. 
Stained slices were then washed using TBS (3x10 min), mounted unto slides with 0.15% gelatin 
solution, and imaged with a Zeiss LSM 710 confocal microscope. Images were analyzed with 
Zeiss LSM Image Browser software.  
For electron microscopic analyses, after development of the immunostaining, the sections 
were treated with 0.5% OsO4, dehydrated in an ascending series of ethanol and acetonitrile 
solutions, and finally embedded into Durcupan
TM
 ACM Fluka (Sigma). During dehydration, 
sections were also treated with 1% uranyl acetate in 70% ethanol for 20 minutes. After overnight 
incubation in Durcupan, the sections were mounted onto glass slides and coverslips were sealed 
by polymerization of Durcupan at 56 ºC for 48 hours. From sections embedded in Durcupan, 
areas of interest from the CeAL were re-embedded and re-sectioned for electron microscopy. 
Sections were collected on Formvar-coated single-slot grids, stained with lead citrate, and 
examined with a Hitachi 7100 electron microscope (Hitachi High-Technologies Corporation, 
Tokyo, Japan).  
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CHAPTER III 
 
 
EXAMINATION OF ENDOCANNABINOID SIGNALING ELEMENTS AT CeAL 
GLUTAMATERGIC SYNAPSE 
 
 
Introduction 
Endocannabinoids are a class of bioactive lipids produced by neurons and glia (Kano et al., 
2009a). 2-arachidonoylglycerol (2-AG) is thought to be the primary eCB that mediates 
retrograde synaptic signaling at central synapses (Castillo et al., 2012). 2-AG is post-synaptically 
synthesized by diacylglycerol lipase  (DAGL) via calcium- and Gαq-protein-coupled receptor 
(GαqPCR)-dependent mechanisms (Hashimotodani et al., 2007; Hashimotodani et al., 2005; 
Ohno-Shosaku et al., 2005; Ohno-Shosaku et al., 2012). In contrast to 2-AG, the mechanisms 
regulating synaptic anandamide (AEA) synthesis are not well understood, but can involve 
GαqPCR activation (Chavez et al., 2010a; Grueter et al., 2010a; Huang and Woolley, 2012). 
Once produced, 2-AG and AEA are primarily degraded by monoacylglycerol lipase and fatty 
acid amide hydrolase, respectively (Cravatt et al., 2001b; Dinh et al., 2002; Long et al., 2009b), 
both of which were previously demonstrated to exhibit weak expression patterns within the 
CeAL (Gulyas et al., 2004a; Yoshida et al., 2011b). This expression, albeit weak, alludes to the 
potential of eCB mediated signaling despite earlier studies demonstrating the lack of expression 
and CB1 receptor mediated signaling in this region (Kamprath et al., 2011; Katona et al., 2001). 
In this study, we address this discrepancy by utilizing new reagents to examine the expression of 
eCB signaling elements at CeAL glutamatergic synapses. Subsequently, we also examine 
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whether these signaling elements mediate eCB-mediated synaptic plasticity of CeAL 
glutamatergic neurotransmission. 
Results 
Localization of CB1 Receptors in the CeAL 
Although prior studies suggested a negligible role of eCBs in the modulation of CeA synaptic 
signaling (Katona et al., 2001), our in situ hybridization studies revealed a detectable CB1 
receptor (CB1) in situ signal within the CeAL and strong expression in the basolateral amygdala 
(BLA) of wild-type, but not CB1 knockout (KO; CB1
-/-
), mice (Figure 8A-C). The presence of 
CB1 mRNA in the majority of BLA neurons suggests that BLA-CeAL glutamatergic terminals 
may express CB1 protein (Figure 8C). If this were true, we would expect to see CB1 
immunoreactivity in the CeAL, in spite of its low CB1 in situ signal, as CB1 receptors are 
preferentially targeted to presynaptic elements (Fukudome et al., 2004b; Kawamura et al., 2006). 
To test this hypothesis, we employed a CB1 antibody previously used to localize CB1 receptors 
on excitatory terminals in other brain regions (Uchigashima et al., 2007c) (Yoshida et al., 
2011a). Using this antibody, CB1 receptors were detected at high levels in both the CeAL and 
CeAM of wild type, but not CB1
-/-
 mice (Figure 8D-F). Additionally, electron microscopic (EM) 
examinations revealed CB1 receptor expression in the majority of presynaptic boutons forming 
asymmetric synapses onto dendritic shafts and spines within the CeAL (Figure 8G1-2 and I). 
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Figure 4. CB1 Receptors are Present on Excitatory Terminals in the CeAL.  
(A) In situ hybridization reveals the presence of CB1 mRNA in both the CeA and the BLA of 
wild type mice. (B) The specificity of the riboprobe is confirmed by using CB1
-/-
 animals. (C) 
The very high levels of CB1 mRNA observed in a few scattered neurons in the BLA likely 
correspond to GABAergic interneurons. The vast majority of BLA neurons express moderate 
levels of CB1 mRNA. In contrast, CB1 mRNA expression in the CeA was only slightly above 
detection threshold. (D-E) Immunoperoxidase staining demonstrates the presence of the CB1 
protein in both the CeA and BLA, which was confirmed in our CB1
-/-
 samples. (F) Higher 
magnification light micrographs reveal the dense CB1 labeling in the neuropil throughout the 
CeAL. Asterisks depict CB1-immunonegative cell bodies, whereas CB1-immunopositive 
labeling appears as punctate staining indicating the compartmentalized distribution of the 
protein. (G1-G2) Serial electron micrographs illustrate the selective presynaptic accumulation of 
CB1 in boutons (b+), which form mainly asymmetric (flanked by black arrowheads) and 
sometimes symmetric (white arrowheads) synapses with dendrites (d) and spine heads (s). CB1 
staining remained under detection threshold in a few axon terminals (b-), which highlights 
quantitative differences in CB1 expression between terminal types innervating the CeAL.  (H-I) 
The anatomical nature of the synapse type is illustrated at higher magnification. Scale bars: A, B, 
D, E are 200 µm; C is 50 µm; F is 20 µm; G1, G2, H, I are 100 nm. 
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Localization of DAGLα Expression in the CeAL 
Considering that 2-AG is one of the primary ligands mediating eCB retrograde signaling at 
central synapses, we next examined the expression of the 2-AG synthesizing enzyme, DAGL, 
in the CeA. In situ hybridization confirmed the expression of DAGL mRNA in both the BLA 
and CeAL (Figure 5A-C). Subsequent immunohistochemical analyses, using an anti-DAGL 
antibody whose specificity in the forebrain has been confirmed in DAGL-/- mice (Ludanyi et 
al., 2011), uncovered punctate staining patterns throughout the CeAL (Figure 5D-E). 
Furthermore, double immunofluorescence labeling and subsequent confocal microscopy revealed 
DAGL-positive puncta in close apposition to and a few immunoreactive overlap with MAP2 
labeled dendritic shafts in the CeAL (Figure 5F-H). These results suggest that DAGLα is 
localized within and outside of dendrites either in pre- or postsynaptic compartments. To 
differentiate between these two possibilities, we performed immunoperoxidase labeling and 
utilized EM to visualize DAGL at the synaptic level. We found that DAGL was indeed 
localized postsynaptically in the majority of dendritic shafts and spine heads forming asymmetric 
synapses in the CeAL (Figure 5I-L). Taken together these data conclusively demonstrate the 
presence of eCB signaling elements at glutamatergic synapses in the CeAL. 
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Figure 5. DAGLα is a Postsynaptic Enzyme in the CeAL. 
(A-B) In situ hybridization demonstrates the expression of DAGLα mRNA in both the BLA and 
CeA. AS and S depicts experiments performed by antisense and sense riboprobes, respectively. 
(C) Expression of DAGLα mRNA is notably higher in the BLA compared to the CeA. (D) 
However, at the protein level there is less difference between the two regions. (E) High 
magnification of the boxed region in D reveals that granular DAGLα-immunoreactivity (labeled 
by arrows) is present in the neuropil among cell bodies. (F-H) Confocal immunofluorescence 
analysis shows that DAGLα-immunoreactivity (red puncta indicated by white arrows) outlines 
MAP2-positive dendritic profiles (green). Asterisks denote CeAL cell bodies. (I-L) Electron 
micrographs provide ample evidence for the postsynaptic localization of DAGLα. 
Immunoreactivity represented by the black diaminobenzidine (DAB) precipitate was often 
present in dendrites (d+) and spine heads (s+), but never in boutons (b). Black arrowheads 
indicate the edge of the asymmetric synapses. Black arrowheads highlight asymmetric synapses. 
Scale bars: A-B are 200 µm; C-D are 50 µm; E is 20 µm; F is 5µm; G-H are 2.5µm; I-L are 100 
nm. 
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CB1 Receptors Modulate Glutamate Release onto CeAL Neurons 
To determine the functional significance of CB1 receptor expression in the CeAL, we conducted 
whole-cell voltage-clamp electrophysiological recordings in the presence of saturating 
concentrations of the GABAA receptor antagonist, picrotoxin (25-50M), to isolate 
glutamatergic currents. Consistent with the localization of CB1 receptors on excitatory axon 
terminals in the CeAL, we found that activation of CB1 receptors with the cannabinoid agonist 
,CP55940 (5M), significantly depressed eEPSC amplitude to 52±4% of baseline in CeAL 
neurons from wild-type (WT) mice (WT 52.47±3.94% vs. CB1
-/-  
114±8%; t(8)=7.18, p<0.0001; 
Figure 6A-B). No significant effect on PPR was observed following 5M CP55940 application 
to WT or CB1
-/-
 cells (normalized PPR: WT 1.06±0.06 vs. CB1
-/-
 0.89±0.06; t(8)=2, p=0.08; 
Figure 6C). Additional analyses of spontaneous EPSCs (sEPSCs) revealed a selective effect of 
5M CP55940 to reduce sEPSC frequency (vehicle 4.35±0.92 Hz vs. CP55940 1.59±0.27 Hz; 
U=50.00, p=0.008).  
Although the selective effect of CP55940 on frequency, but not amplitude, of sEPSCs 
suggests a presynaptic locus of action, the lack of effect on PPR was surprising. Therefore, we 
evaluated the effects of 2-AG-ether, a metabolically stable analog of 2-AG (Laine et al., 2002), 
to better elucidate the mechanisms by which eCB signaling with an endogenous (Hanus et al., 
2001a), rather than a synthetic, agonist modulates glutamate release. Indeed, 50 M 2-AG-ether 
caused robust synaptic depression (baseline 100.3±1.2% vs. 2-AG-ether 49.1±9.5%; t(3)=6.13, 
p<0.01 by paired t-test; Figure 6G ) that was associated with a significant increase in PPR 
(t(3)=3.9, p<0.05 by paired t-test; Figure 6G inset). Collectively, these data indicate that CB1 
function to suppress glutamate release onto CeAL neurons.  
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Since CB1 receptors in other brain regions robustly modulate GABAergic transmission 
(Castillo et al., 2012; Kano et al., 2009a), we also tested the effects of CP55940 (5M) on 
GABAergic currents in the CeAL recorded in the presence of CNQX (20M) and AP-5 (50M). 
Generally consistent with our previous report (Katona et al., 2001), and our electron microscopic 
observation of only a few CeAL GABAergic terminals being CB1-positive (Figure 4G1-G2 and 
H), the effects on GABAergic transmission were small and inconsistent (baseline 100.0±0.0% 
vs. 76.19.3%; t(7)=2.6, p<0.05; Figure 6H). When compared to the effects of CP55940 (5M) 
on glutamatergic transmission (from CeAL cells depicted in Fig. 6B), CP55940-induced 
depression of GABAergic transmission showed a significantly greater variance compared to 
effects on glutamate release (F-test to compare variances, p<0.05; Figure 6I). These data suggest 
that the major role of CB1 signaling in the CeAL is to broadly regulate glutamatergic 
transmission, while synapse- or cell type-specific modulation of GABAergic transmission may 
also occur. 
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Figure 6. Activation of CB1 Receptors Modulate Glutamate Release in the CeAL. 
(A-C) CP55940 depresses eEPSC amplitude in WT but not CB1
-/-
 mice, but does not affect PPR. 
(D-F) CP55940 reduces sEPSC frequency (E) but not amplitude (F). (G) 2-AG-ether depresses 
eEPSC amplitude and increases PPR (inset). (H) CP55940 decreases eIPSC amplitude. (I) 
Comparison of CP55940 effects on eIPSC and eEPSC amplitude. *p<0.05, **p<0.01. 
Calibration scale bars in (A): 200pA, 25ms. Calibration scale bars for sEPSCs (D) at lower 
magnification (10pA, 100ms) and higher magnification (10pA, 20ms). All other scale bars: 
10ms, 100pA. Data presented as mean ± SEM.  
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Figure 6 continued (contd.). CeAL Glutamatergic Synapses Exhibit DSE. 
(J-L) Effects of postsynaptic depolarization on eEPSC amplitude; DSE in representative cell (J-
K), and summary data of DSE after 2, 5 or 10 seconds of postsynaptic depolarization relative to 
corresponding baseline (L). (M-N) Effects of SR141716 on DSE after 10- second depolarization. 
(O) Summary data showing effects of SR141716, CB1 deletion, THL, and intracellular BAPTA 
loading on DSE magnitude relative to control 10 second DSE. Control group in (O) represents 
the same data set as 10 second depolarization in (L). *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001. Numbers of tested cells are indicated in bars for this and subsequent figures. All 
scale bars: 10ms, 100pA. Data presented as mean ± SEM. Also see Figure 7. 
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Figure 7. Effects of intracellular BAPTA on baseline glutamatergic transmission in the 
CeAL, related to Figure 6. 
Intracellular BAPTA does not affect CeAL spontaneous excitatory postsynaptic current (sEPSC) 
(A) frequency or (B) amplitude. (Frequency: control 4.350.9 Hz vs. BAPTA 4.11.0 Hz, 
p>0.05; Figure 7A); (Amplitude: control 21.01.0 pA vs. BAPTA 25.12.6 pA, p>0.05; Figure 
7B). Statistical comparison performed using unpaired t-test. 
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Ca
2+
-Driven eCB Release in the CeAL 
We next examined whether CeAL glutamatergic synapses express depolarization-induced 
suppression of excitation (DSE), a Ca
2+
-DAGL-dependent form of 2-AG-mediated eCB 
retrograde signaling (Ohno-Shosaku et al., 2012). Two-way ANOVA revealed a significant 
effect of DSE (depolarization) and postsynaptic depolarization duration (Figure 6J-L) on eEPSC 
amplitude. Post-hoc Sidak’s analysis revealed depolarization of CeAL neurons from   -70 to 0 
mV resulted in a transient depression of eEPSC amplitude that was significantly different from 
corresponding baseline values after 5 (p<0.001) and 10 seconds (p<0.001) of postsynaptic 
depolarization. One-way ANOVA followed by Dunnett’s post hoc analysis revealed that CeAL 
10 second DSE was blocked by the CB1 receptor antagonist, SR141716 (control 77.65±2.06% 
vs. 5M SR141716 95.84±4.84%, p<0.001; Figure 6M-O) and absent in CB1-/- mice (CB1-/- 
102.5±3.84%, p<0.0001; Figure 6O). DSE was also blocked by the DAGL inhibitor THL (10M 
THL 91.20±2.13%, p<0.05; Figure 6O) and postsynaptic calcium chelation with 40mM BAPTA 
(BAPTA 92.07±1.46%, p<0.05; Figure 6O), indicating that Ca
2+
-driven short-term eCB 
mobilization at CeAL glutamatergic synapses is mediated by 2-AG activation of CB1 receptors. 
Intracellular loading of BAPTA alone did not affect frequency or amplitude of eEPSCs in CeAL 
neurons (control frequency 4.350.9 Hz vs. BAPTA 4.11.0 Hz, p>0.05; control amplitude 
21.01.0 pA vs. BAPTA 25.12.6, p>0.05; Figure 7).  
Discussion 
eCB Signaling Components are Present at CeAL Glutamatergic Synapses 
Our results demonstrate DAGLα and CB1 receptor are expressed and functional at CeAL 
glutamatergic synapses. DAGL protein expression is observed in the CeAL at both the mRNA 
and protein level, with ultrastructural studies demonstrating clear localization within 
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postsynaptic dendritic spine heads and dendritic shafts adjacent to asymmetric synapses. This 
localization of DAGLα to dendritic spine heads and shafts is consistent with earlier studies 
showing: 1) DAGLα present, but not forming perisomatic clustering, within the CeA (Yoshida et 
al., 2011b) and 2) a similar pattern of DAGLα synaptic localization at CB1-expressing excitatory 
terminals in other brain regions such as the hippocampus, cerebellum, and striatum 
(Uchigashima et al., 2007c; Yoshida et al., 2011b). 
In contrast to DAGLα, our high-resolution analyses showed CB1 localized to presynaptic 
terminals forming asymmetric synapses onto postsynaptic dendrites and dendritic spines (Kano 
et al., 2009b). Earlier expression studies demonstrate CB1 present within the CeA (Matsuda et 
al., 1990; Tsou et al., 1998a), yet later studies argued against CB1 receptor expression in this 
region (Kamprath et al., 2011; Katona et al., 2001). As such, we utilized an antibody previously 
used to detect CB1 expression at glutamatergic synapses to conclusively address this discrepancy 
(see (Katona et al., 2006a; Uchigashima et al., 2007b). These experimental results 
unambiguously demonstrate the presence of CB1 protein at excitatory CeAL terminals. 
We hypothesize that the lack of CB1 detection in earlier studies arose as a result of two 
reasons. The first is potential qualitative differences in CB1 characteristics at glutamatergic and 
GABAergic terminals that differently affect CB1 antigen recognition. Such differences may 
include differential masking by anchoring proteins such as CB1-receptor interacting protein 
(CRIP) (Niehaus et al., 2007) or distinct intracellular conformations that result in disparate levels 
of access to the CB1 antibody recognition site at the two terminals. In support of this hypothesis, 
antibodies that successfully detected CB1 receptor expression within the CeA targeted the N 
termini of CB1 (Matsuda et al., 1990; Tsou et al., 1998a) while antibodies that failed to detect 
CB1 expression above detection threshold where targeted to the C-termini, which is located 
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intracellularly (Kamprath et al., 2011; Katona et al., 2001). The antibody used in this study 
addresses this problem as it is a polyclonal antibody, thus it is a mixture of ~30 individual 
monoclonal IgGs which increases the probability of having IgGs that are able to recognize a 
broader scale of CB1 receptor conformations that perhaps include unique receptor conformations 
unique to glutamatergic terminals. If this hypothesis were true, CB1 expression on glutamatergic 
terminals of the CeAL would be above threshold using this as compared to previously utilized 
antibodies.  
Alternatively, quantitative differences in CB1 receptor expression in the CeAL may also 
underlie the lack of previous CB1 detection in this region. Immunohistological experiments in 
other brain regions have noted a difference of up to 30 fold on GABAergic terminals as 
compared to glutamatergic terminals (Kawamura et al., 2006). If this pattern of high CB1 density 
detection is true for all brain regions, CB1 levels at CeAL glutamatergic synapses may be below 
threshold in density and, thus, remained undetected by previously utilized antibodies. Given that 
we are able to successfully demonstrate CB1 expression at glutamatergic synapses, the CB1-
antibody used in this study likely has anti-CB1 IgGs in a high enough titer to be able to bind to 
the few CB1 that are expressed in this region. However, a final measurement of IgG 
concentrations, using spectrophotometry, for this and previously used CB1 antibodies would be 
needed to provide stronger support for this latter hypothesis. 
Functional CB1 Receptors are Present at CeAL Glutamatergic Synapses 
Consistent with the anatomical data, our additional analysis of eCB signaling also supports the 
presence of functional CB1 in the CeAL. We found that direct activation of CB1 reliably reduced 
eEPSC amplitude, while effects on GABAergic transmission were more variable. The greater 
CB1 sensitivity of glutamatergic as compared to GABAergic synapses is consistent with our 
70 
 
anatomical data, which shows less CB1 receptors expressed at inhibitory synapses. This data also 
explains the lack of CB1 sensitivity reported earlier (Katona et al., 2001) and is a potential 
mechanism for eCB signaling modulation of inhibitory signaling within the CeAL 
microcircuitry. 
This pattern of terminal bias in CB1 density and sensitivity, however, is inconsistent with 
that which is observed in other brain regions (Kano et al 2009). As alluded to earlier, CB1 
receptors display a higher density and greater CB1 sensitivity at inhibitory as compared to 
excitatory terminals in other regions of the amygdala (Yoshida et al 2011) and extra-amygdalar 
CB1-sensitive brain regions (Kano et al., 2009a). Utilizing a similar CB1 antibody (Fukudome et 
al., 2004b), these studies revealed CB1 receptor expression differences that ranges from 3-4 fold 
in striatum (Uchigashima et al., 2007c) to 30 fold in the hippocampus (Kawamura et al., 2006).  
Analogous to the terminal-differences in CB1 sensitivity found in our study, the difference in 
CB1 density in these brain regions corresponds with a similar disparity in the CB1 activation 
threshold for both terminal types (Tanimura et al., 2012; Tanimura et al., 2010). As such, the 
CeAL appears to be unique in its terminal preference for CB1 receptor density and sensitivity 
and, given the role of glutamatergic signaling in driving CeAL activity (Ciocchi et al., 2010), 
suggests that eCB signaling at CeAL glutamatergic terminals is positioned to strongly modulate 
central amygdala activation and, therefore, function. 
Potential Mechanisms for CB1 Mediated Synaptic Depression at CeAL Glutamatergic 
Synapses 
Consistent with a presynaptic locus of CB1 activity, 2-AG-ether and DSE both induce synaptic 
depression associated with an increase in PPR, i.e. paired pulse facilitation (PPF). This 
presynaptic locus of CB1 activity is further supported by changes in the frequency, but not 
amplitude, of sEPSCs following CP55940 (CP) bath application. However, in contrast to these 
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data, CP55940 application reduced evoked EPSCs (eEPSCs) without having an effect on PPR 
which suggests that CP-mediated inhibition of eEPSC does not occur through CB1-induced 
decreases in glutamate release probability. This result is surprising given our other data 
supporting a presynaptic locus of CB1 receptor activity in this region. Furthermore, previous 
studies have observed a presynaptic locus of CB1 agonist-mediated glutamatergic depression as 
indicated by CP-induced PPF in the extended amygdala (Puente et al., 2011a) and decreased 
coefficient of variation in the prefrontal cortex (Lafourcade et al., 2007). Traditionally, most 
experimental interrogations of exogenous CB1 agonist-mediated synaptic depression have 
utilized WIN 55212-2 (WIN), a member of the aminoalkylindole class of cannabinoid agonists 
(Howlett et al., 2002). These experiments have consistently demonstrated a presynaptic locus, 
via PPF, of CB1-inhibition of synaptic transmission (Kano et al., 2009a). As such, our CP 
mediated effects on CeAL eEPSCs is not consistent with our other data or with that of other CB1 
exogenous agonists application to eEPSCs in other brain regions.  
The inconsistency in CP-mediated effects on CeAL eEPSCs can be explained by the 
following possibilities. First, WIN 55212-2 and CP55940 are dissimilar structurally and generate 
different receptor conformations upon agonist binding (Georgieva et al., 2008), with WIN shown 
to interact with distinct residues than those targeted by classical, non-classical, and eicosanoid 
agonists (Shim and Howlett, 2006). These differences are thought to be one of the underlying 
reasons why WIN is the least restrictive of the cannabinoid agonists in its ability to activate all 
CB1-G protein subtypes (CB1-Gαi = CB1-Gαs > CB1-Gαq/11= CB1-Gαo). Conversely, CP 
demonstrates greater selectivity in CB1-G protein activation as it preferentially activates CB1-
Gαi signaling (Bonhaus et al., 1998; McIntosh et al., 2007) and thus was our agonist of choice. 
Therefore, CP55940 activation of CB1 may selectively target the synaptic release machinery 
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primarily via Gαi/o coupled mechanisms which, based on the WIN-induced pleiotropic CB1-G 
protein signaling, may manifest as a different manner of presynaptic inhibition than that 
observed with WIN or other CB1 agonists (Hudson et al., 2010b). 
One such mechanism, which serves as a second possibility for the observed 
inconsistencies, is Ca
2+
-independent attenuation of vesicle release. Though Gαi/o-coupled 
inhibition of synaptic release via Ca
2+
-dependent mechanisms, i.e. decreased [Ca
2+
]i, is well 
established (Kreitzer and Regehr, 2001) (Herlitze et al., 1996; Ohno-Shosaku et al., 2001; Wu 
and Saggau, 1995a), Ca
2+
-independent inhibition is also observed following the activation of 
Gαi/o-coupled GPCRs (Blackmer et al., 2001; Delaney et al., 2007; Silinsky, 1984). In vitro 
experiments demonstrate that this mechanism occurs via  βγ interactions with the C-terminus of 
the SNAP-25 protein which, in turn, occludes the synaptotagmin-SNAP25 interactions needed 
for calcium dependent vesicular release (Yoon et al., 2007; Zhao et al., 2010) following activity 
induced increases in [Ca
2+
]i. This alternative pathway explains receptor-mediated inhibition of 
spontaneous release events (mEPSCs) that occurs independently of evoked calcium entry in the 
peripheral and central nervous system (Silinsky, 1984; Stephens, 2009). Additionally, both Ca
2+
-
dependent and -independent forms of Gβγ signaling: 1) co-exist in the same terminal yet are 
recruited by different types of presynaptic receptors (Hamid et al., 2014) and 2) can be mobilized 
by the same GPCR localized in different brain regions (Cox et al., 2000; Wu and Saggau, 
1995b). Though the mechanisms underlying this diversity is not well understood, agonist-
induced functional selectivity of recruited effectors and regional differences in the expression of 
Gβγ subunits, respectively, are potential reasons underlying this diversity in Gαi/o-recruited Ca
2+
-
dependent and -independent vesicular release (Betke et al., 2014).  
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Likewise, noradrenergic-α2A receptor activation inhibit Ca
2+
 channels in sensory neurons 
(Dunlap and Fischbach, 1978), yet ex vivo examinations of noradrenergic-α2A receptors reveal a 
Gαi/o-coupled Gβγ/SNARE-mediated inhibition of vesicular release at CeAL excitatory terminals 
(Delaney et al., 2007). Given the lack of [Ca
2+
]i dependence on the inhibition of synaptic release, 
agonist-induced-Gβγ/SNARE interactions affected the number of presynaptic release sites (N), 
with no measurable effects of PPR. Given that these excitatory terminals are also recruited in our 
population of evoked EPSCs, the potential for CP-induced Gβγ/SNARE mediated synaptic 
inhibition, despite evidence of CP-Ca
2+ 
dependent mechanisms in other brain regions, potentially 
explains the lack of change in PPR.  
eCB Mobilization by CeAL Neurons Mediates Short-Term Synaptic Plasticity of Excitatory 
CeAL Synapses 
Consistent with our studies demonstrating eCB signaling elements at CeAL excitatory synapses 
and CB1 receptor-mediated depression of glutamatergic signaling, we found that CeAL neurons 
express prototypic 2-AG-mediated eCB signaling, i.e. DSE, mediated via a calcium-dependent, 
THL-sensitive, and CB1-dependent mechanism.  Congruent with the calcium dependency of 
eCB mobilization at central synapses (Kreitzer and Regehr, 2001), increasing CeAL postsynaptic 
depolarization time increases DSE magnitude as also observed at excitatory synapses within the 
striatum (Uchigashima et al., 2007c) and the BLA (Yoshida et al., 2011b). Though not 
significantly different from CB1
-/-
 conditions, BAPTA and THL DSE conditions exhibit non 
significant residual DSE which may reflect activity-induced residual DAGLα and Ca2+-
independent forms of CB1 receptor signaling (Azad et al., 2004). 
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Conclusion 
Collectively, these data support the well-established anatomical substrate for retrograde eCB 
signaling at central synapses (Katona and Freund, 2012). Furthermore, these studies adds to the 
previous demonstration of FAAH and MAGL expression in the CeAL (Gulyas et al., 2004a), 
recent demonstration of DSE in the CeAM (Kamprath et al., 2011), and tonic eCB release at 
CeAM GABAergic synapses (Roberto et al., 2010b). As discussed above, there are distinct 
differences in the density and non-classical agonist induced CB1 signaling that appear to be 
unique to the CeAL as compared to other regions that exhibit eCB mediated synaptic plasticity. 
As will be discussed in subsequent chapters, anomalous characteristics of CeAL eCB signaling 
emerges as a strong theme in our analysis of eCB mobilization mechanisms at CeAL 
glutamatergic synapses. 
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CHAPTER IV 
 
 
CeAL GLUTAMATERGIC SYNAPSES EXHIBIT SHORT-TERM PLASTICITY: ROLE 
OF MUSCARINIC RECEPTOR ACTIVATION 
 
 
Introduction 
In addition to Ca
2+
-dependent eCB-STD, pharmacological- and afferent stimulation-induced 
activation of Gαq/11-receptors also facilitate 2-AG and AEA-mediated synaptic plasticity (Kano et 
al., 2009a). These mechanisms of eCB-mediated synaptic modulations are known as: 1) calcium-
assisted receptor driven eCB release (Ca
2+
-RER) produced from the synergistic effect of 
depolarization induced [Ca
2+
]i elevation and Gαq/11-coupled receptor activation (Hashimotodani 
et al., 2005) as well as 2) Gαq/11-receptor-driven eCB release (RER) under basal Ca
2+
 conditions 
(Maejima et al., 2001)—both of which results in enhanced eCB production at central synapses 
via the mobilization of PLCβ  following Gαq/11-coupled receptor activation (Kano et al., 2009a).  
Of particular relevance to the CeAL is Gαq/11- coupled muscarinic receptors (mAChRs) 
given that the CeAL receives dense cholinergic inputs from the basal forebrain (Hecker and 
Mesulam, 1994) in addition to exhibiting high expression of Gαq/11- mAChRs, namely M1/M3 
muscarinic receptor subtypes (Levey, 1993; Roozendaal et al., 1997b; van der Zee et al., 1997) 
,as well as, other cholinergic synaptic components (Schafer et al., 1998a). As such, the substrate 
for Gαq/11–coupled mAChR mediated Ca
2+
-RER and RER are present within the CeAL. Indeed, 
other brain regions with similar expression patterns of cholinergic signaling components, such as 
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the hippocampus and striatum, exhibit mAChR-mediated enhanced eCB mobilization (Kim et 
al., 2002b; Narushima et al., 2007b; Uchigashima et al., 2007c). Furthermore, acute and chronic 
stress exposure enhances cholinergic signaling in limbic brain regions such as the hippocampus 
(Finkelstein et al., 1985; Gilad et al., 1987; Gonzalez and Pazos, 1992) and amygdala (Mark et 
al., 1996), thus increased cholinergic signaling in the CeAL may enhance eCB influence on 
CeAL functionality in the stress response.  
To determine whether mAChR-mediated forms of eCB mobilization takes place at CeAL 
glutamatergic synapses, we first examined whether Gαq/11-coupled mAChRs are expressed and 
functional in the CeAL. Subsequently, we determined whether mAChR activation can induce 
eCB mobilization in the form of Ca
2+
-assisted- and mAChR receptor-driven eCB release at 
CeAL glutamatergic synapses. 
Results 
Depolarization-dependent mACh-Receptor Driven eCB Release Occurs in the CeAL 
Following Prolonged mAChR Activation 
To determine whether activation of mAChRs drives eCB mobilization in the CeAL, we first 
sought to examine the functional effects of mAChR activation on CeAL glutamatergic 
transmission. Experimental results from CeAL field potential recordings (fEPSPs) demonstrated 
that bath application of the mAChR agonist, Oxo-M (1M), reduced the amplitude of fEPSPs to 
44.40±3.69% of baseline (baseline 100.90±1.18% vs. maximal Oxo-M-induced depression 
44.40±3.69%, p<0.0001 by paired t-test; Figure 8A), an effect that reversed following drug 
washout (baseline 100.90±1.18% vs. post Oxo-M washout 96.14±7.13%, p=0.79 by paired t-test; 
Figure 4A). To test whether this Oxo-M induced depression was mediated by mAChR activation, 
we bath applied 1M atropine, a non-selective mAChR antagonist, prior to and during Oxo-M 
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(1M) application. Atropine application completely blocked the effect of 1M Oxo-M on 
fEPSPs (baseline 100.3±0.79% vs. atropine+Oxo-M 96.47±4.38%, p=0.87 by paired t-test; 
Figure 8A). Using whole-cell recordings we found that Oxo-M caused robust depression of 
eEPSC amplitude, an effect reduced by the M1-preferring antagonist, pirenzepine (1M; 
p<0.0001) and eliminated by the M3-preferring antagonist 4-DAMP (500 nM, p<0.0001; Figure. 
8B). Oxo-M-induced synaptic depression was associated with a large increase in PPR, which 
was attenuated by pirenzepine (p<0.001) and blocked by 4-DAMP (p<0.0001; Figure 8C), 
suggesting Oxo-M induced synaptic depression is mediated by M1/M3 receptor activation and 
expressed presynaptically. Importantly, neither pirenzepine nor 4-DAMP exerted any effects on 
basal glutamatergic transmission when applied alone to control CeAL slices (Figure 9). 
Additionally, our immunofluorescence confocal microscopy data revealed a moderate expression 
of the M1 receptor subtype throughout the CeAL (Figure 8E1-E2). At high magnification, M1 
staining appears as tiny puncta closely apposed to, but not overlapping with, MAP2-positive 
dendrites and perikarya. Together, these data demonstrate the presence of functional M1/M3 
mAChRs in the CeAL.  
mAChR Activation Enhances CeAL DSE in a CB1 and M1/M3 Dependent Manner 
On account of M1/M3 mAChRs functionally present at CeAL glutamatergic synapses, we 
next evaluated the presence of mAChR-driven eCB release at excitatory synapses within the 
CeAL. It has been previously reported that DSE is effectively enhanced by the coincidental 
activation of Gαq/11-coupled receptors, such as M1/M3 receptors, via a mechanism involving Ca
2+ 
enhancement of PLCβ  activity (Hashimotodani et al., 2005; Kim et al., 2002a; Narushima et al., 
2006). Consistent with the presence of Ca
2+
-assisted Gαq/11-receptor driven eCB mobilization, 
our results revealed that pretreatment with Oxo-M (1M), for at least 30 minutes, significantly 
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enhanced 10s DSE as compared to DSE examined under control conditions (control DSE 
84.823.0% vs. Oxo-M DSE 60.72±5.76%; t(18)=4.1, p<0.001; Figure 8F and H). DSE under 
control and Oxo-M conditions were both associated with increases in PPR (p<0.05 and p<0.01 
respectively by paired t-test; Oxo-M DSE PPR is significantly greater than control DSE PPR 
p<0.05; Figure 8G). Thereafter, we investigated the concentration and postsynaptic 
depolarization-time dependency of oxo-M-mediated DSE enhancement. Two-way ANOVA 
revealed a significant effect of depolarization time (F(2,101)= 20.11, p<0.0001)  and oxo-M 
treatment (F(3,101)=6.87, p=0.0003; Figure 8H
1
) on CeAL DSE  
Since mAChR activation enhances CeAL DSE, we next investigated the mechanisms by 
which Oxo-M facilitated DSE enhancement of CeAL glutamatergic transmission. One-way 
ANOVA revealed that 1M Oxo-M-mediated DSE enhancement was attenuated in both CB1-/- 
CeAL cells (Oxo-M-WT 57.16±2.56% vs. Oxo-M-CB1
-/- 
87.03±3.77%, p<0.0001; Figure 8 I and 
L) and CeAL cells pretreated with 10M THL for at least 60 minutes (Oxo-M 57.16±2.56% vs. 
THL+ Oxo-M 86.08± 2.73%, p<0.0001; Figure 8I and L). These results suggest that the 
simultaneous activation of mAChRs and postsynaptic depolarization results in the facilitation of 
2-AG release at excitatory synapses within the CeAL. We next examined the muscarinic 
subtypes involved in the Oxo-M-mediated enhancement of depolarization-induced 2-AG release. 
Application of the M1- or the M3-preferring antagonists, 1μM pirenzepine or 500nM 4-DAMP 
respectively, significantly reduced the 1μM Oxo-M-dependent DSE enhancement (Oxo-M 
57.16%±2.56% vs. Oxo-M+pirenzepine 73.92±3.92%, p<0.01; Oxo-M 57.16±2.56% vs. Oxo-
M+4-DAMP 75.32±4.75%, p<0.01, Figure 8J-L). Collectively, these results suggest that both M1 
and M3 receptors play a role in the mAChR-mediated enhancement of CeAL DSE. Interestingly, 
in CB1
-/-
 mice and THL (10μM) pretreatment conditions, 10 second depolarization in the 
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presence of Oxo-M elicited a small residual DSE (CB1
-/-
 baseline 100.00.0% vs. Maximal DSE 
87.03±3.77%, THL baseline 100.0%±0.0% vs. Maximal DSE 86.08%±2.73%,  p<0.01 by paired 
t-test for each condition), suggesting possible CB1- and M1/M3- independent residual effects 
induced by depolarization in the presence of Oxo-M.  
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Figure 8. mAChRs Modulate Glutamate Release.  
(A) 1 M Oxo-M depresses fEPSP amplitude, which is blocked in the presence of atropine. (B) 
Oxo-M-induced eEPSC depression is blocked by pirenzepine and 4-DAMP pretreatment. (C) 
Oxo-M increases PPR, which is blocked by pirenzepine and 4-DAMP pretreatment. (D) 
Representative traces of Oxo-M-induced eEPSC depression under vehicle, pirenzepine and 4-
DAMP conditions. (E) Distribution of M1 receptor (red) and the dendritic marker MAP2 (green) 
in the CeAL at low magnification; higher magnification shows punctate M1 staining in close 
apposition to MAP2 positive dendritic shafts (arrows in inset) (E1; scale bar 100m, E2; bar 
5m, inset 7.5m). **p<0.01, ***p<0.001, ****p<0.0001. Scale bars: 10ms, 100pA. Data 
presented as mean ± SEM. Also see Figure 9.  
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 Figure 8 contd. mAChRs Activation Enhance CeAL DSE. 
(F) 1M Oxo-M enhances DSE induced by 10 second depolarization. (G) PPR is increased by 10 
second depolarization in both control and Oxo-M conditions. (H) Representative traces of 
control and Oxo-DSE. * p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. Scale bars: 10ms, 
100pA. Data presented as mean ± SEM.  
H
1
 
82 
 
           
 Figure 8 contd. mAChRs-DSE Enhancement is CB1-and M1/M3- Receptor Dependent.  
(I) DSE in the presence of OXO-M is attenuated by THL and in CB1
-/-
 mice. (J-K) Effects of 
pirenzepine and 4-DAMP on DSE in the presence of 1M Oxo-M; grey faded lines represent 
Oxo-M only DSE condition from (I) for visual comparison purposes. (L) Summary data of the 
effects of THL, CB1 deletion, pirenzepine, and 4-DAMP on 10 second DSE in the presence of 
Oxo-M. **p<0.01, ****p<0.0001. Data presented as mean ± SEM. Also see Figure 9. 
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Figure 9. mAChR antagonists do not affect baseline glutamatergic transmission during 
prolonged drug exposure, related to Figure 8. 
Neither pirenzepine nor 4-DAMP affect fEPSPs in the CeAL.  
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Prolonged mAChR Activation Drives Ca
2+
- and DAGL-Dependent eCB Release  
Given the presence of Ca
2+
-assisted eCB release at CeAL glutamatergic synapses, we next 
examined 
 
mAChR driven endocannabinoid mobilization in the absence of depolarization, i.e., 
receptor driven eCB release (RER). However, as alluded to earlier, one potential confound of 
Oxo-M’s use is CB1- and M1/M3- independent effects of Oxo-M resulting from its high affinity 
for the largely presynaptic Gαi/o mAChRs subtypes, i.e. M2/M4 receptors. To exclude the 
possibility of the CB1-independent component of Oxo-M potentially confounding our analysis, 
we selectively evaluated CB1-dependent synaptic effects of Oxo-M by examining the effects of 
CB1 inhibition in the absence and presence of Oxo-M. We reasoned that if prolonged mAChR 
activation induces tonic eCB release and activation of CB1 that subsequently depresses 
glutamatergic transmission, bath application of a CB1 receptor antagonist should progressively 
relieve this tonic eCB inhibition and cause an apparent synaptic potentiation. Thus, this 
experimental design would allow us to isolate eCB-CB1 mediated synaptic effects induced by 
prolonged mAChR activation.  
To do this we pretreated slices with 1M Oxo-M for ≥ 60 minutes and subsequently 
performed whole-cell patch clamp experiments where, after obtaining a stable baseline, we bath 
applied 5μM SR141716 in the continued presence of 1M Oxo-M (see Figure10A for 
experimental design). Consistent with our hypothesis, SR141716 (5μM) wash-on significantly 
increased eEPSC amplitude in slices pretreated with 1M Oxo-M relative to control (no Oxo-M) 
conditions (Figure10B-D). Maximal potentiation induced by SR141716 in the presence of 
continuous Oxo-M was 143.20±6.59% compared to 113.30±4.09% under control conditions 
(p<0.001; Figure10B-D). Interestingly, unlike eCB release following brief Oxo-M application, 
continuous mAChR activation appeared to promote eCB mobilization through a THL- and a 
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Ca
2+
-dependent mechanism as pretreatment with 10M THL or 20mM intracellular BAPTA 
completely abolished SR141716-induced synaptic potentiation (p<0.0001 for each condition; 
Figure10C-E). Maximal SR141716-induced enhancement after 10M THL pretreatment (vehicle 
113.30±4.09% vs. THL + Oxo-M 107.60±7.54%, p=0.88; Figure10C-D) or 20mM BAPTA 
postsynaptic loading (vehicle 113.30±4.09% vs. BAPTA+ Oxo-M 99.25±6.10%, p=0.34; 
Figure10C-D) was not significantly different from SR141716-induced synaptic potentiation 
under control (no Oxo-M) conditions.  
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Figure 10. Persistent mAChR Activity Drives Ca2+- and DAGL-Dependent eCB Release. 
(A) Diagram of experimental design. (B-C) Representative cells and group data showing that in 
the continuous presence of Oxo-M, SR141716 causes synaptic potentiation relative to vehicle 
conditions. (C) Co-incubation of THL and Oxo-M prevents SR141716-induced synaptic 
potentiation, as does intracellular BAPTA loading. (D) Summary data showing the effects of 
SR141716 under vehicle, Oxo-M, Oxo-M+THL, and Oxo-M+BAPTA pre-treatment conditions. 
(E) Representative traces of summary data in (D). ***p<0.001, ****p<0.0001. Scale bars: 10ms, 
100pA. Data presented as mean ± SEM. 
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Discussion 
Prolonged Activation of Gαq/11-coupled mAChRs Mobilizes 2-AG to Induce Short-Term 
Depression of CeAL Glutamatergic Transmission 
These experimental results reveal that mAChR activation facilitates eCB-mediated synaptic 
depression of CeAL excitatory neurotransmission. Though other brain regions exhibit mAChR-
LTD via postsynaptic mechanisms downstream of mAChR activation (Huang and Hsu, 2010; Jo 
et al., 2010; McCoy and McMahon, 2007), our initial experimental studies uncovered a 
reversible synaptic depression following mAChR agonism. These experimental results are 
consistent with parallel examinations of inhibitory synaptic transmission (Edwards et al., 2006b; 
Hashimotodani et al., 2005) within the hippocampus as well as this and earlier studies 
demonstrating the strong expression of Gαq/11-coupled mAChRs within the CeAL (Levey et al., 
1991b; Yoshida et al., 2011b). Our subsequent experimental results also determined that mAChR 
activation for ~ 30-60 minutes, which was previously determined to cause limited M1 mAChR 
internalization and down-regulation (Thomas et al., 2009), enhances 2-AG-mediated synaptic 
modulation in the form of Ca
2+
-assisted-RER and RER at CeAL glutamatergic synapses.  
Continuous M1/M3 mAChR Activation Enhances CeAL DSE via Increased 2-AG Synthesis 
As similarly observed at striatal inhibitory synapses following the activation of Gαq/11-coupled 
mGluRs (Uchigashima et al., 2007c), examinations of Ca
2+
-RER under conditions of continuous 
mAChR activation reveals a concentration and depolarization-time dependency of CeAL DSE 
enhancement. Also consistent with other brain regions (Kano et al., 2009a), this mAChR-
enhancement of DSE is THL-sensitive, as well as M1/M3- and CB1-dependent, thus implicating 
2-AG as the eCB mobilized following prolong mAChR activation.  
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eCB-independent From of Synaptic Depression Present at CeAL Excitatory Synapses 
Under these experimental conditions, postsynaptic depolarization also generates a statistically 
significant THL insensitive, CB1- and M1/M3- independent depression of CeAL glutamatergic 
synapses potentially a consequence of depolarization induced phasic nitric oxide (NO) synthesis 
as is also observed in the hippocampus following DSE induction subsequent to mAChR 
activation (Makara et al., 2007). Through the mAChR subtype(s) involved in that study remain 
uncharacterized, previous studies have noted that M2/M4 mAChRs, also found postsynaptically 
at striatal dendritic shafts and spines (Hersch et al., 1994), couple to the activation of nitric oxide 
synthase (Waid et al., 2000; Wang et al., 1997), the biosynthetic enzyme of NO (Garthwaite and 
Boulton, 1995). Of further note, both M2/M4 mAChRs and neuronal nitric oxide synthase are 
strongly and weakly (respectively) expressed in the CeAL (Lange et al., 2012; Levey, 1993), 
thus the biosynthetic substrates for mAChR-NO synthesis and downstream modulation of 
synaptic transmission is present within the CeAL and may have been recruited under our 
experimental conditions. 
Prolonged mAChR Activation Induces a DAGL- and Ca
2+
 Mediated eCB Release at CeAL 
Glutamatergic Synapses 
In accordance with enhanced phasic 2-AG mobilization following prolonged mAChR activation, 
continuous mAChR activation (≥ 60 minutes) also enhanced tonic 2-AG release at CeAL 
glutamatergic synapses. Under these experimental conditions, our SR141716 wash-on studies 
revealed strong synaptic potentiation following CB1 blockade in slices incubated with Oxo-M, 
as compared to vehicle pretreatment conditions. This synaptic potentiation required intracellular 
calcium and was THL-sensitive, strongly suggesting that this Oxo-M-induced tonic eCB signal is 
mediated by 2-AG synthesized by the canonical calcium-DAGL-dependent pathway (Kano et al., 
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2009a). These findings are consistent with recent studies in MAGL knock-out mice, which 
suggest that 2-AG can act as a tonic eCB retrograde messenger (Pan et al., 2011).  
Mechanisms underlying mAChR-driven 2-AG Synthesis at CeAL Glutamatergic Synapses 
Collectively, these data argue that prolonged mAChR activation mobilizes 2-AG to modulate 
afferent glutamatergic transmission within the CeAL. In light of this study and previous 
examinations of Gαq/11-coupled eCB mobilization at central synapses (Hashimotodani et al., 
2005; Jung et al., 2012; Tanimura et al., 2010), it appears that M1/M3 mAChR activation results 
in the sequential recruitment of PLCβ, which produces DAG, and DAGLα ,which converts DAG 
to 2-AG, thereby facilitating eCB mediated retrograde suppression of excitation in this region. 
Our morphological studies described in Chapter 3 have shown that DAGLα is present at 
asymmetric synapses within the CeAL while earlier work by Watanabe and colleagues 
(Watanabe et al., 1998) demonstrated that PLCβ1 mRNA is also highly expressed in the CeAL 
region. Furthermore, earlier studies as well as this study have shown that Gαq/11-coupled mAChR 
subtypes are highly expressed in the CeAL (Levey et al., 1991a), thus the molecular substrate for 
mAChR-2-AG synthesis and mobilization are present at CeAL excitatory synapses; perhaps 
forming a  eCB signalosome: a focal point for the generation of a 2-AG pool specifically 
recruited under conditions of prolonged Gαq activation (Jung et al., 2012).  
Functional Implications of mAChR-mediated eCB Mobilization at CeAL Glutamatergic 
Synapses 
The CeAL receives strong cholinergic input from cells within the nucleus basalis (NB) which, as 
demonstrated by rodent models, exhibit increased firing rates following exposure to threatening 
cues (Whalen et al., 1994). Though the NB contains both cholinergic and non-cholinergic cell 
bodies (Gritti et al., 1997), stress-induced increases in ACh content in both the amygdala and 
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other NB projecting brain regions (Mark et al., 1996) lends support to increased amygdala ACh 
content as a result of threat-induced increases in the firing rate of NB cholinergic cells. A 
consequence of this increased endogenous ACh is persistent activation of Gαq/11 coupled mAChR 
which, based on our experimental results, tonically mobilize 2-AG in the form of RER. 
Alternatively, increased endogenous ACh may also provide a state in which depolarization-
induced [Ca
2+
]i, as is elicited by backpropagating action potentials in the presence of mAChR 
agonists (Nakamura et al., 2000) or NMDA receptor activation (Ohno-Shosaku et al., 2007), can 
readily facilitate phasic 2-AG attenuation of afferent input to this region. 
Conclusion 
In the present study we show, for the first time, crosstalk between the eCB and cholinergic 
systems to facilitate attenuation of CeAL excitatory transmission. Following mAChR activation, 
2-AG mediated synaptic depression in the forms of Ca
2+
 assisted- RER and RER mediated 2-AG 
signaling are observed at CeA glutamatergic afferents. Given the key role of the CeAL in 
facilitating physiological and behavioral changes in response to threat exposure (Iwata et al., 
1987; LeDoux et al., 1988a), molecular interactions between the cholinergic and eCB system 
may act as an essential substrate for eCB’s stress attenuating physiological and behavioral 
properties. However, in light of recent insight into the CeA microcircuitry (Ciocchi et al., 2010; 
Li et al., 2013), additional work will have to be undertaken to determine the cell-type specific 
effects of mAChR-2-AG mobilization on CeAL circuitry and stress-related functionality. 
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CHAPTER V 
 
 
FUNCTIONAL SEGREGATION BETWEEN DAGL-AND-Ca2+- DEPENDENT AND -
INDEPENDENT ENDOCANNABINOID MOBILIZATION AT CENTRAL AMYGDALA 
GLUTAMATERGIC SYNAPSES: CENTRAL ROLE OF TIME-DEPENDENT 
MUSCARINIC RECEPTOR ACTIVATION 
 
 
Introduction 
As discussed in Chapter 4, prolonged muscarinic receptor (mAChR) activation facilitates a Ca
2+
 
and DAGLα-dependent form of 2-AG mediated phasic and tonic depression of glutamatergic 
transmission in the CeAL. However, previous studies have also determined that acute activation 
of Gαq/11 –coupled GPCRs can induce Ca
2+
- and/or  2-AG-independent forms of CB1- synaptic 
plasticity in other brain regions such as the hippocampus (Edwards et al., 2006a; Kim et al., 
2002b; Zhang et al., 2011), dorsal raphe nucleus (Haj-Dahmane and Shen, 2005) and cerebellum 
(Maejima et al., 2001). Therefore, to fully achieve the aim of these studies it is also important to 
determine whether both acute and prolonged mAChR activation mobilize similar eCBs at CeAL 
glutamatergic synapses. To test this, we acutely activated mAChRs (for ~20 minutes) and used 
pharmacological and genetic approaches to determine whether acute mAChR activation drives 
CB1 synaptic depression. After this experimental approach, we next determined which eCB 
facilitated this form of eCB-mediated synaptic plasticity. 
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Results 
Acute mAChR-driven eCB signaling in the CeAL 
To determine whether acute application of Oxo-M can induce eCB release at CeAL 
glutamatergic synapses in the absence of depolarization, we applied Oxo-M for ~20 minutes and 
assessed eCB release during this period, using pharmacological and genetic approaches (see 
Figure 11A for experimental design). Our results revealed that Oxo-M application dose-
dependently suppressed eEPSC amplitude with maximal depression observed with 1M Oxo-M 
(baseline 99.77±0.54% vs. Oxo-M 34.61±1.36%, p<0.0001 by paired t-test; Figures 5B-D and 
K). We next explored the contribution of CB1 activation to Oxo-M-mediated synaptic 
depression. Maximal Oxo-M-mediated depression was significantly attenuated in the presence of 
the CB1 receptor antagonist SR141716 following either 0.3μM Oxo-M (Oxo-M 46.24±4.25% vs. 
Oxo-M+SR141716 59.93±2.81%; t(8)=2.69, p<0.05) or 1 M Oxo-M application (Oxo-M 
34.61±1.36% vs. Oxo-M+SR141716 53.11±2.73%; t(17)=5.98, p<0.001; See Figure11C-D and 
K).  
We also examined the effects of SR141716 on Oxo-M induced elevation in PPR and 
found that SR141716 pretreatment significantly attenuated the 1M Oxo-M-induced increase in 
PPR (p<0.0001; Figure11E). Importantly, the residual Oxo-M depression in SR141716-treated 
slices was associated with a residual increase in PPR (p<0.001; Figure11E), indicating that the 
non-CB1 component of Oxo-M-induced depression is also presynaptic in nature. Given these 
findings following the pharmacological inhibition of CB1 receptors, we next sought to confirm 
our pharmacological results using CB1
-/-
 mice. In these experiments, Oxo-M induced synaptic 
depression was significantly attenuated in CB1
-/-
 mice (WT Oxo-M 37.912.83% vs. CB1-/- Oxo-
M 55.945.32%; t(12)=3.0, p<0.05; Figure11F) and the maximal 1μM Oxo-M-mediated increase 
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in PPR was also significantly attenuated in CB1
-/-
 mice (p<0.001; Figure11G). Collectively, 
these data indicate that Gαq/11-receptor driven eCB mobilization can be initiated by mAChR 
activity in the CeAL, which in turn, contributes to Oxo-M-mediated synaptic depression of 
CeAL glutamatergic transmission.  
Acute mAChR Activation Drives Ca
2+
- and DAGL-Independent eCB Release 
In light of previous studies, the roles of intracellular Ca
2+
 and DAGL in Gαq/11-receptor driven 
eCB release remain uncertain (Edwards et al., 2006a; Hashimotodani et al., 2005; Kim et al., 
2002a; Tanimura et al., 2010; Zhang et al., 2011). Therefore, we next examined the requirement 
for Ca
2+
 and DAGL activity in acute mAChR-driven eCB mobilization in the CeAL. First, we 
tested whether Oxo-M-mediated eCB release requires increases in intracellular Ca
2+ 
concentrations [Ca
2+
]i. Postsynaptic loading of the fast Ca
2+
 chelator, BAPTA (20mM), did not 
affect 1M Oxo-M-mediated synaptic depression and the maximal Oxo-M induced depression 
did not differ significantly from those observed under control conditions (p>0.05; Figure 11H 
and 11K). Similarly, THL pretreatment (10M, ≥60 minutes) did not inhibit 1 M Oxo-M-
mediated depression of eEPSC amplitude (p>0.05; Figure11I and K). Lastly, since a recent study 
suggested cytoplasmic phospholipase A2 (cPLA2) may facilitate 2-AG synaptic signaling in the 
cerebellum (Wang et al., 2012) and M1 mAChR orthosteric agonism has also been shown to 
recruit cPLA2 -mediated signaling (Liu et al., 2006). As such, we tested the involvement of 
cPLA2 in Oxo-M-mediated synaptic depression as an alternate mechanism by which mAChR 
activation could release 2-AG. However, the cPLA2 inhibitor, AACOCF3 (10M), did not 
significantly affect Oxo-M-mediated synaptic depression (p>0.05; Figure11J and K). These data 
suggest that acute mAChR-driven eCB release within the CeAL occurs independently of 
increased [Ca
2+
]i, DAGL, and cPLA2 activity—indicative of a 2-AG-independent synaptic 
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depression at CeAL glutamatergic synapses. Collectively, these data suggest a possible time-
dependent switch from a BAPTA- and THL-insensitive to a BAPTA- and THL-sensitive 
mAChR-receptor-driven eCB release mechanism following mAChR stimulation at CeAL 
glutamatergic synapses. 
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Figure 11. Acute mAChR Activity Drives Ca2+- and DAGL-Independent eCB Release. 
(A) Diagram of experimental design. (B-D) Oxo-M induced eEPSC depression is partially 
blocked by SR141716 at 0.3M and 1 M Oxo-M conditions. (E) 1 M Oxo-M-induced 
increase in PPR is attenuated by SR141716; residual depression in the presence of SR141716 is 
associated with a residual increase in PPR. (F) 1M Oxo-M induced eEPSC depression is 
attenuated in CB1
-/-
 mice. (G) The increase in PPR after Oxo-M application is attenuated in CB1
-
/-
 mice. (H-K) Effects of intracellular 40mM BAPTA .*p<0.05, ***p<0.001, ****p<0.0001. 
Scale bars: 10ms, 100pA. Data presented as mean ± SEM.  
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Figure 11 contd. Acute mAChR Activity Drives Ca2+- and DAGL-Independent eCB 
Release. 
(H), THL (I), and the PLA2 inhibitor AACOCF3 (J), on 1M Oxo-M-induced eEPSC 
depression. (K) Bar graph and representative traces of summary data depicting the effects of 
SR141716, THL, BAPTA, and AACOCF3 on 1M Oxo-M-mediated maximal eEPSC 
depression. ****p<0.0001. Scale bars: 10ms, 100pA. Data presented as mean ± SEM. 
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Acute mAChR Activation Drives Synaptic AEA Release  
Given that acute mAChR activation promotes a 2-AG independent form of CB1-mediated 
synaptic depression at CeAL glutamatergic synapses, we next assessed whether the other major 
eCB in the CNS, AEA, was mediated this depression. Several studies have indicated that 
pharmacological or afferent stimulation-induced activation of Gαq/11-coupled receptors can 
mobilize AEA mediated synaptic plasticity within the amygdala (Azad et al., 2004), 
hippocampus (Chavez et al., 2010b; Huang and Woolley, 2012), and nucleus accumbens 
(Grueter et al., 2010b). Given this evidence, we next sought to investigate whether the Ca
2+
- and 
DAGL-independent acute Oxo-M-mediated synaptic depression is mediated by AEA, rather than 
2-AG, synthesis and mobilization. 
In comparison to 2AG, the biosynthetic pathway for AEA is poorly characterized (Leung 
et al., 2006), as such, assessments of AEA mediated eCB-mediated synaptic plasticity have 
largely been limited to pharmacologically and genetically inhibiting fatty acid amide hydrolase 
(FAAH) (Chavez et al., 2010b; Grueter et al., 2010b; Huang and Woolley, 2012), the primary 
catabolic enzyme of AEA (Cravatt et al., 2001c). To test the involvement of AEA in mediating 
acute Oxo-M mediated synaptic depression, we assessed the effects of 1uM Oxo-M application 
on CeAL glutamatergic transmission using mice models with global FAAH loss (FAAH
-/-
). 
These experiments revealed no differences between age-matched wildtype (WT) controls and 
FAAH
-/- mice (WT+0.3μM Oxo-M 53.76%±5.51% n=6 vs. FAAH-/- + 0.3μM Oxo-M 
48.25%±3.0% n=8, p>0.05, Figure 12I). Compensatory mechanisms in FAAH
-/- 
conditions could 
account for the lack of difference between the WT and FAAH-/- conditions (Merritt et al., 2008). 
To determine whether this is indeed the case, we also determined the effects of pharmacological 
FAAH inhibition on Oxo-M-mediated acute synaptic depression (see Figure 12A for 
experimental design). Pretreatment with the selective FAAH inhibitor, PF-3845 (5M), 
98 
 
attenuated Oxo-M-mediated synaptic depression at both 0.3M and 1 M Oxo-M concentrations 
(p<0.01 for each condition) (Vehicle+ 1μM Oxo-M 55.06%±0.01 n=11, PF 3845+ 1μM Oxo-M 
77.26% ±2.03%; Figure 12B-D).  
We also tested the effects of the monoacylglycerol lipase (MAGL) inhibitor, JZL-184 
(2M), on Oxo-M-induced synaptic depression to further rule out a role for 2-AG in acute Oxo-
M-mediated synaptic depression. Consistent with the lack of BAPTA and THL sensitivity, 
prolonged MAGL blockade did not significantly affect subsequent Oxo-M-mediated acute 
synaptic depression at either 0.3M or 1M Oxo-M concentration (p>0.05 for each; Figure 12B-
D). Together these data indicate that inhibiting AEA, but not 2-AG, degradation modifies acute 
Oxo-M-mediated synaptic depression, however the direction of effect was somewhat 
unexpected. Specifically, if acute Oxo-M application causes release of AEA, blocking AEA 
degradation would be expected to increase Oxo-M synaptic depression rather than decrease it. 
Furthermore, the lack of enhancement was not due to a floor effect as both maximal (1μM) and 
sub-maximal (0.3μM) concentrations of Oxo-M showed reduced efficacy in the presence of 
FAAH, but not MAGL, inhibition.  
An alternate explanation for our results is that PF-3845, but not JZL-184, occludes the 
effects of Oxo-M. If this were the case, PF-3845 would be expected to cause increased AEA and 
a CB1- dependent synaptic depression, thereby occluding subsequent AEA-mediated synaptic 
depression initiated by acute Oxo-M application. Consistent with this hypothesis, 5M PF-3845 
wash-on produced a CB1-dependent synaptic depression of glutamatergic transmission (PF-
3845+vehicle 83.31%±5.34% vs. PF-3845+SR141716 102.80%±3.91%; t(14)=2.79, p<0.05; 
Figure 12E-F). These data, combined with the lack of occlusion of acute Oxo-M-mediated 
synaptic depression by the MAGL inhibitor, JZL-184, strongly implicate AEA, rather than 2-
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AG, as the eCB ligand subserving synaptic depression induced by acute Oxo-M application. 
However, it is possible the lack of occlusion by MAGL inhibition could be due to the fact that 
JZL-184 alone did not significantly increase 2-AG content. To exclude this possibility and 
strengthen the support for an AEA-mediated process, we tested the ability of JZL-184 to cause 
synaptic depression of glutamatergic transmission. Consistent with our hypothesis, JZL-184 
produced a CB1-dependent synaptic depression of glutamatergic signaling (JZL-184+ vehicle 
74.29%±4.24% vs. JZL-184+SR141716 96.38%±2.97%; t(9)=4.1, p< 0.01; Figure 12G-H). 
Taken together, these data provide converging evidence that acute Oxo-M-mediated synaptic 
depression causes synthesis/release of AEA that acts on CB1 receptors to reduce glutamate 
release. Conversely, prolonged Oxo-M stimulation of mAChRs enhances DSE and elicits tonic 
CB1-mediated synaptic depression via the release of 2-AG through the canonical calcium-
DAGL-dependent biosynthetic pathway (Figure 18).  
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Figure 12. Acute mAChR Receptor Activity Drives Synaptic AEA Signaling.  
(A) Experimental design for B-D. (B-D) Oxo-M-induced acute synaptic depression (0.3 M and 
1 M) is partially occluded by the FAAH inhibitor PF-3845, but not the MAGL inhibitor JZL-
184; time-course for 1M Oxo-M condition shown in (B). (E-F) Effects of PF-3845 on synaptic 
depression under control or CB1 antagonist, SR141716, pretreatment conditions. (G-H) Effects 
of JZL-184 on synaptic depression under control or CB1 antagonist, SR141716, pretreatment 
conditions. (I) Diagrammatic representation of differences between acute vs. prolonged mAChR 
activation with Oxo-M. Acute Oxo-M application induces a short-lived “burst” of AEA to reduce 
afferent glutamate release, while prolonged mAChR activation causes a tonic calcium- and 
DAGL-dependent 2-AG release. (J) During prolonged mAChR activation, tonic 2-AG release 
continues and calcium-assisted mAChR-driven 2-AG release is induced by co-incident 
postsynaptic depolarization (i.e. DSE enhancement in the presence of continuous Oxo-M). (+): 
activate; AEA: anandamide; 2-AG: 2-arachidonoylglycerol; Ca++: calcium; Ca
2+
R-eCBR: 
calcium-assisted receptor driven eCB release; CB1: CB1 receptor; DAGL: diacylglycerol lipase; 
M1/3: M1/3 mAChR; PLC: phospholipase C. *p<0.05, **p<0.01. Scale bars: 10ms, 100pA. Data 
presented as mean ± SEM. Also see Figure 13. 
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Figure 12 contd. (I) Acute mAChR Receptor Activation Elicits the Same Degree of eEPSC 
Depression in WT and FAAH -/- mice.  
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Lack of Oxo-M-Mediated Acute or Tonic eCB Signaling At Excitatory Synapses of the 
Striatum 
Thus far, our data indicate that acute Oxo-M activation of mAChRs drives AEA release and 
subsequent depression of glutamatergic signaling via CB1 activation. In contrast, prolonged 
mAChR activity results in 2-AG-mediated tonic CB1 activation and enhancement of DSE. Since 
this is the first demonstration, to the best of our knowledge, of time-dependent generation of 
AEA and 2-AG following Gαq/11 GPCR activation, we wanted to examine whether this was a 
generalizable phenomenon. Therefore, we tested this phenomenon in the striatum given the 
strong morphological, hodological, and cytoarchitectural similarities between the striatum and 
the CeAL (McDonald, 1982b). Acute application of Oxo-M (1M) caused robust presynaptic 
depression in the striatum, however, this depression was not affected by SR141716 pretreatment 
(p>0.05; Figure 13A-C). Similarly, SR141716 failed to produce synaptic potentiation in the 
presence or absence of prolonged Oxo-M (1M) pre-treatment (Figure 13D). In contrast, 
prolonged Oxo-M (1M) application was able to enhance DSE relative to control conditions 
(p<0.01; Figure 13E) and this enhancement was blocked by SR141716 (p<0.0001). These data 
indicate that Oxo-M (1M) is able to enhance DSE in the striatum, but that mAChRs do not 
trigger acute AEA or tonic 2-AG release to regulate glutamatergic transmission in this region. 
Thus, mAChR-driven multimodal eCB release may not be a generalized feature of central 
synapses.  
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Figure 13. Oxo-M does not elicit acute or tonic eCB release at Excitatory Synapses of the 
dorsal lateral striatum. 
 (A-B) Acute application of Oxo-M causes synaptic depression in dorsal striatal neurons, which 
is not affected by pre-incubation with the CB1 receptor antagonist, SR141716. (C) Oxo-M 
induced eEPSC depression is associated with an increase in PPR which is not affected by 
SR141716. (D) After continuous Oxo-M incubation, SR141716 does not induce synaptic 
potentiation. Top and bottom rows are representative current traces from experiments (A) and 
(D), respectively. (E) Oxo-M enhanced DSE magnitude in dorsal striatal neurons, which is 
blocked by the CB1 antagonist, SR141716. **p<0.01, **** p<0.0001 by ANOVA followed by 
Sidak’s multiple comparisons test.   
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Discussion 
Acute mAChR Activation Mediate CB1-Dependent and -Independent Attenuation of CeAL 
Glutamatergic Transmission 
Our data indicate that acute application of Oxo-M causes a robust presynaptically-expressed  
synaptic depression that is partially mediated by CB1 activation. Similar experimental studies by 
Lau and Vaughan (2008) in the periaqueductal grey (PAG), suggest that the CB1-independent 
effect may results from direct suppression of glutamate release via activation of Gαi/o-coupled 
M2 mAChRs. In support of this, previous studies have also shown that M2 mAChRs are highly 
expressed in the CeAL(Buckley et al., 1988). Though the functional implications of partial 
mAChR-CB1 signaling are not entirely clear, cholinergic recruitment of eCB signaling may 
supplement mAChR-driven synaptic plasticity under conditions of high neuronal activity such as 
that observed for a subset of CeAL neurons following exposure to threatening cues (Ciocchi et 
al., 2010; Haubensak et al., 2010) 
In contrast to this partial mAChR-CB1 synaptic depression observed at excitatory 
synapses of the CeAL and PAG, inhibitory synapses in other brain regions such as the 
hippocampus (Edwards et al., 2006b) and the striatum (Narushima et al., 2007b; Uchigashima et 
al., 2007c) exhibit complete mAChR-CB1 mediated synaptic depression. As such, it appears that 
excitatory synapses have a decreased ability to initiate eCB-mobilization via mAChR activation, 
a claim further supported by the lack of mAChR-eCB/CB1 synaptic depression observed at 
excitatory synapses within the dl striatum in our study and similar studies performed by 
Uchigashima and colleagues (Uchigashima et al., 2007c). This difference between excitatory and 
inhibitory dl striatal synapses is not observed following acute Gαq/11-mGluR- CB1 mediated 
synaptic depression (Kreitzer and Malenka, 2005; Uchigashima et al., 2007a), thus excluding the 
possibility of generalizable differences in Gαq/11 signaling between excitatory and inhibitory 
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synapses. This synapse specific distinction may perhaps be explained by greater segregation 
between M2- and M1/M3-exclusively containing synapses for inhibitory as compared to 
excitatory synapses (Fukudome et al., 2004b). Alternatively, distinct subcellular localizations of 
postsynaptic mAChRs at excitatory synapses may result in a relatively less efficient functional 
coupling of postsynaptic mAChRs to the eCB synthesis machinery as is hypothesized, based on 
the subcellular localization of M1 mAChRs, for mAChR-eCB mobilization at striatal 
glutamatergic terminals (Uchigashima et al., 2007a). 
Acute mAChR Activation Results in a THL and Ca
2+
-insensitive CB1 Synaptic Depression 
at CeAL Glutamatergic Synapses 
Mechanistically, acute mAChR-CB1-mediated synaptic depression does not require elevations in 
intracellular calcium, is THL-insensitive, and does not require cPLA2 activity. Moreover, 
inhibition of 2-AG degradation with JZL-184 did not significantly attenuate acute Oxo-M-
mediated synaptic depression, although a trend towards attenuation was observed possibly 
resulting from partial FAAH inhibition observed in vitro and in vivo studies by the Cravatt group 
following JZL-184 treatment (Long et al., 2009a; Long et al., 2009c; Schlosburg et al., 2010). 
Collectively, these data appear to exclude 2-AG as the eCB ligand mediating the acute CB1-
dependent synaptic depression induced by short-term mAChR activation.  
Acute mAChR Activation Mobilizes Anandamide within the CeAL 
In addition to 2-AG, Gαq/11 proteins also appear to couple to AEA biosynthesis as demonstrated 
by rodent models of Gαq/11 forebrain specific deletion which exhibit decreased hippocampal 
AEA content as compared to wildtype controls (Wettschureck et al., 2006). Furthermore, 
activation of Gαq/11-coupled mGluRs in other regions of the amygdala also recruits a Ca
2+
-
independent
  
forms of AEA-synaptic depression (Azad et al., 2004), thus Ca
2+
-independent forms 
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of Gαq/11-AEA interactions may also occur within the CeAL as well. Given this evidence, we 
wondered whether the observed THL and Ca
2+
 insensitive acute mAChR synaptic depression 
was facilitated by AEA release at CeAL glutamatergic synapses.   
We found that FAAH inhibition, which on its own caused a CB1-dependent synaptic 
depression of glutamatergic transmission, partially occluded acute Oxo-M-mediated synaptic 
depression to the same degree as similar experiments performed following genetic and 
pharmacological inhibition of CB1. As such, it appears that AEA may facilitate acute mAChR 
mediated synaptic plasticity. Huang and Woolley (2012), who showed that estrogen/ Gαq/11-
mGluR1-induced depression of GABAergic transmission in the hippocampus was occluded by 
FAAH inhibition, but not MAGL inhibition, also reached similar conclusions (Huang and 
Woolley, 2012). Given that PF 3845 application alone causes a CB1-dependent synaptic 
depression to the same degree as that which is observed in our occlusion studies, it appears that 
continuous FAAH inhibition may maximize the AEA synthetic capacity of CeAL cells thereby 
excluding AEA metabolites from contributing to the recycling, synthesis, and release of new 
AEA (Placzek et al., 2008). Thus, under these conditions, further Gαq/11-mAChR mediated AEA 
synthesis would be occluded as is observed under our experimental conditions. In support of this, 
in vitro studies by McFarland and colleagues (2006) have demonstrated that the AEA 
metabolites, arachidonic acid and ethanolamine, accumulate in lipid rafts in a FAAH dependent 
manner (Day et al., 2001) and this act as microdomains for AEA re-synthesis from its 
metabolites (McFarland et al., 2004; McFarland et al., 2006).   
Potential Mechanism Underlying Time-Dependent Dissociation of Multimodal eCB 
Signaling 
Previous studies have demonstrated that cells within the same brain regions can produce both 
AEA and 2-AG that act as retrograde eCBs signals (Huang and Woolley, 2012; Kim and Alger, 
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2010; Lerner and Kreitzer, 2012; Mathur et al., 2013; Puente et al., 2011b). Similarly, several 
studies have also demonstrated that activation of Gαq/11-coupled receptors can induce 2-AG or 
AEA release in several brain regions (Chavez et al., 2010a; Grueter et al., 2010a; Hashimotodani 
et al., 2013; Lerner and Kreitzer, 2012; Maccarrone et al., 2008a). However, to the best of our 
knowledge, our data are the first to provide experimental evidence that AEA and 2-AG can be 
released in response to activation of the same Gαq/11-coupled receptor depending only on the 
duration of Gαq/11-receptor stimulation. Specifically, acute mAChR activation causes short-lived 
AEA-mediated synaptic depression, while as discussed in Chapter 4, prolonged mAChR 
stimulation causes 2-AG-mediated phasic and tonic depression of CeAL glutamatergic 
transmission. Thus, in CeAL neurons, mAChR stimulation can initiate multimodal eCB signaling 
depending only on the duration (e.g., minutes or hours) of mAChR Gαq/11-receptor stimulation. 
The mechanistic basis for this temporal “switch” in eCB signaling the CeAL remains to be 
determined, but may likely be related to time-dependent differences in the coupling of mAChRs 
to distinct signaling pathways important for AEA and 2-AG synthesis (Mangoura et al., 1995; 
McKenzie et al., 1992a; Schmidt et al., 1995a) or the functional inhibition of 2-AG biosynthesis 
via AEA-mediated suppression of Gαq/11 –glutathione mediated 2-AG biosynthesis, as is 
observed in the ventral striatum (Cristino et al., 2006; Maccarrone et al., 2008b). However, clear 
delineation of the biosynthetic pathway for synaptic AEA synthesis and the development of 
pharmacological tools to probe these claims system will be required to conclusively assign AEA 
as the eCB ligand mediating acute Oxo-M driven synaptic depression.   
Functional Implications of Time-Dependent AEA and 2-AG Recruitment at CeAL 
Glutamatergic Synapses   
Recent studies have begun to highlight the dissociable roles of AEA and 2-AG signaling at 
central synapses. For example, in the bed nucleus of the stria terminalis, AEA mediates long-
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term depression (LTD), while 2-AG mediates short-term depression (STD) in the form of DSE 
(Puente et al., 2011b). Furthermore, different forms of associative neural activity can elicit both 
AEA- and 2-AG-mediated LTD (Lerner and Kreitzer, 2012) at excitatory synapses of the 
striatum. More recently, inhibitory synapses in the striatum have also been shown to release 
AEA and 2-AG in a synapse specific and state-dependent manner (Mathur et al., 2013). Thus, 
AEA and 2-AG appear to not be “redundant” eCB signaling molecules but, rather, rely on 
distinct duration-, activity-, and synapse-dependent mechanisms for biosynthesis and release. In 
support of the non-overlapping mechanisms for AEA and 2-AG synaptic mobilization, both 
eCBs have distinct subcellular localizations of molecular pathways relevant for their synthesis 
and degradation which may provide the anatomical substrate for AEA and 2-AG to be produced 
and released from defined cellular compartments in response to precisely timed stimuli.  
Furthermore, more recent work has begun to shed light on the functional relevance for these 
largely non-overlapping characteristics of AEA and 2-AG. Work by our group (2005) amongst 
others have revealed that both AEA and 2-AG amygdalar content are differentially regulated 
(decreased and increased, respectively) by chronic stress exposure. Furthermore, additional 
evidence strongly suggests that these differential changes in AEA and 2-AG play distinct roles in 
the physiological and behavioral adaptations to chronic homotypic stress exposure (Hill et al., 
2010c; Patel et al., 2005d). Given the enhancing effects of acute and chronic stress exposure on 
acetylcholine synaptic release and content (Das et al., 2000; Finkelstein et al., 1985; Gilad et al., 
1987; Mark et al., 1996), chronic stress may also enhance amygdalar acetylcholine content and, 
in a time dependent manner, recruit distinct eCBs to facilitate CeAL mediated adaptations of 
physiological and behavioral responses to chronic homotypic stress exposure. However, 
additional work will have to be carried out to determine: 1) whether CeAL acetylcholine content 
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changes in response to chronic stressors of diverse duration and saliency and 2) the impact of 
inhibiting CeAL muscarinic signaling on measures of stress response adaptations. 
Conclusion 
Our acute mAChR experiments reveal a partial CB1 synaptic depression at CeAL glutamatergic 
synapses that appears to be mediated by AEA mobilization which is in contrast to the eCB 
mobilized following prolonged mAChR activation at these synapses. As such, it appears that 
mAChR activation causes a time-dependent switch in coupling to AEA and 2-AG release, a 
mechanism that appears to be unique to excitatory synapses of the CeAL. Though shown to be 
mediated via afferent activity dependent mechanisms, other brain regions have also demonstrated 
that the same cell types can mobilize both AEA and 2-AG in response to different stimulation 
profiles. Here we add to this eCB signaling diversity by demonstrating time dependent-
dissociated mobilization of AEA and 2-AG signaling in response to mAChR activation. 
Continued investigation of multimodal eCB signaling could provide insight into the activity-
dependent mechanisms that modulate synaptic efficacy.  
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CHAPTER VI 
 
 
EFFECTS OF CHRONIC RESTRAINT STRESS ON ENDOCANNABINOID 
SIGNALING AT CeAL GLUTAMATERGIC SYNAPSES 
 
 
Introduction 
Stress initiates a collection of adaptive processes that engages physiological, neuroendocrine, 
and behavioral responses elicited to allow an organism to cope with imminent threat (Herman, 
2013; LeDoux, 2014). However, when these mechanisms are persistently recruited the adaptive 
benefits of the acute stress response diminishes as prolonged or cumulative stress exposure 
enlists deleterious changes, ranging from structural (Vyas et al., 2002) to behavioral (Hill et al., 
2011b; Zhong et al., 2014) that often preclude normal function. Accordingly, chronic exposure to 
psychosocial stress is a major risk factor for the development of stress-related psychiatric illness, 
such as post-traumatic stress disorder (PTSD) (Jovanovic and Ressler, 2010). In rodent models, 
chronic psychosocial stressors recapitulate many of the biochemical, structural, and behavioral 
aspects of stress-related psychiatric disorders (Pittenger and Duman, 2008). Thus, parallel studies 
of chronic stress exposure in both rodent models and humans hold significant translational 
advantages for understanding the pathophysiology of and developing critical treatment 
paradigms for stress-related psychiatric disorders.  
Such studies have identified the eCB system, an important regulator of stress responsivity 
(Hill et al., 2010c), as a promising target for the treatment of chronic-stress associated 
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psychiatric illnesses (Fraser, 2009; Leweke et al., 2012). In support of this, genetic (Haller et al., 
2002; Haller et al., 2004b; Hill et al., 2011a; Kamprath et al., 2006b; Marsicano et al., 2002) or 
pharmacological disruption (Hill et al., 2009b; Patel et al., 2004; Steiner et al., 2008c; Varga et 
al., 1995; Wade et al., 2006) of eCB signaling in humans and rodent models precipitates 
phenotypic states similar to those elicited by chronic stress exposure (Christensen et al., 2007; 
Hill et al., 2009d; Moreira et al., 2009). Furthermore, an attractive quality of the eCB system is 
its role in facilitating stress adaptations: a progressive decrease in the recruitment of stress 
responses to limit the deleterious actions that accompany prolonged recruitment of the stress 
response (Herman, 2013). Significant data suggests that the eCB system’s highly dynamic nature 
produces temporally and anatomically distinct changes in eCB signaling components within 
stress-regulating brain regions following exposure to repetitive stress (Hill et al., 2010c). These 
changes, in turn, are thought to be critical for the habituation of the stress response to the 
aversive characteristics of threatening stimuli (Kamprath et al., 2011).    
In human studies, structural changes of neurons within the amygdala as well as increased 
amygdalar activity are associated with PTSD pathology (Price and Drevets, 2010; Shin and 
Liberzon, 2010)—phenotypic states that are also recapitulated in rodent models of chronic stress 
(Vyas et al., 2002; Vyas et al., 2004). Given these stress-induced changes, the amygdala is 
thought to act as a key anatomical substrate in the pathophysiology of stress-related psychiatric 
disorders. In light of this, more recent studies have begun to focus on the functional intersections 
between the amygdala and the eCB system in an effort to determine whether eCB-related 
signaling in this region shapes stress-related pathologies. In doing so, most experimental 
attentions have focused on the BLA which demonstrate changes in both eCB content (i.e. 
increases and decreases in 2-AG and AEA, respectively) (Patel et al., 2005d) and eCB- mediated 
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short- and long-term synaptic plasticity subsequent to repetitive psychosocial stress exposure 
(Hill et al., 2009b; Patel et al., 2009b; Patel et al., 2005d; Rademacher et al., 2008; Ramikie and 
Patel, 2011; Sumislawski et al., 2011). Additionally, work by Hill and colleagues (2013) have 
extended these findings to demonstrate that these stress-engendered changes to the BLA eCB 
system act to facilitate adaptations in the physiological and behavioral responses to repetitive 
stress exposure (Hill et al., 2013b).  
Though these changes in the eCB system have shed light on BLA-eCB functions in stress 
adaptations, less is known about whether these stress-induced changes in eCB function also 
occur at the level of CeAL, the main output nuclei of the amygdala. The CeAL is a key regulator 
of the physiological, endocrine, behavioral responses to aversive stimuli (Bouret et al., 2003; 
Ciocchi et al., 2010; Feldman et al., 1994; Iwata et al., 1987; LeDoux et al., 1988b). Critical to 
the orchestration of these responses is the extensive convergence of excitatory inputs at the level 
of the CeAL. These excitatory inputs arise from stress-responsive brain regions such as the 
cortex, thalamus, and amygdala (Delaney et al., 2007; Li et al., 2013; Tye et al., 2011) which, in 
turn, drive the activity of the CeAL microcircuitry— the output of which activates descending 
projections to brain regions responsible for initiating outcome measures of the stress response 
(Haubensak et al., 2010; Li et al., 2013; Tye et al., 2011). As such, excitatory afferents of the 
CeAL act as crucial custodians of the neural substrates underlying the stress response and are a 
potential site for the regulation of CeAL-mediated stress responses. Indeed, CeAL glutamatergic 
synapses express several forms of synaptic plasticity hypothesized to be important for a variety 
of adaptive and pathological forms of stress-related behaviors (Delaney et al., 2007). In support 
of this, recent work by Li and colleagues (2013) demonstrate that exposure to threatening cues 
recruits experience-dependent synaptic plasticity of CeAL glutamatergic transmission in a cell-
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type specific and bidirectional manner (Li et al., 2013; Penzo et al., 2014). This experience-
dependent synaptic plasticity, the authors argue, ultimately determined the strength and nature of 
CeAL-mediated stress responses.  
As demonstrated in the last three Chapters, activation of the CeAL eCB system is also 
well positioned to modulate synaptic transmission at this critical locus and, perhaps, this 
modulation acts as a neural substrate for the eCB system’s stress attenuating properties. In 
support of this functional intersection between the eCB system and CeAL excitatory synapses, in 
vivo activation of CeA CB1 receptors are anxiolytic as measured by elevated plus maze 
measurements in rodent models (Zarrindast et al., 2008), whilst in vivo inhibition of CeA CB1 
receptors acutely inhibit measures of behavioral adaptations to conditioned aversive stimuli 
(Kamprath et al., 2011). In light of this, we examined the effects of repetitive restraint stress 
exposure on eCB-mediated signaling at CeAL glutamatergic synapses. 
Results 
Effects of Repetitive Restraint Stress on DSE of Locally Evoked CeAL Glutamatergic 
Transmission 
In earlier studies, Kamprath and colleagues (2011) demonstrated enhanced DSE, in the CeAM, 
following prior exposure to aversive stimuli (Kamprath et al., 2011). These results were 
reversible and suggested that excitatory synapses within the CEA are susceptible to transient 
stress-induced modifications of phasic eCB-mediated synaptic plasticity. To test the validity of 
this argument, we also assessed whether prior exposure to stressors also sensitized phasic eCB 
signaling at excitatory CeAL synapses. Given that 10 sec postsynaptic depolarization (10 sec 
DSE) elicited DSE at CeAL excitatory synapses in our earlier experiments (see Chapters 3), we 
first examined whether  similar experimental paradigms would also promote phasic eCB-
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mediated suppression of locally evoked CeAL glutamatergic transmission following repetitive 
stress exposure. Similarly to our previous experiments, excitatory postsynaptic currents 
(eEPSCs) were evoked upon non-specific local electrical microstimulation within the CeAL. To 
induce DSE, CeAL neurons were depolarized from -70mV to 0mV through direct current 
injections (duration of current injections =10 seconds) and the effects of this depolarization on 
eEPSCs were examined. Our experimental analyses revealed that subsequent to 10 consecutive 
days of 1 hour restraint, we observed a significant enhancement (p<0.05) of maximal DSE at 
CeAL glutamatergic synapses (63.37%±3.31% of baseline n=8, Figure 14C and 14D) as 
compared to behaviorally naïve mice (76.67%±3.88% of baseline n=10, Figure 14C and 14D). 
However, our analysis of late DSE (average amplitude of last 10 eEPSCs of the experiment) 
revealed no difference between our control and chronic stress conditions (control 93.62%±2.23% 
n=10 vs. stress 98.34%±2.24% , n=8; p>0.05, Figure 14A). 
Furthermore, stress-induced enhancement of maximal CeAL DSE exhibited a 
postsynaptic depolarization dependency, with significant enhancement of CeAL DSE also 
observed following shorter postsynaptic depolarization times of 5 sec (control 80.52%±2.53% 
n=10 vs. stress 68.53%±3.52%,  n=9; p<0.05, Figure 14B, D), while 2 sec postsynaptic 
depolarization exhibited a non-significant enhancement of CeAL DSE (control 93.86%±3.34% 
n=10 vs. stress 81.25%±6.59%,  n=6; p=0.07, Figure 14C-D). Collectively, these data 
demonstrate that chronic stress exposure enhances phasic eCB signaling at CeAL synapses. 
Restraint Stress-Enhancement of CeAL DSE is CB1 Receptor Dependent  
As enhanced CeAL DSE is observed under our chronic restraint stress conditions, we next 
examined whether this augmented DSE is CB1 dependent given that other retrograde signaling 
molecules that mediate depolarization-induced synaptic depression, such as nitric oxide    
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(Makara et al., 2007), can be increased by chronic restraint stress exposure (Olivenza et al., 
2000). To determine whether the CeAL short-term depression is CB1 dependent, we repeated 
our DSE protocols in the presence of the CB1 receptor antagonist, SR 141716. Following 
pretreatment with the CB1 receptor antagonist, SR 141716 (SR;5μM), maximal CeAL DSE was 
abolished in our chronic stress conditions as compared to controls (stress+vehicle: 
63.37%±3.31%,  n=8 vs. stress+SR: 92.22%±4.15%,  n=10, p<0.0001, Figure 14E). Thus, 
consistent with previously reported modulatory effects of stress exposure on the eCB system, 
chronic restraint stress augments CB1 receptor signaling at CeAL glutamatergic synapses. 
Increased 2-AG Biosynthesis at CeAL Glutamatergic Synapses Facilitates Enhanced DSE 
Using a similar restraint stress paradigm, earlier studies have demonstrated that amygdalar 2-AG 
content increases following repetitive exposure to stress (Patel et al., 2005e; Rademacher et al., 
2008) (Hill et al., 2010a; Hill et al., 2010c; Malcher-Lopes et al., 2006). In an effort to increase 
the resolution of these earlier studies, our lab has more recently shown that at the level of the 
BLA, homotypic stress exposure increases 2-AG content and phasic signaling capacity at 
inhibitory synapses (Patel et al., 2009a; Sumislawski et al., 2011). This precedence for stress-
induced elevations in amygdalar 2-AG signaling led us to hypothesize that CeAL DSE 
enhancement resulted from stress-induced increases in phasic 2-AG biosynthesis.  
To test this hypothesis, we pharmacologically inhibited the 2-AG biosynthetic enzyme, 
DAGLα (Tanimura et al., 2010), prior to assessing CeAL DSE in our chronic stress conditions. 
Consistent with stress-induced increases in 2-AG biosynthesis, pretreatment with the DAGL 
inhibitor, THL (10μM), significantly attenuated the enhanced CeAL DSE following chronic 
restraint stress (stress+vehicle: 63.37%±3.31%, n=8 vs. stress+THL: 88.63%±2.81%, n=4, 
p<0.001 Figure 14E). Collectively, these data suggests that the enhanced 2-AG phasic 
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biosynthesis, rather than 2-AG metabolism, is one of the mechanisms by which repetitive-stress 
enhances phasic 2-AG signaling at CeAL glutamatergic synapses.  
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Figure 14. Chronic Restraint Stress Enhances CeAL DSE.  
(A-C) Effects of postsynaptic depolarization on CeAL eEPSCs subsequent to chronic restraint 
stress (CRS). D) Average maximal CeAL DSE under control conditions and subsequent to 
chronic restraint stress paradigm. E) CRS-CeAL DSE is inhibited in the presence of the CB1 
receptor inhibitor, SR 141716 (5μM) and the DAGL inhibitor, THL (10μM) as compared to 
vehicle conditions.  *p<0.05, **p<0.01, ****p<0.0001. Data presented as mean ± SEM.  
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Afferent Specific Effects of Homotypic Restraint Stress on CB1 Signaling at Amygdalar 
Glutamatergic Terminals  
Though our experimental examinations thus far implicate augmented 2-AG biosynthesis as one 
of the underlying mechanism for enhanced CeAL DSE, stress-related increases in CB1 receptors 
signaling may also act in parallel and contribute to phasic inhibition of synaptic transmission. If 
enhanced CB1 activity were indeed an underlying mechanism for enhanced phasic 2-AG 
mobilization at these synapses, our current experimental approach of non-specific afferent 
stimulation, via local electrical microstimulations, may mask afferent specific changes in CB1 
receptor signaling following chronic stress exposure. To address this potential confound, we 
targeted the medial glutamatergic afferent pathway of the CeAL to increase the specificity of our 
electrical stimulation and directly assessed CB1 receptor signaling using the exogenous CB1 
receptor agonist, CP 55940 (10μM).   
In our initial experiments, we electrically stimulated glutamatergic fibers arising medial 
to the CeAL (medial glutamatergic pathway; MP). This pathway consists of afferents originating 
in the lateral parabrachial nucleus (Bernard et al., 1993; Delaney et al., 2007; Lopez et al., 2004) 
,which convey ascending nociceptive information to the CeAL, and thalamic inputs that convey 
sensory-related information to the CeAL (Ehrlich et al., 2009). To directly assess these 
glutamatergic afferents, we examined the effects of direct CB1 receptor activation on evoked 
MP-CeAL postsynaptic potentials. These experiments revealed that 10μM CP 55940 application 
results in a similarly depressed electrically stimulated MP CeAL glutamatergic inputs under both 
control and chronically stressed conditions (control+CP 59.32% ±3.93% n=9 vs. stress+CP 
52.88%±3.837% n=5, p>0.05, Figure 15B). Through the maximal CB1-mediated depression did 
not differ between the two treatment groups, for our chronic stress experimental conditions, our 
two-way ANOVA analysis revealed a significant effect of time (p<0.001), and repetitive stress 
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exposure (p< 0.001) but no interaction effect (p>0.05). Collectively, these data indicate that 
chronic stress exposure does not enhance CB1-mediated suppression of CeAL glutamatergic 
afferents. 
In an alternative experimental approach, we next examined whether this experimental 
result also occurred in other regions of the amygdala that implicated in the stress response. As 
such, we targeting the glutamatergic afferents of the lateral amygdala (LA), as these inputs relay 
critical stress-related sensory information to the LA allowing the LA to, in turn, relay polymodal 
sensory information from the thalamus and cortex to the CeAL (Quirk et al., 1995). In doing so 
the LA-CeAL circuitry modifies CeAL micro-circuitry and functionality in the stress response 
(Li et al., 2013; Quirk et al., 1997). Following repetitive exposure to restraint stress, we 
electrically stimulated the external capsule (EC) to evoke field excitatory postsynaptic potentials 
(fEPSPs) within the LA and subsequently bath applied the CB1 receptor agonist, CP 55940 
(10μM;CP). These experiments reveal that 10μM CP 55940 application maximally suppressed 
fEPSP amplitude to 52.52%±5.69% of baseline (n=5; Figure 15A) in control mice. However, in 
mice exposed to 10 days of restraint stress CP-induced depression was significantly less 
(stress+CP 74.79%±6.29% n=6; Figure), with the maximal CP-induced eEPSP depression 
significantly reduced in our chronic stress conditions as compared to control conditions (p<0.05). 
Two-way ANOVA analysis reveal a significant effect of repeated stress (p<0.0001), time 
(p<0.0001), as well as an interaction between the two parameters (p<0.0001). These data indicate 
that repetitive restraint stress decreases the sensitivity of CB1 receptors localized to 
glutamatergic terminals in the LA but has no effect on MP-CeAL synapses.  
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Chronic Stress Exposure Enhances 2-AG Biosynthesis at MP-CeAL Synapses 
To determine whether increased 2-AG biosynthesis at MP-CeAL synapses also supports CeAL 
DSE enhancement observed in our earlier experiments, we next examined the effects of 
inhibiting MAGL, 2-AG’s primary catabolic enzyme, on CeAL DSE. We reasoned that if 
chronic stress were to increase 2-AG biosynthesis at MP-CeAL excitatory synapses, inhibiting 
tonic MAGL activity would cause greater 2-AG mediated synaptic depression in our chronically 
stressed mice as compared to controls. Consistent with this hypothesis, our experimental results 
indeed show that bath application of  the MAGL inhibitor, JZL-184 (2μM), caused an enhanced 
depression of MP evoked excitatory CeAL potentials in chronic stress conditions as compared to 
non-stressed controls (Figure 15C). Two-way ANOVA analysis showed a significant effect of 
chronic stress (p < 0.0001) and time (p < 0.0001), but no interaction (p>0.05) between the two 
treatment groups. Collectively, the results suggest that repetitive stress augments 2-AG 
biosynthesis at MP-CeAL synapses that enhanced the attenuation of glutamatergic drive to the 
CeAL. 
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Figure 15. Region Specific Effects of Chronic Stress on eCB Signaling at CeAL 
Glutamatergic Synapses. 
(A) CP 55940 (10μM) depresses LA-CeAL fEPSPs greater in behaviorally naïve controls as 
compared to chronically restraint mice. (B) CP 55940 (10μM) depresses MP-CeAL fEPSPs to a 
greater degree in chronically restrained mice as compared to controls. ( C) MP-CeAL 
glutamatergic synapses of chronically restraint mice demonstrate larger JZL-184 (2μM)-induced 
synaptic depression as compared to behaviorally naïve controls. ***p<0.001, ****p<0.0001. 
Data presented as mean ± SEM.  
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Effects of Repetitive Stress Exposure on MP-CeAL LTD 
Our experimental results, thus far, indicate an enhanced capacity for phasic 2-AG synthesis and 
synaptic plasticity at excitatory synapses arising from glutamatergic inputs medial to the CeAL. 
Given that eCB-mediated short-term depression is augmented by chronic stress exposure, we 
next determined whether long-term depression at MP-CeAL synapses was also regulated by 
repetitive stress. Previous reports by Sumislawski and colleagues (2011) have shown that chronic 
stress enhances low-frequency stimulation (LFS)- induced LTD of BLA inhibitory synapses 
through augmented 2-AG signaling (Sumislawski et al., 2011). To determine whether CeAL 
excitatory synapses were similarly affected by chronic stress, we first assessed whether 
administration of another low-frequency stimulation (LFS) paradigm (4Hz, 1-ms stimuli 
alternating with 1 sec of rest for 180 iterations for a total of 6 minutes), previously shown to 
elicit eCB-mediated LTD of hippocampal excitatory synaptic transmission (Kellogg et al., 2009),  
also elicited LTD of MP-CeAL synapses.  In wildtype conditions, administration of this LTD 
stimuli paradigm to MP arising glutamatergic afferents resulted in the persistent suppression of 
MP-CeAL fEPSPs to 77.26%±2.07% (of baseline n=6 ); an effect largely absent in age-matched 
global CB1
-/- 
mice (99.06%±3.37%  n=11, p<0.0001, Figure 16A). 
 Given that our LTD paradigm induces a persistent CB1-dependent depression of evoked 
MP-CeAL glutamatergic responses, we next determined whether this LTD is also modulated by 
prior stress exposure. Following our chronic restraint paradigm, our LTD induction protocol at 
medially arising glutamatergic afferents resulted in a persistent depression of MP-CeAL 
glutamatergic synapses that was significantly larger than that elicited under control conditions 
(control 78.97%±4.06% n=12 vs. stress 58.49%±4.50% n=11, p<0.01, Figure 16B ). 
Collectively, this experimental evidence suggested that chronic stress facilitates enhanced CB1-
mediated LTD at MP-CeAL excitatory synapses. 
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Figure 16. MP-CeAL Synapses Also Exhibit Enhanced LTD following Chronic Restraint 
Stress. 
(A)Low-frequency stimulation (LFS)-induced LTD of MP-CeAL fEPSPs is present in WT mice 
but absent in CB1
-/-
. (B) LFS-induced LTD of MP-CeAL excitatory synapses is enhanced in 
chronically stress mice as compared to behaviorally naïve controls. **p<0.01, ****p<0.0001. 
Data presented as mean ± SEM.  
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Effects of Augmented 2-AG levels on HPA Axis Activation  
Our data thus far suggests that chronic repetitive stress augments phasic 2-AG mobilization and 
CB1-mediated LTD at CeAL glutamatergic synapses. These stress-dependent changes in the 
CeAL eCB system, we hypothesize, will decrease glutamatergic-mediated activation of the 
CeAL and subsequently attenuate CeA-mediated components of the stress response, such as the 
activity of the HPA axis (2001; Ciocchi et al., 2010; Kolber et al., 2008; LeDoux et al., 1988a). 
In a proof of principle experiment, we next tested whether pharmacologically enhancing 
endogenous 2-AG content could attenuate CeA-mediated functions such as basal HPA axis 
activity. To increase endogenous 2-AG levels, 1 hour before exposure to acute restraint stress we 
systemically treated mice with the MAGL inhibitor, JZL 184 (16mg/kg), at a concentration we 
have previously shown increases brain 2-AG levels (Sumislawski et al., 2011). These 
experiments revealed that acute restraint stress increases basal HPA axis activity, as indicated by 
stress-induced increases in corticosterone plasma levels. Furthermore, this stress-corticosterone 
release was significantly attenuated in our JZL-pretreatment conditions as compared to our 
vehicle treated animals (vehicle+ stress 132ng/ml±29.43 vs. JZL184+stress 88.34±21.79ng/ml 
n=5/treatment condition, p<0.05, Figure 17). Collectively, the data presented thus far suggest 
that augmented 2-AG signaling at CeAL glutamatergic synapses may serve to attenuate 
excitatory drive and decrease activation of CeA mediated functions of the stress response.  
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Figure 17. Systemic Increase in 2-AG Attenuates Acute Stress Induced HPA Axis 
Activation. 
Systemic JZL-184 (16mg/kg) treatment significantly attenuated acute stress induced HPA axis 
activation.*p<0.05. Data presented as mean ± SEM.  
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Discussion 
The principal findings from this work are that repetitive restraint stress exposure enhances eCB 
mediated short-and long-term synaptic depression of CeAL glutamatergic synapses. This 
conclusion is supported by evidence demonstrating enhanced phasic 2-AG signaling as well as 
augmented CB1-mediated long-term depression of CeAL excitatory synapses. Furthermore, 
chronic restraint stress elicits afferent-dependent changes in CB1 receptor signaling at stress-
regulating glutamatergic terminals within the amygdala. We reached this conclusion as CB1 
signaling at LA, but not MP-CeAL, glutamatergic afferent terminals is attenuated following 
chronic stress exposure. Lastly, in an effort to determine the functional implications of stress-
dependent enhancement of CeAL 2-AG content, we show that pharmacologically increasing 
systemic 2-AG levels attenuated HPA axis activation—a CeAL-mediated component of the 
stress response. Similar to other studies in our lab, these data suggests that repetitive stress 
exposure sensitizes the eCB system at central synapses of the amygdala. Here we have shown 
that, at the level of CeAL glutamatergic synapses, homotypic chronic restraint stress augments 2-
AG, consequently enhancing eCB-mediated synaptic modulation of CeAL excitatory 
transmission.  
Repetitive Restraint Stress-Induced Enhancement of CeAL DSE  
Prior biochemical and electrophysiological data suggest that repetitive restraint stress exposure 
results in adaptations in amygdalar 2-AG content and signaling capacity (Patel et al., 2009a; 
Rademacher et al., 2008; Sumislawski et al., 2011). In an effort to extend these findings, we 
tested whether this increased amygdalar 2-AG content correlates with enhanced 2-AG 
mobilization at CeAL excitatory synapses. Consistent with this hypothesis, our data reveal that 
repetitive restraint stress exposure enhances the maximal DSE of locally recruited CeAL 
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glutamatergic transmission in a CB1 and 2-AG dependent manner, while causing no change the 
late CeAL DSE. This lack of effect on late CeAL DSE implicate enhanced 2-AG biosynthesis as 
one of the mechanisms underlying enhanced 2-AG phasic synaptic modulation of CeAL 
glutamatergic synapses following chronic stress exposure. 
Interestingly, these outcomes are the converse of experimental observation in the BLA, a 
neighboring amygdala subnuclei that also exhibits increased 2-AG levels and signaling following 
repetitive stress exposure (Hill et al., 2010c). At inhibitory synapses of the BLA, a similar 
restraint stress paradigm did not affect maximal DSE but, on the other hand, enhanced late DSE 
(Patel et al., 2009a). Though these stress-dependent synaptic changes are different, this 
discrepancy in the maximal DSE and the time course of 2-AG mediated synaptic plasticity 
between the two amygdala subnuclei may be explained by morphological differences at 
inhibitory BLA synapses as compared to excitatory synapses of the CeAL. Recent work by 
Yoshida and colleagues (2011) have show that 2-AG mediated DSE is more readily induced and 
saturated at postsynaptic depolarization profiles as low as 0.1 seconds. This, they strongly argue, 
is a consequence of perisomatic invaginating synapses enriched with the molecular components 
of the eCB biosynthetic machinery that are uniquely present in the BLA, but absent in the CeAL 
(Yoshida et al., 2011b). Thus, the 5 seconds postsynaptic depolarization protocol used in our 
earlier studies (Patel et al., 2009a) may have saturated the maximal 2-AG biosynthetic capacity 
at BLA inhibitory synapses, thus occluding detectable differences in the 2-AG biosynthetic 
capacity between behaviorally naïve and repetitively stressed mice. 
Alternatively, two mechanistically distinct modes of action may support stress-induced 
increases in 2-AG levels in the BLA and the CeAL. The enhanced maximal CeAL DSE in our 
chronic stress conditions, with no difference in late CeAL DSE, suggests that stress-induced 
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increases in 2-AG biosynthesis perhaps through increased DAGL activity or postsynaptic 
mechanisms upstream of DAGLα activation, such as Gαq receptor activation (Jung et al., 2012), 
may potentially be at play. On the other hand, augmented 2-AG content and DSE at BLA 
inhibitory synapses were found to be a consequence of repetitive stress-induced MAGL down-
regulation (Patel et al., 2009b). Collectively, these results suggest that repetitive stress exerts 
subregional specific regulation of 2-AG levels by differentially targeting 2-AG biosynthesis and 
metabolism within distinct amygdalar nuclei. However, additional experimental analyses of 
CeAL DAGL expression and activity will be needed to conclusively determine whether this 
chronic stress- dependent differential effect is indeed the case. 
CeAL Glutamatergic Synapses Exhibit Afferent Specific Regulation by Repetitive Stress 
Exposure 
The CeAL receives intra-and inter-amygdaloid afferent inputs largely thought to relay different 
sensory modalities to the CeAL, which results in activity dependent changes in the CeAL 
microcircuitry and stress-related functionalities. CeAL afferents arising medial to the CeAL 
contain afferents originating in the lateral parabrachial area (Bernard et al., 1993; Neugebauer et 
al., 2003)  (Lopez de Armentia and Sah, 2004b) and thalamus (Pitkanen et al., 1995; Sun et al., 
1994; Yasui et al., 1991); each convey nociceptive and sensory related information, respectively.  
Our experimental results reveal that repetitive stress exposure does not affect maximal CB1 
dependent synaptic depression at CeAL glutamatergic synapses. Unlike the CeAL, glutamatergic 
inputs to the LA exhibit functional downregulation of CB1 receptors signaling following 
repetitive stress exposure as compared to behaviorally naïve controls. These experimental results 
are consistent with decreased CB1 receptor signaling in the paraventricular nucleus of the 
hypothalamus (Wamsteeker et al., 2010), BLA (Patel et al., 2009b), and striatum (Rossi et al., 
2008a) subsequent to other chronic stress paradigms (Hill et al., 2005). Given that glutamatergic 
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terminals within the LA facilitate the relay of polymodal sensory information from the LA to the 
CeAL, this stress dependent effect on eCB modulation of LA excitatory drive may have an 
indirect effect on the CeAL microcircuitry. As such, though stress-dependent changes in CeAL 
glutamatergic synapses are not observed following chronic stress exposure, other chronic-stress 
mediated changes in synaptic CB1 receptor functions within the amygdala can still modify the 
information flow through the CeAL microcircuitry and affect the physiological and behavioral 
functions elicited by CeAL activity. 
Conversely, medially arising afferent pathways of the CeAL display enhanced eCB 
signaling (i.e. increased phasic 2-AG biosynthesis) subsequent to repetitive stress exposure as 
compared to controls. Furthermore, these synapses are also sensitive to CB1 mediated LTD, 
which is also enhanced in a chronic stress-dependent manner. Though our initial DSE studies 
suggests that enhanced 2-AG biosynthesis may facilitate this enhanced LTD in our chronic stress 
conditions, additional work will have to be done to determine the eCB (i.e. 2-AG or AEA) 
mediating this persistent depression. As such, MP-CeAL synapses are highly sensitive to eCB-
mediated regulation following repetitive restraint stress exposure. Collectively, these 
experimental results illustrate that chronic restraint stress differentially affects the CB1 
regulation of glutamatergic inputs to CeAL as well as other amygdalar nuclei whose activation 
regulate CeAL outflow.  
Functional Implications of Chronic Restraint Stress-Induced Regulation of CeAL 
Glutamatergic Afferents 
In human studies, converging lines of evidence parallel preclinical findings of stress-induced 
modulation of the eCB system acting as a mechanism for stress adaptation. Work by Hill and 
colleagues (2009) have shown that acute social stress increases circulating levels of 2-AG while 
Chouker and authors (2010) have also reported exaggerated stress responses observed in humans 
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who do not show elevations in 2-AG following exposure to parabolic flight stress (Chouker et 
al., 2010; Hill and Gorzalka, 2009). Thus, consistent with our rodent studies, stress-induced 
elevated 2-AG appears to be an adaptive response that constrains stress responsivity by 
contributing to the termination of the stress response (Evanson et al., 2010; Hill et al., 2011a). 
Similar studies in chronic-stress related psychiatric disorders, such as depression and PTSD, are 
however less clear. Reduction in plasma 2-AG or AEA plasma concentrations are seen in 
individuals with PTSD (Hill et al., 2009b; Hill et al., 2008b). Though future studies will have to 
be undertaken to determine the variables (e.g. trauma differences, genetic background, duration 
and acuity of stress exposure, etc.) that may explain the differences between studies, a theme of 
retained capacity to mount a 2-AG response following exposure to stress is still observed in 
studies that found reduced basal eCB levels. Consistent with this, sustained elevations of 2-AG 
and AEA are found in trauma-exposed populations with PTSD, where the magnitude of the 
stressor is associated with the activation of eCB system (Hill et al., 2013a). Thus, despite the 
differences observed in the studies, the eCB system is mobilized by threat exposure to buffer 
against the negative consequence of stress (Hauer et al., 2013). 
Conclusion 
Overall, these data strongly suggest that eCB signaling mechanisms are modulated by chronic 
repetitive stress and this enhanced eCB-mediated synaptic plasticity potentially facilitate stress-
adaptations through the regulation of excitatory inputs into the CeAL. Though increased 
anatomical resolution of our ex vivo experimental studies will be needed to fully assess the 
behavioral effects of enhanced afferent specific CB1 signaling, our initial studies suggests that 
eCB signaling mechanisms under naïve and repetitive stress conditions provides a locus for eCB 
regulation of CeAL circuitry activation following repetitive stress exposure.  
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CHAPTER VII 
 
 
      GENERAL CONCLUSION AND FUTURE STUDIES 
 
 
Mechanistically Distinct Modes of Endocannabinoid Mobilization is Present at CeAL 
Excitatory Synapses 
Collectively, our data demonstrates that eCB signaling mechanisms are present at CeAL 
glutamatergic synapses. Under control conditions, eCB mediated short-and long-term synaptic 
plasticity are present at CeAL glutamatergic synapses, suggesting that eCB signaling 
mechanisms can be recruited under conditions of strong neuronal activity. Consistent with the 
dynamic nature of the eCB system, diverse experimental contexts such as acute and prolonged 
mAChR activation, as well as, chronic restraint stress exposure augments the eCB-synthesis 
capacity of CeAL neurons. These data demonstrate that the eCB synthesis machinery at CeAL 
glutamatergic synapses is sensitive to the changing contexts within this region and strongly 
implicates the eCB system in the regulation of CeAL activity as well as CeAL-elicited 
physiological and behavioral components of the stress response. In support of this claim, our 
analysis of increased endogenous 2-AG on stress responsivity reveal an attenuation of acute-
stress-induced HPA axis activation. This data suggests that increased eCB content may affect 
CeAL-mediated functions. More detailed analysis will be needed to fully determine the effects of 
eCB-attenuation of CeAL afferent input on its functionality in the stress response. Such analyses 
should include genetic and optogenetic tools that will allow for a more acute analysis of whether 
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eCB-signaling regulate CeAL glutamatergic, or even local inhibitory, synapses in a cell-type or 
afferent-specific manner. 
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Figure 18. Multiple Mechanistically Distinct Modes of Endocannabinoid Mobilization is 
Present at CeAL Excitatory Synapses. 
Under control conditions, CeAL synapses exhibit DSE. However, under conditions of prolonged 
mAChR activation, 2-AG is mobilized under conditions of basal Ca
2+
 levels (R-eCBR) and 
following depolarization-induced increases in [Ca
2+
]i. Conversely, acute mAChR activation 
drives AEA , not 2-AG, mobilization suggesting a time-dependent coupling of mAChRs to 
diverse signaling transduction pathways responsible for the successive synthesis of AEA and 2-
AG. Of further note, this phenomenon appears to be unique to the CeAL. 
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Future Studies 
Endocannabinoid Signaling at the Level of the CeAL Micro-circuitry 
Here, we show that eCB signaling suppresses afferent glutamatergic transmission onto CeAL 
neurons, which could represent an important synaptic mechanism regulating stress response 
physiology and anxiety-like behaviors. As discussed in the Introduction section, the CeAL is 
composed of heterogeneous neurons that form a functional microcircuitry that gates the 
expression of fear- and stress-related responses via different glutamatergic afferent inputs. For 
the experiments discussed in this body of work, we have examined eCB signaling at CeAL 
excitatory synapses without regard of cell type or glutamatergic afferent. However, to truly 
determine the effects of eCB signaling on CeAL microcircuitry output and overall function in the 
stress response, the next steps must involve performing similar studies in a cell-type and afferent 
specific manner as eCB signaling at specific cell types or afferents will have different effects on 
the functionality of the CeAL microcircuit. For example, eCB-mediated inhibition of excitatory 
drive to protein kinase C-δ-expressing GABAergic CeAL projection neurons would disinhibit 
CeAM neurons and increase fear and anxiety responses (Ciocchi et al., 2010; Haubensak et al., 
2010). This model is consistent with well-known behavioral effects of high doses of exogenous 
cannabinoids (Patel and Hillard, 2006) and, therefore, could represent a synaptic correlate of 
cannabinoid anxiogenesis. In contrast, inhibition of glutamatergic drive to locally-targeting 
somatostatin-expressing GABAergic neurons would disinhibit CeAL projection cell activity, 
inhibit CeAM activity, and ultimately reduce anxiety and fear responses which is one of the 
physiological function of eCB signaling (Hill et al., 2009a; Lutz, 2007; Riebe et al., 2012). 
Future studies aimed at elucidating the afferent- and cell type-specific effects of eCB signaling 
within the CeA microcircuitry, particularly using in vivo tools, will be critical to advancing our 
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understanding of the synaptic mechanisms by which eCB signaling modulates stress-responses, 
anxiety, and emotional learning.   
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Figure 19. Conclusions: Functional Implications of Experimental Results. 
Collectively, our data supports two possibilities: A) eCB- mediated attenuation of excitatory 
transmission at synapses of PKCδ- CeAL neurons, which subsequently increases inhibition of 
CeAM neuronal output neurons and attenuates stress response activation. B) Alternatively, CB1- 
mediated attenuation of glutamatergic inputs to PKCδ+ CeAL cells disinhibits CeAM projection 
neurons and increases stress responsivity.  
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Mechanisms Driving Repetitive Restraint Stress-Enhancement of CeAL DSE 
Our data suggests that enhanced 2-AG biosynthesis serves as one of the mechanisms driving 
enhancement of CeAL DSE following repetitive stress exposure. A potential avenue of support 
for stress-induced augmentation of 2-AG synthesis is mAChR-mediated increases in 2-AG 
synthesis. Data presented in Chapters 4 and 5, show that mAChR activation can enhance eCB 
mobilization at CeAL glutamatergic synapses. Furthermore, activation of stress circuits is well-
known to lead to increased synaptic acetylcholine levels, increased mAChR affinity, and 
amygdalar acetylcholine content in limbic regions (Finkelstein et al., 1985; Gilad et al., 1985; 
Mark et al., 1996). Therefore, similarly to the eCB system, the cholinergic system also exhibit 
stress-induced adaptations. As a result, acetylcholine-eCB interactions may potentially act as an 
additional mechanism through which 2-AG biosynthesis is enhanced under conditions of 
repetitive stress exposure. In support of this, our previous pharmacological assessments of 
mAChR-mediated eCB mobilization at CeAL excitatory synapses show an enhancement of 
CeAL DSE to the same degree as that which is observed following chronic restraint stress. 
Though not further probed in our study, we also observed enhanced CeAL LTD in our chronic 
stress conditions, which may potentially be due to augmented 2-AG mobilization as a result of 
stress-dependent increases in cholinergic signaling. Given the evidence presented in this thesis, 
the potential for functional intersections between the cholinergic and eCB systems in facilitating 
stress adaptations at the levels of the CeAL excitatory synapses appears to be very promising and 
may be a potential therapeutic tool in the treatment of stress-related psychiatric disorders. 
 Of further note, the CeAL also expresses a number of Gαq/11-coupled GPCRs that have 
also been implicated in driving eCB synthesis in other brain regions (Kano et al., 2009a). Such 
receptors include peptide receptors, such as the orexin receptor , which has been shown to 
stimulate eCB release using in vitro (Turunen et al., 2012) and ex vivo studies (Haj-Dahmane and 
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Shen, 2005). Furthermore, other Gαq/11-protein coupled receptors such as the group I 
metabotropic glutamate (Kolber et al., 2010), adrenoceptor (Delaney et al., 2007), and oxytocin 
receptors (Viviani et al., 2011) are also highly expressed within the CeAL and have been shown 
to induce eCB release in other stress responsive brain regions (Kano et al., 2009a). As such, 
other forms of Gαq/11-coupled eCB release may also be present at glutamatergic synapses of the 
CeAL and is an interesting avenue to explore in future studies. Interestingly, more recent work in 
the CeAL by the Stoop research group have shown that intra-CeA application of the oxytocin 
agonist, TGOT, decreased conditioned freezing (Viviani et al., 2011), which is the opposite 
result that is observed following intra-CeA application of the CB1 receptor antagonist, 
AM251(Kamprath et al., 2011). Collectively, these results suggests that Gαq/11-protein coupled 
receptors-induced eCB release in the CeAL, such as through oxytocin receptor signaling, is 
potentially one of the neural substrates through which eCB mediate its fear and stress attenuating 
properties and may act as a potential therapeutic target for the treatment of fear and stress-related 
disorders.    
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